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Abstract 	   	   	   	  
This dissertation explores the use of personal health messages collected from 
online message forums to predict drug safety using natural language processing and 
machine learning techniques.  Drug safety is defined as any drug with an active safety 
alert from the US Food and Drug Administration (FDA).  It is believed that this is the 
first exploration of patient derived data of this type for pharmacovigilance – the study of 
drugs once released to market for safety.  It is believed that this is the first application of 
machine learning and natural language processing techniques to be used for 
pharmicovigilance on patient derived data.     
We present results demonstrating the identification of drugs withdrawn from 
market as well as predictions of other potential safety alert drugs.  One example includes 
Meridia, a weight loss drug linked with death for those with cardiovascular disease.  The 
drug is identified based on data presented two years before FDA and European Union 
(EU) advisory panels were formed and the subsequent withdrawal of the drug from 
market within the EU and United States.    
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1 Introduction 
Chronic illness affects the lives of approximately half of all Americans.  It 
accounted for 70% of the deaths in the US in 2005 and was responsible for more than 
75% of the nation’s $2 trillion healthcare cost1.   This dissertation explores the possibility 
of utilizing patient derived data from online message groups for pharmacovigilance and 
identification of adverse effect causing drugs within the context of chronic illness 
treatment.  
Chronic illness is defined as any illness lasting more than three months; these 
illnesses affect people of all races, classes and geographic locations and are wide ranging 
illnesses from heart disease to Schizophrenia. A troubling aspect of chronic illness is that 
it is not usually preventable by vaccine or curable by medication, and the number of 
affected people continues to grow steadily: 
Advances in medical science and technology – new diagnostic testing, new medical procedures, 
and new pharmaceuticals – are being used to treat acute illness and maintain a level of health and 
functionality that results in increased numbers of people surviving with chronic conditions.  We 
are also successfully screening and diagnosing chronic conditions with greater frequency and 
success.  Earlier detection means people can live with chronic conditions that used to grow to 
acute care stages before diagnosis (Anderson et al., 2002).   
 
The first baby boomers will reach age 65 around 2011.  This is particularly 
worrisome because the likelihood for having a chronic condition increases with age.  Half 
of all people with chronic conditions have multiple conditions or co-morbidities and 
those with five or more co-morbidities are responsible for two-thirds of Medicare 
spending (Anderson et al., 2002).   
Those with chronic illness are on a myriad of drugs ostensibly for the rest of their 
life.  Many drugs lack the rigorous long term testing necessary for lifelong treatment 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  http://www.cdc.gov/chronicdisease/overview/index.htm 
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plans.  Pharmacovigilance is the study of drugs once released to market and is an 
important component of public health.  While clinical trials aim to prove a drug’s safety 
before it is brought to market, many drugs have been marketed that are unsafe or 
responsible for numerous deaths or deformities; however, as the World Health 
Organization states, “safety is not absolute, and it can be judged only in relation to 
efficacy, requiring judgment on the part of the regulators in deciding on acceptable limits 
of safety” (World Health Organization [WHO], 2002).   
Inherent problems exist with clinical trials due to their controlled environment 
and small numbers of participants.  Clinical trials may not observe rare life threatening 
effects; for example, fatal blood dyscrasia might occur in 1 in 5,000 patients treated with 
a drug that will likely be recognized after 15,000 patients have been treated provided that 
a causal association with the drug is clear and there is zero background incidence of it 
occurring (WHO, 2002).      These studies are in a controlled environment not taking into 
account the differing ways people take medications along with over the counter drugs, 
co-morbidities, and long-term effects.  There are many drug-drug interactions, genetic 
variations that are not present in sample populations, or even interactions with food that 
will not surface for some time after drugs are marketed.  Grapefruit juice is an excellent 
example of a seemingly innocuous and healthy drink that people might want to take in 
conjunction with medication; however, it can, “markedly augment oral drug 
bioavailability...the duration of effect of grapefruit juice can last 24h...At least 20 other 
drugs have been assessed for an interaction with grapefruit juice” (Baily et al., 1998).    
The Untied States Food and Drug Adminstration (FDA) which is in charge of 
drug safety in the United States, continues to monitor drugs for safety once they are 
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marketed in Phase IV trials. The FDA constructs panels to advise on specific drugs’ 
safety.  While the FDA usually follows its’ own panel’s advice, it is not obligated to do 
so.   Drug safety is ultimately a political process.  It is not always clear whether or not to 
pull a drug from market even though it has dangerous side effects if it also has the 
potential to do good, especially for life-threatening conditions.  The public at large has 
influence over drugs that concern a subset of the population (for example those with rare 
diseases) and yet mass media and other influences can dictate the withdrawal of drugs 
from market.   
The Adverse Effect Reporting System (AERS) consists of two components, the 
first of which is mandatory reports from drug manufacturers, distributors, and healthcare 
facilities.  The second component is voluntary reports from consumers or patients as well 
as from care providers or physicians.  A diagram of the FDA drug review process once a 
drug is released to market is depicted in Figure 1.  
The reports in AERS are evaluated by the Center for Drug Evaluation and 
Research (CDER) and the Center for Biologics Evaluation and Research (CBER) groups 
within the FDA.  CDER regulates over-the-counter and prescription drugs, including 
biological therapeutics and generic drugs. This work covers more than just medicines. 
For example, fluoride toothpaste, antiperspirants, dandruff shampoos and sunscreens are 
all considered drugs.  If a potential safety concern is identified in AERS, further 
evaluation might include epidemiological studies. Based on an evaluation of the potential 
safety concern, FDA may take actions as described in the figure below.  
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We hope to enrich the existing AERS system using online health forum messages.  
We believe that this source of data is currently untapped and has the potential to provide 
much data.  Spontaneous reporting systems such as AERS have been known to have 
under report rates as high as 98% (Fletcher, 1991).  Numerous high-profile safety 
problems have resulted, not from the lack of the FDA’s authority to regulate drugs, but 
Figure	   1:	   Flow	   chart	   of	   FDA	   AERS	   system.	   	   Medwatch	   3500a	   is	   the	  
mandatory	  form	  submitted	  by	  facilities,	  distributors,	  and	  manufacturers	  of	  
drugs	   or	   devices.	   	   Form	   3500	   is	   voluntarily	   submission	   by	   healthcare	  
professionals	  and	  consumers	  for	  spontaneous	  adverse	  events	  surfacing	  in	  
the	   course	   of	   clinical	   care.	   	   The	   resulting	   forms	   are	   processed	   and	  
anonymized,	  released	  then	  further	  action	  is	  pursued.	  
Initial Processing 	  	   Anonymized Version  
Possible Outcomes: 
• Monitoring of adverse events by FDA for trends. 
• Request from the FDA to the submitter of the report for 
additional details. 
• Recall of drug by the manufacturer. 
• Change in drug labeling such as drug warnings and instructions 
on use.   
• Decision to stop marketing drug by manufacturer.   
• Public health notification (PHN) by FDA to healthcare providers 
detailing drugs risks and advice for reducing risk. 
• Issuance of safety related communications by FDA for patients. 
• FDA inspection of drug manufacturer. 
• Change in FDA’s future regulatory decision making ie. (test 
methods/requirements, design, labeling). 	  	  
Voluntary Report Mandatory Report 
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lack of post marketing surveillance information about drugs (McClellan, 2007). It has 
been demonstrated that the quality of patient reporting is similar to that of healthcare 
professionals and that patients are more likely to report adverse drug reactions when they 
believe that their healthcare professional has not paid attention to their adverse reaction 
(Leamon et al., 2010).    
Patients look to physicians and other healthcare professions as their main source 
of health information.  Yet many physicians do not have a clear picture of their patient’s 
health.  It is commonly understood that patients usually spend a very limited amount of 
time per year directly interacting with a medical doctor, nurse, or health-care system.  A 
typical face-to-face patient-physician encounter is between 15 and 20 minutes long 
(Travaline, 2005). This is often an insufficient amount of time for a physician to review 
all aspects of a patient’s medical history. This problem is further compounded by the fact 
that a physician may not have sufficient information through interactions and a patient’s 
medical record to make informed decisions about care. Much of this data is not available 
in electronic medical records or discussed with health care practitioners; patients are not 
always honest with their physicians or compliant with treatment plans.  Patients construct 
their own drug regimens consisting of both prescription and non-prescription medication 
utilized in ways in which they are not intended.  Our previous work shows that patients 
are more honest with peers, “I can't take potassium and only take Lasix as needed,” and 
share patient derived regimens, “I found that 2 Flexiril and a benydryl help me relax and 
go to sleep.”2  As a primary source of information, physicians need this information to 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  These quotes were taken from messages on Yahoo! Health groups.	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accurately assess a patient’s condition and to help a patient arrive at a useful treatment 
plan.   
Many times patients share such information in online health forums or chat 
groups, “60% of e-patients, or one third of adults access social media related to health” 
(Fox and Jones, 2009).   These social media forums include social networking sites such 
as MySpace and Facebook.  Social media has become entrenched in our daily lives; for 
example: Facebook has an estimated 500 million active users.  Social media forums also 
include smaller health specific sites such as CHFpatients.com, a site specifically targeted 
at people with or caring for those with Congestive Heart Failure, “41% of e-patients have 
read someone else's commentary or experience about health or medical issues on an 
online news group, website, or blog” (Fox and Jones, 2009).  While the topic of health as 
a social networking site theme is nascent, there are numerous other groups, message 
forums, and other online communities where people may gather.  As of May 25, 2008, 
there were 162,742 health-related groups on Yahoo Health.  The number of community 
health related sites has grown steadily and will increase as more people turn to online 
sources for information, support, and decision making help.   
Patients seek others like them to share information, support and advice within 
these forums establishing interpersonal relationships.  For rare conditions there may be a 
limited  number of individuals within a close geographic space and for those with serious 
conditions, they maybe limited in the people they can physically see.  People turn to 
online communities to supplement and augment real world community, information and 
support system.  These interpersonal relationships between patients within a forum or 
support group form a community and social network.   Within these networks patients are 
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among peers and can share common experiences about their situation.  It is known that 
people do what their peers do, such as friends, family members, or those people with 
whom they regularly interact (McPherson, 2001).  
People want to know what others think and these opinions are important in the 
decision making process (Pang and Lee, 2008).   People often ask family, friends or other 
peers for recommendations on goods and services or have consulted Consumer Reports 
for product reviews.   Outside of physicians and other healthcare providers, family and 
friends are the highest rated source of information for online health seekers.  In such 
studies, however, it is not known if the information derived from health forums were 
considered online sources, friends, or both.  The Internet enables the discovery of 
opinions and experiences of all different types of people from professional critics to 
grandmothers.  This information is used with increasing frequency for many products; in 
two separate studies of more than 2,000 American adults the following was found (Pang 
and Lee, 2008): 
• 81% of Internet users (or 60% of Americans) have done online research on a 
product at least once. 
• 20% (15% of all Americans) do so on a typical day.  
• Among readers of online reviews of restaurants, hotels, and various services 
(e.g., travel agencies or doctors), between 73% and 87% report that 
reviews had a significant influence on their purchase.   
• 32% have provided a rating on a product, service, or person via an online ratings 
system, and 30% (including 18% of online senior citizens) have posted an 
online comment or review regarding a product or service. 
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Sentiment or opinions expressed in online forums towards a particular treatment 
is an implicit review for that treatment option.  Often these sentiments are causal in 
nature; for example, “I don’t like drug X because it gives me headaches.”  The causality 
of these opinions or inclusion of adverse drug events is similar in nature to spontaneous 
drug reporting systems like ones which the FDA has in place such as MedWatch.  The 
MedWatch voluntary report by consumers asks a patient to, “describe event, problem, or 
product use error,”3 and includes sections about “other relevant history, including 
preexisting medical conditions” which occur in discussions on online health forums.  The 
combination of opinion and latent history is equivalent to reports entered into a 
spontaneous, even reporting system like MedWatch.  It is widely understood that these 
systems are useful in the area of pharmacovigilance – the study of drugs in populations 
once introduced into the market (Edwards and Aronson, 2000).  
Much of what occurs on in these online health forums is information and 
experience sharing.  Information and experiences about drugs can inform the general 
public about potential problems not found during clinical trials and should be utilized as 
an information gathering point for pharmacovigilance.  Patients often seek people with 
first hand experience with treatment options much like consumers seeking product 
reviews.  People do what their peers do; the social network a person resides in informs 
them and generates information about them.  Is this information regarding drugs 
accurate?  Can it be leveraged to form the basis of pharmacovigilance techniques, or are 
the social network’s aggregate sentiment toward a drug the results of mass effects?  Does 
what peers think correlate to FDA watch list?   The goals of this dissertation are to 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  From the MedWatch form available at: http://www.fda.gov/downloads/Safety/MedWatch/ 
HowToReport/DownloadForms/UCM082725.pdf 
	  
 
 9	  
explore these questions and determine if sentiment within such networks is a useful 
indicator of FDA watch list potential.  
Not only is it important to understand whom a patient interacts with, but also how 
patients interact with one another and utilize the information shared within their 
networks.   I aim to address the following research questions in exploring the idea of 
utilizing patient derived data within the context of online message forums: 
Q1:  Can we develop machine learning classification methods utilizing 
textual features derived from online health forum messages to 
differentiate between FDA watch list drugs and non-watch list drugs. 
Q2:  Are sentiment (positive and negative) and drug effect entities useful 
features in differentiating FDA watch list drugs and non-watch list 
drugs? 
1.1 Contribution of Work 
 The main contribution of this work is the exploration of Yahoo! public health 
message forums as a potential data source for adverse drug event mining and use in 
pharmacovigilance techniques.  Through this exploration I will develop protocol to test 
the feasibility of utilizing this source, which is then generalizable to other potential 
sources such as private message groups, blogs or other social media sources.    
Currently it has not been shown that machine learning techniques such as 
classification have been successfully used in predicting drugs correlated with adverse 
events or FDA watch list drugs.  This dissertation is also an exploration on the 
application of classification techniques to assess the ability to discern FDA watch list 
drugs from those that are not utilizing textual features. 
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2 Literature Review  
2.1 Adverse Drug Events 
Any drug or treatment option that causes a positive effect is also capable of 
producing an unwanted or adverse effect. These effects are far ranging from minimal 
(near zero) to high, such as in the case of immunosuppressive or highly toxic 
chemotherapy treatments. The World Health Organization (WHO) (1972) defines an 
adverse drug reaction as “a response to a drug that is noxious and unintended and occurs 
at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for 
modification of physiological function.”  However, this definition excludes error as a 
source of adverse effects and reactions due to contaminants or supposedly inactive 
excipients in a formulation.  Edwards and Aronson (2000) suggest that an adverse drug 
reaction is “an appreciably harmful or unpleasant reaction, resulting from an intervention 
related to the use of a medicinal product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the dosage 
regimen, or withdrawal of the product.” 
Though adverse events may occur when taking a drug it is hard to attribute 
causality that the drug caused the adverse event. If causality is established then the 
adverse event is an adverse reaction. A report about a possible adverse reaction is listed 
as an adverse event until causality is established. Edwards and Aronson (2000) describe 
differing types of adverse drug events such as dose-related, time-related, withdrawal and 
developed types of mnemonics to describe them. The table below is taken from that 
publication and succinctly describes the various types of drug reactions.  
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Table	  1:	  Table	  discussing	  various	  types	  of	  adverse	  drug	  events	  from	  Edwards	  
and	  Aronson	  (2000).	  
 
Currently within the United States the governing organization that oversees drug 
safety is the U.S. Food and Drug Administration (FDA). As part of programs for post-
marketing and safety surveillance the FDA has created computerized information 
databases, the Adverse Event Reporting System (AERS) and Vaccine Adverse Event 
Reporting System (VAERS).  
Both consumers – including patients and family members and health care 
professionals such as physicians, pharmacists and nurses may voluntarily report adverse 
events to AERS or to drug manufacturers. If a manufacturer receives an adverse event 
report, it is required to send the report to FDA as specified by government regulations. 
The reports in AERS are evaluated by the Center for Drug Evaluation and Research 
(CDER) and the Center for Biologics Evaluation and Research (CBER). Based upon 
these evaluations the FDA may take regulatory action such as updating a product’s 
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labeling information, restricting the use of the drug, communicating new safety 
information to the public, or, in rare cases, removing a product from the market.4 
VAERS is similar to AERS; however, it is specifically targeted at vaccines. It was 
created as an outgrowth of the National Childhood Vaccine Injury Act of 1986 (NCVIA) 
and is administered by the FDA and Centers for Disease Control and Prevention (CDC).5 
The goal of medical regulators such as the FDA is to make decisions based on the 
best evidence available with the aims of promoting and protecting public health (Waller, 
2001). Regulators are charged with the task of making prompt decisions such that delays 
of new medications with positive effects are minimized. The FDA and other governing 
bodies rely on clinical trials to demonstrate drug safety and efficacy. However such 
studies exclude certain types of patients and situations, for example, women and the 
elderly are often underrepresented in pre-marketing clinical trails leading to significant 
differences (as much as 63%) from drug studies to real world observations of 
effectiveness and safety (Martin et al., 2001).  
These factors highlight the need for post-marketing drug surveillance. This type 
of post-marketing surveillance falls within the realm of pharmacovigilance, “a principle 
concern of pharmacovigilance is the timely detection of adverse drug reactions that are 
novel by virtue of their clinical nature, severity, and/or frequency” (Hauben et al., 2005). 
The table below from Edwards and Aronson (2000) highlights different methods of post-
marketing surveillance indicating their advantages and disadvantages.  
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4  http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ 
AdverseDrugEffects/default.htm 
5 http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/ 
      VaccineAdverseEvents/Overview/default.htm 
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Table	   2:	   	   Various	   types	   of	   post	   marketing	   surveillance	   from	   Edwards	   and	  
Aronson	  (2000).	  
 
There is much interest in developing automated surveillance and 
pharmacovigilance techniques. Databases such as AERS and VAERS provide early 
warnings of possible safety problems that are difficult to detect during clinical drug 
development and trials due to power limitations, constricted range of demographics, 
exclusion of patients with extensive co-morbid illness and co-medications, and limited 
duration of follow up. However, while databases such as these provide information, they 
contain much 'noise' where reports are associated with treatment indications, co-morbid 
illness, protopathic bias, channeling bias, and/or other reporting bias (Hauben et al., 
2005). These present two challenges in utilizing this data: the necessity of waiting until 
enough data accumulates to differentiate a 'signal' from 'noise' and also developing data 
mining algorithms capable of differentiating 'signal' from 'noise'.  
Hauben et al. (2005) present an overview of key algorithms, databases used and 
their findings. The authors discuss common approaches including contingency tables and 
dis-proportionality measures, employing a statistical measure of “interestingness” 
comparing a drug's likelihood to cause an adverse event compared to other drugs. 
Regression modeling is also employed to address some of the shortcoming associated 
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with previous two methods, namely leading to false conclusions due to incorrectly 
modeling the underlying causal models generating the data. However, regression 
modeling fails to address dependencies between adverse effects and fails to take into 
account unmeasured or unrecorded measures and often requires assumptions that are not 
necessarily appropriate.  
Other studies have utilized information available to hospitals such as hospital 
discharge records, clinical notes, laboratory, pharmacy and administrative data. See Bates 
et al. (2003) for a review article on detecting adverse events using information 
technology for numerous studies. This dissertation suggests another source of data, online 
health forums which contain colloquial information through patient-patient and patient-
health care professional interactions. This is most similar to studies utilizing clinical 
notes or text of outpatient encounters like those in Hongiman et al. (2001). However, this 
study did not use natural language processing, instead it utilized simple keyword search 
yet still obtained encouraging results (Hongiman et al., 2001). While natural language 
processing has been utilized to a wide extent within the health domain it has been used 
within the context of electronic medical records or other clinical setting data (Bates et al., 
2003).  
2.2 Online Life 
The Internet has become increasingly pervasive in all aspects of people’s lives 
satisfying varieties of informational, communicative and entertainment needs (Cotton and 
Gupta, 2004).  It allows people to keep in touch and expand social networks; keep abreast 
of news; purchase goods and services; and search for product information and reviews 
(Pang and Lee, 2008)(Cotton and Gupta, 2004).   
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Social activities such as social media and networking sites have become an 
increasingly important part of people’s use of the web.  Social media consists of all forms 
of media including blogs, podcasts, video whose dissemination is through social means.  
The number of blogs has increased dramatically in the last decade (Gilbert, Bergstrom 
and Karahalios, 2009).  Similarly the number of people on social networking sites such as 
Facebook has increased as well; currently there is an estimated 750 million users on 
Facebook of which 50% log on each day.6  Social networking sites such as Facebook and 
online communities like those formed within CHFpatients.com allow people to maintain 
friendships and relationships formed in the physical world (Kendall, 1999).  However, 
such sites also allow people to find people like themselves in a variety of ways including 
but not limited to hobbies or interests, sexual orientation, religious affiliation, and chronic 
illness or disability (Kraut et al., 2002)(Warschauer, 2003).  Such sites allow people to 
cross traditional geographic boundaries enabling those with low mobility or rare illness to 
find others similar to them to interact with.   
Of the various ways people interact socially, this dissertation focuses primarily on 
online health forums or support groups in which people can communicate with one 
another within a group setting.  Various types of sites fulfill this requirement, for example 
a blog may provide a venue where others can comment to an initial post, however the 
overarching goal of a blog is to voice the opinion of the owner.  Social media and 
networking sites blend in various ways taking components of one another.   
The increase in popularity of such sites and the connectivity it creates between 
people has created an area of research on computer-supported social networks (CSSN).  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 http://www.facebook.com/press/info.php?statistics 
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Garton et al. (1997) consider a computer network that connects people or organizations a 
social network.  Research in CSSN shifts from individualism in social sciences towards 
structural analysis of the relationships between people looking for patterns explaining the 
behavior and attitudes of network members (Garton, Haythornthwaite and Wellman, 
1997).   
2.3 Support Groups for Chronic Illness 
 It is well understood that participation in support groups is an important 
component in the social support network for those with chronic illness; they ideally allow 
the fusion of ideas, answering practical questions while also allowing the exchange of 
common concerns and experiences (Silver, 2002).  Thus people no longer feel alone and 
helpless; support groups afford the opportunity to share feelings with people of similar 
diagnosis, and who therefore understand them in ways that others cannot.  In a study of 
patients with diabetes, it was indicated that support groups were as important as support 
from family or friends (Landis, 1996).   Silver (2002) considers family and friends a type 
of support group who help patients deal with numerous drug regimens, doctor 
appointments and dietary restrictions.   
Support groups help patients deal with the bitterness and anger often associated 
with chronic illness that often inhibits successful treatment of the illness.  Depression 
often goes hand in hand with chronic illness, nearly 40% of patients with heart failure in 
the US have depression and even in the Chinese medical literature, one of the symptoms 
of heart failure is depression (Silver, 2002).    
Physical and face-to-face interactions provide additional cues such as pausing, 
intonation and facial expression that are not available in purely text-based forums (Walter 
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and D’Addario, 2001).  Human contact – touch, also lacks in these encounters.  The 
impact of a touch in the form of hugs for example, correlates positively in the treatment 
of fibromyalgia, autism, and general health; touching helps to reduce stress and pain, 
leading to improvements in the ability to cope and in overall general health 
measurements (Denison, 2004)(Grandin, 1992)(Weze et al., 2005). 
2.4 Online Support Groups 
 Online support groups are gaining traction and are seen as a way to augment 
existing social support networks and in some cases possibly supplant them (Houston, 
Cooper and Ford, 2002).  Work looking at the role of online support groups spans a 
variety of chronic illnesses from depression to cancer (Houston, Cooper and Ford, 
2002)(Eysenbach et al., 2004).   Online support groups are similar in many ways to 
traditional support groups and provide avenues for people to meet others that have similar 
conditions, learning from their experiences as well as socializing them to their illness and 
providing information and support (Mittem and Cain, 2001)(Lieberman and Goldstein, 
2006).   
Pennebaker (1997) demonstrates the positive effects – reduction of stress and 
promotion of physical and mental well-being-of writing about traumatic experiences.  
Talking and writing about emotional experiences provide comparable biological, mood, 
and cognitive effects such as t-helper cell growth, antibody response to Epstein-Barr 
virus and to hepatitis B vaccinations, various short term changes in autonomic activity 
such as lowered heart rate and electro-dermal activity.  Further studies show that 
communicating and sharing experiences with peers reduces depression, stress, emotional 
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distress and feelings of social isolation (Gustafason et al., 2001)(Lindsay et al., 
2007)(Winzelberg et al., 2003).   
2.5 Privacy 
It is well understood that health is an extremely private and personal part of one's 
life.  The US government has created provisions for privacy regarding health information 
within the Health Insurance Portability and Accountability Act (HIPAA) of 1996 
(P.L.104-191).  The HIPAA Privacy Rule regulates the use and disclosure of Protected 
Health Information (PHI) held by “covered entities” such as health insurance companies 
or medical service providers when engaging in certain types of transactions (Terry, 
2009).  PHI consists of personally identifiably information held by a covered entity 
concerning health status, payment for healthcare or provision of healthcare (45 C.F.R. 
164.501).   
HIPAA regulations are currently being augmented through Subtitle D of the 
Health Information Technology for Economic and Clinical Health Act (HITECH Act), 
enacted as part of the American Recovery and Reinvestment Act of 2009.  The HITECH 
Act aims to addresses the privacy and security concerns associated with the electronic 
transmission of health information. It extends the policies for disclosure requirements to 
information that is used to carry out treatment, payment and health care operations when 
an organization is using an electronic health record (EHR).  Along with this new policy 
covering disclosure requirements are extensions of HIPPA privacy provisions to business 
associates of covered entities and notification requirements if a breach of unsecured PHI 
occurs.  
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However, while there are privacy safeguards concerning EHRs there is no 
legislation involving privacy or use of patient volunteered health information on health 
message boards, forums or websites such as webmd.com or mayoclinic.com.  In a study 
of 1,009 US adults released in January 2000 by the California HealthCare Foundation and 
the Internet Healthcare Coalition, it was found that: 
 75% of people are concerned about health web sites sharing information without 
their permission. 
 40% would not allow physicians online access to their medical records. 
 25% would not buy or refill prescriptions online.  
 17% of people don't go online to seek health information due to concerns over 
privacy. 
 A significant percentage of people would not engage in certain health related 
activities due to concerns over privacy and security. 
 16% of people would not register on websites. 
Internet security and privacy regarding health information is significant.  While a 
patient volunteers this information there are key differences in the information provided 
by a patient regarding health and other types of information on similar message boards or 
websites.  Some types of data are more sensitive than others; a study of attitudes toward 
online information practices found that while 82% of respondents were comfortable 
providing information of their favorite television show about themselves and 52% for a 
child, only 18% were comfortable providing medical information about themselves and 
4% for a child (Cranor, Reagle, and Ackerman, 1999).   
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Previous studies have focused on the privacy policy of health sites themselves, 
scrutinizing them for compliance, readability, and protecting visitors’ privacy (Goldman, 
Hudson and Smith, 2000).  However, few studies consider how the personal health 
information is utilized on the site, and if it changes, how and what information people are 
willing to disclose.  How information is used also dictates people's willingness to share 
information. Internet users are more likely to provide information if they remain 
anonymous and if people understand the purpose for which the information is being 
collected and used (Cranor, Reagle and Ackerman, 1999).   
 While this dissertation does not elicit information directly, it depends on patient 
volunteered information from online sources such as message boards and websites.  As 
such, exploring the mechanisms for sharing information and understanding people’s 
aversions to contributing information is important future work to enable the induction of 
as much information as possible.   
2.6 Crowdsourcing and Collective Intelligence 
 Crowdsourcing is a term coined by Jeff Howe in 2006 describing the use of the 
distributed labor networks – akin to “outsourcing” instead of sending jobs to other places 
or countries, using populations of laborers found online due to the diminishing gap 
between professionals and amateurs.  One example, Mechanical Turk, Amazon’s online 
marketplace allows people to outsource work, often very small tasks for small amounts of 
money. Examples might include labeling pictures, giving feedback on short videos or 
evaluating real and hypothetical products7.  These tasks are considered human 
intelligence tasks, tasks that humans are good at where computers often falter.    
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 https://www.mturk.com/mturk/welcome 
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Crowdsourcing enables the participation of many people for short amounts of 
time with relatively little recruitment or administrative effort and cost.  However such 
systems including Mechanical Turk, have drawbacks as Downs et al. (2010) highlight, 
the anonymity and lack of accountability – one of the draws of such systems attract 
people to game the system by participating in many tasks without fully engaging in them.  
However, Crowdsourcing has been successfully used in academic situations such as 
evaluating information retrieval results.  There have also been many positive examples of 
Crowdsourcing with larger payouts and accountability, such as InnoCentive8, where 
payouts from companies such as Colgate-Palmolive have reached between $10,000 and 
$100,000 for innovative ideas for challenging problems.   
We can pose the pharmacovigilance task as a crowdsourcing task with caveats.  
Within this paradigm, there is currently no financial incentive for individuals and instead 
compensations are derived through social engagement or individual feelings of 
accomplishment.  Secondly, the input is not directly usable and in our case requires 
natural language processing work to extract useful information.   
In many ways the pharmacovigilance task as posed is similar to collective 
intelligence or information cascades.  Surowiecki (2004) explored the idea that the 
aggregation of information from groups results in decisions that are often better than 
those that could be made by a single member of the group.  This differs slightly from 
information cascades where people follow the actions of others, making similar choices.  
People rely on the choices others have made, making a rational decision based upon 
limited information (Easley and Kleinberg, 2010).  One such example of an information 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8 http://www2.innocentive.com/ 
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cascade is deciding on a restaurant based on the number of people already eating there.  
Cascades can be wrong or derived from little information and cause short-lived spikes 
such as fads, fashion trends, or runs on banks.   
One can imagine people basing drug decisions based on information cascade 
effects, doing what their group of peers does.  Similarly people within a group can come 
to a consensus of the safety of a drug and that notion, wrong or not, can stick or spread 
within online health communities.  It is worthwhile to look at such trends and sources of 
information about drug safety within online health forums.   
2.7 Research Tools and Methodologies 
2.7.1 Language Analysis 
The words people use correlate with their physical and mental health (Pennebaker 
and Campbell, 2000).  Content analysis introduced in the 1960’s detects a person’s 
affective or immediate feeling state based solely on variations in the content of verbal 
communications (Gottschalk and Gleser, 1969).  This technique utilized human 
interpretation and coding of transcripts of people who were interviewed.  The same 
technique was used in the late 1970’s to differentiate schizophrenics from non-
schizophrenics (Rosenberg and Tucker, 1979).  However, Rosenberg and Tucker’s 
(1979) work utilized computational analysis of transcripts between patients and doctors.  
Later work focused on written text, finding variations in language usage between 
depressed and depression-vulnerable students (Rude, Gortner and Pennebaker, 2004).  In 
the Rude et al. experiment, essays were written by college students, then analyzed 
computationally removing the interviewer from the process.   
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Words are not the only elements of analysis that provide necessary emotional 
insights.  Face to face communication has many elements providing backchannel 
communication to speakers including intonation, pauses, or body language.  Sarcasm is 
often indicated by a different intonation that is not easily conveyed in written language, 
for instance, “you look great” can be interpreted in multiple ways but unless there is 
context or backchannel cues it is difficult to understand what the writer meant.  People 
have augmented computer-mediated communication to provide the same richness of face-
to-face interactions through the use of nonverbal elements (Walter and D’Addario, 2001).  
Emoticons are nonverbal expressions and are often textual representations of writer’s 
facial expressions (Gajadhar and Green, 2005).  For example :) or :-) would correspond to 
a smile indicating happiness.  These cues indicate to the reader the author’s intentions 
that can be hard to determine in informal written communication.  Other backchannel 
cues include spacing within instant messaging to indicate pauses like those in normal 
conversation. 
Chung and Pennebaker (2005) discuss the possibility of assessing people’s quality 
of life through computerized analysis of their responses to open ended questions.    They 
look at function words such as positive/negative emotion words, negations (not, nor, 
never), prepositions, articles, first person singular pronouns (I, me, my), and other 
pronouns (she, they we) to determine how these correlated with the Satisfaction with Life 
Scale.  The way people speak reliably related to depression, self-esteem, feelings of 
isolation and togetherness, self- and other-deception, cognitive complexity and hormone 
levels.  Most importantly they suggest that much information about a person’s 
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satisfaction with life lies in analyzing the way people talk about their lives and not only 
what they say.  
2.7.2 Sentiment Analysis and Opinion Mining  
 Looking at what a person says can inform others on what they think.  Determining 
what other people think is an important task in information gathering behavior (Pang and 
Lee, 2008).  This can be evidenced by the large number of product review sites online or 
the feedback found on shopping websites such as Amazon.com. The Internet enables the 
discovery of opinions and experiences of all different types of people from professional 
critics to grandmothers.  This information is used with increasingly frequency for many 
products; in two separate studies of more than 2,000 American adults the following was 
found (Pang and Lee, 2008): 
• 81% of Internet users (or 60% of Americans) have done online research on a 
product at least once. 
• 20% (15% of all Americans) do so on a typical day.  
• Among readers of online reviews of restaurants, hotels, and various services 
(e.g., travel agencies or doctors), between 73% and 87% report that reviews 
had a significant influence on their purchase.   
• 32% have provided a rating on a product, service, or person via an online ratings 
system, and 30% (including 18% of online senior citizens) have posted an 
online comment or review regarding a product or service. 
 Sentiment analysis involves performing some or all of the following processes on 
text: analyzing, extracting, aggregating and representing information.  This information is 
subjective in nature as it is derived from opinion.  Since opinions are subjective, opinion 
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mining is inherently difficult.  If humans cannot agree on a sentiment score reliably it is 
even more difficult for machines to learn to score text accurately.  In fact, machine 
learning based methods of sentiment classification do not perform as well as machine 
learning topic-based binary classification ones (Pang, Lee, and Vaithyanathan, 2002).   
There are multiple methods of assigning sentiment scores to a given piece of text; often 
these are in the form of machine learning based methods employing classifiers utilizing 
word features, ngrams (multiple words or phrases), part of speech information, and 
syntax, to classify a piece of text as positive or negative (Pang and Lee, 2008).  However, 
this list glosses over the discussion of level of specificity; sometimes merely labeling a 
piece of text as positive, neutral or negative is not enough and there needs to be degrees 
of positivity or negativity.  There is also the problem of document segmentation; 
documents are composed of multiple ideas with multiple degrees of sentiment applying to 
some or all of those ideas; attributing sentiment to a particular idea or salient thought is 
difficult.  The reader is directed to Pang and Lee, (2008) for an in-depth discussion of 
many of these ideas.    
 Sentiment analysis tools are highly domain dependent like many other NLP tools, 
as the language people use to express emotion differs between domains; for example in 
the area of movies, unexpected is often thought of as a positive trait, whereas in 
describing the handling of a car it is often considered a negative feature (Turney, 2002). 
While sentiment is often used to aggregate product reviews on the web, there is a 
multitude of non-product evaluation centric based uses of it with regard to applications in 
the medical domain as previously discussed in the language analysis section.   As 
discussed previously many such uses of sentiment and language analysis within the 
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context of medicine is determining mental state and cognitive models.  However, this 
dissertation envisions applying sentiment directly to treatment outcomes and evaluation 
of them.  One technique used to measure the effectiveness of a drug is quantifying the 
side effects that it produces. Sentiment analysis is another way in which we can 
determine drug satisfaction. A drug may have many serious side effects, yet people may 
still have a positive attitude towards it, especially if they believe it helps them in some 
way (Silver, 2002).  
On the surface, it appears that sentiment containing words are domain agnostic for 
words like good, happy, and sad.   However, if one looks deeper into sentiment, one can 
see many non-obvious words refer to someone’s emotional alignment.  For example, if 
someone mentions an actor’s name whom you detest, your reaction could be very 
negative; for you this is a negative sentiment containing term.  Similarly explosions in 
general could be negative sentiment words but for an action movie aficionado this could 
be a positive sentiment term.  In this way, if training examples for both the domain as 
well as population one is trying to track, better performance often results.  A common 
method employs Bayes rule to calculate the sentiment of individual words if a training 
corpus exists where P(word | positive or negative class).  Here we calculate the 
probability of a word given a class – positive or negative sentiment. 
However, in cases where little domain knowledge or training data is available, 
sentiment words that are predominately positive or negative will still provide useful 
information.   These words are often found in existing hand crafted lexical resources such 
as Linguistic Inquiry Word Count (LIWC) or SentiWordNet, which ascribe a score to 
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particular words.  These scores incorporate world knowledge as well as corpus statistics 
to weight the prevalence of a particular sentiment containing word.  
One could use the LIWC scores or SentiWordNet scores (or even the Bayes 
probabilities) to label a piece of text as predominately positive or negative.  All that is 
needed is a scoring metric and a decision rule.  If one has probabilities, if one assumes 
word independence then the probabilities of the words are multiplied and the most likely 
class is assumed given the data (Naïve Bayes classification).  Arbitrary scoring metrics 
are more heuristic in nature but often work in practice.  Whereas Naïve Bayesian 
classification has strong mathematical foundations, it does not accurately reflect real 
world data (the independence between word probabilities) however, it also works in 
practice. 
Other approaches are also employed such as Support Vector Machines (SVM) 
where individual word scores are not necessarily employed but a non-linear mapping of 
features (words) is used.  Conditional Random Fields (CRF) could also be employed 
which take into account the idea that word ordering matters instead of more traditional 
bag of word (BOW) approaches where ordering is ignored.  SVMs and CRFs may leave 
users wondering how a particular classification choice was arrived at due to the 
opaqueness of the algorithms, whereas if individual words are labeled with scores it is 
relatively easy to determine how a particular class label was arrived at.   
Regardless of the method used to determine the polarity of individual words or 
pieces of text, language evolves and word meanings shift over time.  This is apparent 
even within sentiment containing words.  The meaning of “bad” which is a strong 
sentient containing word associated negatively, can and does mean “good” or have a 
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positive connotation depending on the domain as well as the time period.   Such polar 
opposites are likely few and far between but do occur.  I believe that they are also less 
likely to occur with “obvious” or traditional sentiment words like good, hate, death, etc.  
Thus in the same way traditional sentiment words are more stable over time and are less 
likely to change or drift than other domain specific sentiment terms.   
2.7.3 Named Entity Recognition 
 Named entity recognition (NER) is the area of natural language processing and 
information extraction that deals with the identification of specific entity types or 
information units commonly including names of people, locations, organizations, and 
numeric expressions including time, date, money and percent expressions (Nadeau and 
Sekine, 2007).  As Nadeau and Sekine (2007) point out that named entity recognition is a 
task often restricted to entities with one or many rigid designators such as proper names, 
biological species and substances.  However, they point out that this designation has been 
relaxed to include numerical expressions such as dates or months such as June since the 
month itself does not refer to a specific date.   
This dissertation similarly relaxes the constraint on named entities and refers to 
useful information units such as drug names and noun phrase outcome caused by drug 
like side effects. Earlier work by Rindfleisch, Tanabe and Weinstein (2000) identified 
drugs and relations from biomedical literature in Medline.  We extend the idea of drug 
identification to also include the identification of effects from drugs from colloquial 
literature.  Effects include but are not limited to harmful side effects such as headaches or 
vomiting.   
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Many NER techniques focus on the identification of information units from 
unstructured text, the text is generally formal, edited for grammatical and spelling 
correctness as in the case of news wire or biomedical text (Nadeau and Sekine, 2007).  
The use of text available on the web is appealing due to the vast quantities and ease of 
obtaining it.  Previous NLP tasks have utilized web data for tasks in machine translation, 
prepositional phrase attachment, NER, and other-anaphora resolution (Brin, 1998)(Liu 
and Curran, 2006).  However in a comparison of a billion tokens from newswire text to 
general web text there were significant differences in types of tokens.  Web data contains 
significantly larger numbers of misspellings and typographical errors and much fewer 
cases of title case – tokens that start with an uppercase letter followed by lowercase 
letters like “London”  (Liu and Curran, 2006).     
Identification of named entities within corrected text is easier than general web 
data due to consistent capitalization and spelling for proper nouns; grammatically correct 
sentence constructions enabling other supporting NLP tools such as sentence boundary 
identifiers, part of speech taggers, or syntactic parsers with increased accuracy since tools 
utilizing machine learning are often trained on similarly corrected text.  
However, Brin’s (1998) work focused on utilizing lexical features with regular 
expressions to identify book titles and authors from web data.   Later work by Etzioni et 
al. (2005) focused on general named entity identification from web data.  Brin’s (1998) 
work still relies on book titles and author names to follow capitalization conventions 
across websites, whereas Etzioni et al. (2005) rely on web scale data to provide many 
examples to learn from.  The Yahoo dataset often is composed of such web quality data 
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but also includes SPAM messages aimed specifically at confounding traditional natural 
language processing techniques to avoid detection.   
Many techniques are utilized for NER, often hard coded heuristics employing 
patterns such as “city of X” to identify cities, for example “city of London”; dates in the 
form of MM-DD-YYYY; or dictionaries for non ambiguous terms like locations or 
biological names.  Machine learning, both supervised and unsupervised methods are also 
employed utilizing a variety of lexical (X is a city), morphological (“ist” endings as in 
journalist or cyclist), honorifics (Mr. or Dr. before name), capitalization, or part of speech 
(noun or proper noun) features (Nadeau and Sekine, 2007).   
2.7.4 Relationship Extraction 
Hearst (1992) suggested a method for automatic acquisition of the hypononymy 
lexical relation from free text.  The goal of this work was to avoid the need for pre-
encoded knowledge and apply to a wide variety of text.  In the work several examples of 
lexico-syntactic patterns for identifying and extracting hyponyms from free text are 
presented.  These patterns are in the form:  
NP such as {NP, NP, …, (and | or} NP   
such NP as {NP, }* {(or | and)} NP 
NP {,} especially {NP, }* {or | and} NP 
Here NP indicates a noun phrase and italicized words are lexical markers used to identify 
the pattern.  An example might include, “the bow lute, such as the Bambara ndang, is 
plucked and has an individual curved neck for each string,” here the pattern “NP such as 
NP” extracted is illustrated in italics  (Hearst, 1992).  Later work built upon these hand 
crafted patterns for hyponym extraction utilizing machine learning techniques to learn 
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and induce new patterns via the extracted examples from the original patterns (Riloff, 
1996)(Etzioni et al., 2004).   
Inducing new lexico-syntactic patterns automatically resembles the wrapper 
induction problem in the area of information extraction.   The task of automatic wrapper 
induction for information extraction involves building systems that learn patterns to 
extract salient facts from sources providing human-centered interfaces, i.e. web portals 
(Kushmerick et al., 1997).  An example of information extracted utilizing wrappers 
includes extracting name, telephone number pairs from online telephone books or movie 
name, rating, location and time tuples from a movie site.  Whereas lexico-syntactic 
patterns rely only on linguistic features, wrapper induction relies both linguistic and other 
cues such as html or xml tags surrounding text, or placement on a page.   
This work is also related to discourse analysis, specifically the area of speech acts 
involving identification of dialogue acts. Dialogue tags like continuers, assessments, yes-
answers, agreements, incipient-speakership, or acknowledgement tokens are attributed to 
surface level communicative acts in a dialogue or conversation.  Much work in the area 
of dialogue acts involves the classification of act types previously mentioned (Jurafsky et 
al., 1998).  This work focuses on identifying particular types of dialogue acts such as 
statements and opinions with regard to particular subjects (treatments) and intent 
(recommendation).     
2.7.5 Classification 
Classification is a supervised learning task within the area of Machine learning. 
Its goal is to utilize hand labeled instances (in a binary case positive or negative 
instances) to train a machine learning classifier to classify or categorize previously 
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unseen instances as a particular class. Classification is a common task within natural 
language processing (NLP). Machine-learning tasks within NLP fall into two categories: 
unsupervised – clustering, or supervised, classification tasks. Clustering involves 
grouping items based upon features that automatically represent them. Classification 
tasks include part of speech tagging (POS) that labels a word within a sentence with a 
part of speech such as noun, verb, preposition; named entity recognition (NER) assigning 
word(s) to a particular entity class such as person, location, or date; sentiment analysis 
attributing a score to a segment of text based upon how positive or negative the perceived 
effect of the text is; or assigning portions of text as particular classes such as SPAM or 
not. This dissertation looks particularly at NER, sentiment analysis, and assigning class 
labels to portions of text commonly referred to as text classification. 
Many classification algorithms exist; however of these, two are popular for text 
classification applications. This dissertation focuses on these two, Naïve Bayes and 
Support Vector Machines (SVM). Naïve Bayesian classifiers are widely used in machine 
learning NLP approaches due to their efficiency and ability to combine evidence from 
large numbers of features; however, these classifiers make certain assumptions – ignoring 
structure and linear ordering inherent in text taking the “bag of words” approach and 
assuming that words are independent of each other – one intuitively expects the 
likelihood of “president” to be greater given the observation “Obama” (Manning and 
Schutze, 1999). Bayesian statistics are also widely used within the field of 
pharmacovigilance adding support for this method within the area of ADE detection.  
SVMs work by non-linearly mapping input (feature) vectors into a high-
dimensional feature space using a kernel function (Cortes and Vapnik, 1995). In this 
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space a linear decision surface (hyperplane utilizing n-1 features) is constructed that 
maximizes a margin between classes within the higher dimensionality space. Unseen or 
new instances are mapped into the high dimensional space and classified based upon the 
side of the hyperplane they fall. Forman (2003) found empirically that SVM was the best 
performing algorithm in a corpus of 229 text classification problems. Joachims (1998) 
indicates that text classification is an ideal candidate for SVM due to the fact that text 
categorization problems are linearly separable; text contains few irrelevant features – all 
words are important; and that text results in sparse input features - not all words occur in 
every document.  
Whatever type of classifier used, feature reduction is usually an important step to 
reduce the computational time and memory resources needed to train a classifier as well 
as label unseen instances. Forman (2003) advises that in order to reduce the size of a 
dataset “without adversely impacting classification performance to set word cutoff rates 
low (in their experiment words occurring less than 3 times within the dataset were 
removed) and perform aggressive feature selection using a metric with linear running 
time if recall is the sole goal,” then more low frequency words should be eliminated.  
Feature selection utilizes metrics to rate and rank features by their importance in 
making a classification decision. Forman (2003) found that Bi-Normal Separation (BNS) 
outperformed other methods by a substantial margin in most situations and is the top 
single choice except where the goal is to maximize precision where Information Gain 
(IG) yielded the best results. IG also proved the best results when the number of features 
was reduced drastically in situations of 20-50 features. IG measures the decrease when a 
feature exists versus when absent. BNS is a features selection metric developed by 
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Forman(2003). It is defined as F-1(tpr) – F-1(fpr), where F-1 is the standard Normal 
distribution's inverse cumulative probability function, tpr sample true positive rate, fpr is 
the sample false positive rate, and 0.00005 when tpr or fpr = 0. BNS worked best when 
using between 500 and 1000 features, previous works showed little effect of more than 
2000 features (Forman, 2003). 
2.7.5.1 Support Vector Machines 
Support Vector Machines (SVM) are well founded in terms of computational 
learning theory and have demonstrated empirical performance in the area of text 
categorization.  SVMs can deal with high dimensional feature space and sparse feature 
vectors often found when dealing with text classification.  
For the SVM experiments LibSVM is utilized with a radial basis function (RBF) 
kernel which is non-linear in nature.  Though linear kernels have a faster running time 
than RBF kernels and the effectiveness of linear kernels with regard to text classification 
are quite good (Joachims, 1999), some added nonlinearities help obtain finer 
improvements in accuracy which the RBF kernel can provide (Keerthi and Lin, 2003).  
Furthermore in certain cases the RBF kernel behaves like a linear kernel SVM.  While 
kernel selection is one parameter when dealing SVMs it is not the only one.  A RBF 
kernel requires two further parameters C and γ, which are not known apriori.   
Given a training set of instance-label pairs (xi , yi ), i=1,…, l where xi ∈Rn and 
y∈{1, -1}l, the SVM requires the solution of the following optimization problem: 
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Equation	  1:	  The	   series	   of	   equations	  whose	   solution	   is	   the	   linear	  hyperplane	  
with	  the	  maximal	  margin	  in	  a	  higher	  dimensional	  space.	  
 
 
 
Training vectors xi are mapped into a higher dimensional space by the function φ. SVM 
finds a linear separating hyperplane with the maximal margin in the higher dimensional 
space. Where C > 0 is the penalty parameter of the error term.  Furthermore, K(xi , xj ) ≡ 
φ(xi )T φ(xj) from the above equation, in the case of the RBF kernel K(xi , xj ) = exp(−γ 
||xi − xj||2 ), γ > 0. 
 A grid search method utilizing cross-validation is employed to look for 
appropriate values of C and γ due to the relatively few numbers of instances, all of them 
are utilized to find the best combinations of C and γ.  While this is somewhat of a brute 
force approach it is effective and trivial to parallelize since each combination of C and γ 
is independent of other runs.   
2.7.5.2 Naïve Bayesian Classifier 
Naïve Bayesian (NB) classifiers are a probabilistic classifier based on applying 
Bayes’ theorem with independence assumptions (naïve) between features.  The 
assumption is that the presence or absence of features is independent of other features.  
This assumption is not true in real life, for example given the word “wine” it is clear that 
the likelihood of seeing “red” or “white” is greater than other colors like “yellow” or 
“purple”.  Though it is easy to see that this assumption is not true in real life, in practice 
this assumption can still lead to optimal decisions even if probability estimates are 
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inaccurate due to feature dependence (Manning, 1999).  A side effect of this model is 
faster running times due to lower computational complexity.  In the simplest form of NB 
classifiers there are no parameters to tweak and performance is relatively good.  Due to 
the lack of parameters that need tuning and many successful applications for text 
classification, for example in the area of SPAM detection (Sahami et al., 1998), NB 
classifiers make sense as a first step when using statistical modeling for classification.  
The occurrence of terms is used to generate a probability distribution from which 
the likelihood of an instance is calculated based upon the combinations of terms in the 
instance.  The use of word-grams helps to alleviate some of the independence problems 
associated with NB classifiers.  Looking at the classification problem presented we can 
classify drugs based upon the way people talk about them. 
Given a set of word-grams w in the aggregate messages mentioning a particular 
drug, the probability that the i-th word occurs from class C (the classes are watchlist or 
non-watchlist drug) is written as p(wi|C).  Then the probability of a given drug D given a 
class C is p(D|C) = ∏ p(wi|C).  Because we have a binary class watchlist or not we can 
denote the class as W or ¬W then the probability of p(D|W) = ∏ p(wi|W). Due to Bayes’ 
rule this can be written as p(W|D) = p(W)/P(D) ∏ p(wi|W) and p(¬W|D) = p(¬W)/P(D) ∏ 
p(wi|¬W).  In this way we build two probability models.  These two probability models 
combined with a decision rule builds a classifier, we utilize maximum a posteriori (MAP) 
decision rule, which picks the most likely hypothesis.   
2.8 Evaluation Metrics 	   This dissertation focuses on building classification models, and mapping instances 
of drugs into two classes/groups-in this case “watchlist drugs or non-watchlist drugs”.  
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Because there are two classes the classification is binary in nature and we treat watchlist 
drugs as positive examples and non-watchlist drugs as negative ones.   The prediction of 
instances based on these models results in labeling input instances as positive or negative.  
If the prediction is positive and it is a watchlist drug then this is a true positive; however, 
if it is a non-watchlist drug then it is a false positive.  Similarly, if the prediction is 
negative and it is a non-watchlist drug then the result is a true negative and it is a false 
negative if the instance is a watchlist drug.   True positives, true negatives, false positives 
and false negatives are the basis for many evaluation criterions. 
Table	  3:	  Table	  depicting	  the	  confusion	  matrix	  of	  classification	  outcomes.	  
Actual Value 
 p n total 
p’ True Positive False Positive P’ 
n’ False Negative 
True 
Negative N’ 
Prediction 
Outcome 
Total P N P 	  
For the experiments I perform, separate training and test data sets are derived 
from the pool of instances mentioned above.  Within the separate training data, instances 
are withheld when training the model and the same data to train was not utilized to 
generate the results.  These instances, though not used to build the final model are 
utilized for searching the parameter space for model building, and can lead to over-
fitting.   
When building machine learning classifiers it is assumed that an end state is 
reached where the classifier is able to predict the correct class for examples not presented 
during training due to inductive bias.  However, over-fitting occurs when learning was 
performed too long over the instances, for example when searching for optimal 
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parameters in building models and there are few training examples, which is also the case 
for our data.  The models are biased towards specific random features that have no causal 
relation to expected outcome. 
After the parameter space (for SVMs) is searched and a final model is built the 
model is tested against the previously unseen testing data.  Here we can derive separate 
scores for the withheld portion of training data and for the completely unseen testing 
data.   
Given a 90/10 split where 90% of instances are one class and 10% are another, it 
is difficult to outperform a naïve classifier that marks all drugs as non-watchlist will 
achieve an accuracy rate of 90% if we compare the total number of positives (watchlist 
drugs) versus negative (non-watchlist) examples.   While the accuracy ([True Positives + 
True Negatives]/[Positives + Negatives)]) rate appears high this is problematic due to the 
fact that the classifier will never find any watchlist drugs, thereby defeating the purpose 
of classification and predicting watchlist drugs.  The number of true positives of a 
classifier is zero and the associated true positive rate, the number of true positives divided 
by the number of classified positives, is undefined.    
The assumptions built into many machine learning classifiers is that the goal is to 
maximize accuracy and that the classifier will operate on data from the same distribution 
as the training data.  If 90% of instances are of one class, the learning algorithm will be 
hard pressed to perform better than selecting the majority class.  Looking at the data, this 
is the logical thing to do.  However, this idea of merely labeling instances the same as the 
majority class leads to problems as discussed previously.  Similarly it is logical to assume 
that real-world data will behave similarly to the test data insofar as the training data is 
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real-world data.  Generally one relies on past behavior and experience to predict future 
behavior but this is not always accurate.  However, accuracy is intuitive and it is easy to 
determine how accuracy scores changes based on an additional incorrectly classified 
example. 
 There are other methods of model evaluation besides accuracy.  Receiver 
operating characteristic (ROC) curves and the area under the ROC curve (AUC) have 
been employed previously to evaluation machine learning classification models and are 
employed in the evaluation of models in this dissertation.  Receiver operating 
characteristic (ROC) curve and the associated area under the curve (AUC) are graphical 
plots and numerical measures, respectively.  These metrics help to differentiate between 
and select optimal models.  ROC curves have been used in the analysis of signal 
detection such as radar signals, evaluation of diagnostic tests, evaluation of radiology 
techniques, and in epidemiology and medical research (Green and Swets, 1966)(Zweig 
and Campbell, 1993)(Pepe, 2003).   
 ROC curves are plotted over the true positive and false positive rates lying within 
the space (0,0) to (1,1).  It is the plot of sensitivity, the fraction of true positives on the y-
axis versus the fraction of false positives or (1-specificity) on the x-axis.  Here the True 
Positive Rate (TPR)  = True Positives / Positives and the False Positive Rate (FPR) = 
False Positives / Negatives.  The point (0,1) is considered perfect classification and the 
line from (0,0) to (0,1) is the line of no discrimination.   
AUC is equal to the probability that a classifier will rank a positive instance 
higher than a negative one (Fawcett, 2006).  AUC summarizes the ROC curve into a 
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single number.  However, in doing so information about tradeoffs utilizing a particular 
model is lost.  Yet it provides a convenient way to easily compare various models.   
2.9 Health Related Quality of Life 
 Growing numbers of health measures include social and emotional aspects of 
health; these are generally considered quality of life measures, though there is no clear 
distinction between them and other general health status measures.  Interest in quality of 
life is stimulated by the idea that merely surviving is not enough.  Health based quality of 
life indicators were originally derived from those in the social sciences, focusing on 
people's feeling about their circumstances; many resemble indexes of emotion well-being 
and life satisfaction (McDowell, 2006).   
The Centers for Disease Control (CDC) believes that health-related quality of life 
(HRQOL) is important in the measurement of effects of chronic illness on patients’ lives. 
It is used with increasing frequency within the US as well as abroad.  HRQOL is 
important in tracking patient’s perceived physical and mental health over time and 
tracking the effects of multiple diseases and disabilities within patient populations.  It is 
also important to weigh the advantages versus adverse effects of treatment of serious 
chronic illness (deHaes and van Knippenberg, 1985).   The U.S. Food and Drug 
Administration recognized this and included quality of life as a primary criteria in the 
approval of anti-cancer therapies (Johnson and Temple, 1985).  
HRQOL is a broad construct consisting of both objective and subjective measures 
(Chung and Pennebaker, 2005).   Currently many self-reported metrics are used 
including: The Arthritis Impact Measurement Scales, The Physical and Mental 
Impairment-of-Function Evaluation, The Functional Assessment Inventory, The 
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Functional Living Index – Cancer, The Functional Assessment of Cancer Therapy, The 
EORTC Quality of Life Questionnaire (European Organization for Research and 
Treatment of Cancer), The Quality-Adjusted Time Without Symptoms and Toxicity 
Method, The COOP Charts for Primary Care Practices, The Functional Status 
Questionnaire, The Duke Health Profile, The Older Americans Resources and Services 
Multidimensional Functional Assessment Questionnaire, and The World Health 
Organization Quality of Life Scale (McDowell, 2006).    
 While many different HRQOL metrics exist and the appeal of quality of life is 
intuitive, the term still remains relatively undefined, which seems to more often reflect 
the personal values or academic orientation of the research rather than an objective 
attempt to define the concept (McDowell, 2006).   Since most measures are self reported, 
the subjectivity is influenced by factors such as gender, age, social class, and culture; it 
becomes increasingly difficult to draw comparisons between different people’s HRQOL 
rating (Stennar, Cooper, and Skevington, 1993).  Jia et al. (2007) also notice differences 
between groups with differing sociodemographic variables and clinical factors; however, 
these differences were attributed to population health and not individuals.  This work also 
enabled the comparison of two HRQOL metrics, which initially seem quite different but 
show similar patterns of population health (Jia et al., 2007); it is still unclear, however, if 
individuals would rank similarly on differing scales.  Part of the problem stems from the 
endemic problem of how to measure health; measurements are influenced by the way we 
define and think about health (McDowell, 2006).  What does the concept of health 
include and how does it relate to the quality of life and our well-being? 
	  
 
 42	  
 In this chapter we have discussed the foundational topics necessary to frame this 
dissertation.  It is necessary to talk about pharmacovigilance – the study of drugs once 
released to market because this dissertation hopes to explore a new source of data and 
techniques for this field.  However, one is not able to discuss drugs in relation to health 
without also discussing quality of life and the subjectivity which people rate it and rate 
drugs they take.    These drugs or other treatments are talked about emotionally, and 
sentiment analysis enables us to quantitatively analyze the qualitative or descriptive 
review of drugs and treatments by people.  Machine learning enables one to look for 
patterns in these qualitative reviews and compare them to other drugs.     
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3 Description of Data	  
 This chapter describes the data this dissertation will utilize.  Its goal is to inform 
the decision making process of choosing language processing tools and techniques.  
While this data is publically available it is realized that health data is extremely personal 
in nature.  It is possible to personally identify people, from their messages, especially for 
rare and serious conditions where people have included information on gender, age or 
geographic locale.  However, people choose to share as much or little information as they 
want with the understanding that the more they share the greater the potential for others 
to help them or for their information to help others.  Companies such as PatientsLikeMe 
have built businesses around this model of open health sharing.  The data utilized within 
this dissertation is used in aggregate with no particular person’s messages analyzed in 
more detail than others.  No attempt is made to identify the party, or linking messages 
with a profile or email address.   
This chapter aims to look at the tokens within messages utilizing automated 
approaches to decrease the manual annotation time as well as bias and error 
accompanying it.  Here I utilize techniques similar to Liu and Curran, (2006). 
As stated previously the Yahoo! corpus contains approximately 12.5 million 
messages from various groups.  Some meta-data about the messages are available such as 
the name of the group, inception date, if it is moderated, type of group and the language 
of the group.  However much of this information is incorrect or has changed since the 
group was started.  For example moderators may leave groups, the language of the group 
can change over time or the language utilized within the groups is not the one specified 
when the group was created.   
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 The actual content of the messages is unknown as well as statistics about the 
messages. When developing tools to process the messages it is important to understand 
the data contained and the way in which it is represented.  Many machine-learning 
algorithms are trained on newswire text, which is grammatically correct, with relatively 
few spelling errors or colloquial terms.  Information such as average message length is 
also important, for example, to understand the amount of time it will take to process a 
message as well as how much memory each will take.    
 I developed a variety of lexicon to interpret the data and to give statistics about 
the composition of the messages.  If tokens within messages do not occur within the 
lexicon the token is manually inspected.  The inspection process looks at each token and 
evaluates them as a spelling error – differentiating between medical terms (including drug 
names) and general terms, compound words, slang or colloquial terms, abbreviations, 
garbage (long random nonsensical strings of characters), names, foreign language terms, 
web terms (artifacts of html stripping), or numbers (such as combinations of numbers and 
letters indicating numbers like 16lbs).     
3.1 Yahoo Data Description 
 The Yahoo! health message corpus was randomly sampled for 500 messages.  
The messages were sampled utilizing a random number generator to choose message ids 
from the corpus.  The text from the chosen messages were extracted and processed; if the 
message contained plain text and html, the html is preferred as html often contained 
formatting hints and other useful markup data.  For this analysis, the html tags were 
removed.  The extracted text was tokenized on white spaces with trailing punctuation, 
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common numerical tokens (money - $50, percent 10%, dates – 1/2/09), and tokens 
consisting of only punctuation such as emoticons: :) ;-) were removed.    
 The resulting tokens were compared to various lexicons to determine the language 
of the token, if it was spelled correctly and the type of token.  Various lexicon were 
created, for example general English, foreign language, web/slang, medical terminology, 
disease, drug names and other names (people, locations, etc).   
 General language lexicons for English, Portuguese, Italian, Indonesian, Turkish 
(Kurdish), Filipino (Tagalog), Galacian, Spanish, Afrikaans, Malay, Polish, and 
Indonesian were utilized from the spell checking portion of the OpenOffice project9.   
 Drug names were extracted from the Food and Drug Administration’s (FDA) 
Drugs@FDA website10, which “contains prescription and over-the-counter human drugs 
and therapeutic biologicals currently approved for sale in the United States.  
Drugs@FDA includes discontinued drugs and ‘Chemical Type 6’ approvals.”11  
However, not all therapeutic biological products are in Drugs@FDA.   Foreign names of 
drugs or drugs not approved for market in the US are also not included.  Multi-word 
names were tokenized on white spaces resulting in 5,637 unique drug tokens.   
 A medical lexicon was generated from medical terms on MedicineNet12, Inc 
which is owned and operated by WebMD13 the authors of whom also wrote content for 
Webster’s New World™ Medical Dictionary. Similarly, the terms from MedicineNet 
were tokenized and resulted in 11,132 unique tokens. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9   http://extensions.services.openoffice.org/dictionary 10 http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/ 11 http://www.fda.gov/Drugs/InformationOnDrugs/ucm075234.htm#contains 12 http://www.medicinenet.com 13 http://www.webmd.com/ 
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 Often forum posts contain names of people – real names as well as profile - or 
pseudonyms as well as group names; for example names are frequently found in 
salutations such as “Hi angelheart”.  A list of names was compiled from the from and to 
headers of the forum messages from the corpus.  These are often in the form of <email 
address> or Name followed by <email address> as depicted below: 
	   FROM:	  <angelheart@domain.com>,	  	  John	  Smith	  <john.smith@domain.com>	  	   TO:<HigherGround@domain.com>	  
The names before email addresses were extracted as well as the non domain name portion 
(the text before the @ mark in an email address) were added to the names lexicon.  In the 
example above angelheart, john, smith, john.smith, and higherground are added to the 
lexicon.   In addition to these names two other sources were utilized: 1,000 most popular 
male and female (2,000 total) baby names from 2000 to 2008 from the social security 
website14; and the most frequently occurring first names (4,275 female and 1,219 male) 
from the 1990 census15.  A total of 1,308,619 names was added to the lexicon from the 
three sources.   
 After the lexicons were created, the tokens from each message were tagged 
utilizing the provided lexicons.  The tokens first were filtered by the English lexicons, 
web lexicon, followed by the medical terminology/disease ones, then drugs and if the 
token was not tagged as one of those it was tagged as an error for manual inspection. 
 Upon manual inspection of many numbers of what appeared as foreign language 
words, the use of foreign language lexicon were utilized to classify many of the terms as 
a foreign language.  If a word was not a foreign language token then it was inspected and 
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15  http://www.census.gov/genealogy/names/ 
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classified as a specific type: abbreviation, spelling error – general and medical, 
compound word, slang, number, garbage, web, name or unknown.   
The tokens were evaluated in several rounds some of which were easier than 
others.  For example if a token looked like a number or quantity but was not removed by 
the regular expression, for example 1cc, 16wks, 65k, 5'3, 10px, the token was classified 
as a number.  Similarly if the token was unusually long in length with no vowels, many 
consonants in a row, or combinations of numbers with letters that looked nonsensical it 
was classified as garbage; examples include: qv1fxvptv1jbqvhxqhrmufpcw1jdxuz 
erh9rxfk and jqwywptfo02381217r0.  
 Artifacts of html conversion and stripping identified and classified as web 
examples include malformed html tags where the text remains like colspan, href, or nbsp.  
Compound words were identified as two terms that were put together. They include 
typical spelling errors like alot or namebrand; artifact of message splitting and html 
formatting like saiddavid; and medical terms people might inadvertently combine: 
anticardiolipins, invitro, or overmedicated.   
A slang classification was also created to indicate common colloquialism and 
online abbreviations such as: heh, suks, pushin, otoh, kn0w.  Here intentional misspelling 
of a term, for example sucks to sux or suks, was classified as slang as well as intentional 
use of numbers or other characters to replace letters $ for s or 0 for o.   
To determine the type of other errors such as, names and abbreviations, web 
searches were utilized on Google.  Searches were performed using the word and then the 
word in conjunction with the search term “health”.  If the predominant sense in both was 
a name – personal, object, location, etc even if it was in a foreign language - then it was 
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labeled as a name.  Common types of names are listed below with examples from the 
messages.   
Table	  4:	  Tokens	  labeled	  as	  names	  broken	  down	  by	  categories.	  
People Oprah 
Websites Xcitefun, Rocketmail 
Screen name Divine_mercy0901, Fixitman 
Company Makita, Glaxosmithkline, Toshiba 
Location Butang, Waltham 
Software PalTalkScene 
Group/Organization Ostomyland – ostomy support community 
Unitaid – HIV/AIDS medication purchasing organization 
Drug Capitata – from Buchenavia capitata 
Alluna – sleep aid  
Medical Term/Procedure Hepatocytes, Transpalatal 
 
A Google search was performed and if the word looked like a common 
abbreviation (the top hits contained sites referring to it or it was contained in an 
abbreviation lookup site) it was classified as an abbreviation. Some of the abbreviations 
found in the messages include:  afib - Atrial Fibrillation/Flutter, tnb - Trinitrobenzene 
Sulphonic acid, pws - Prader-Willi syndrome 
If the token could not be classified as one of the other categories or was too 
ambiguous to determine what it was, then it was classified as unknown.   
3.2 Pre-Processing 
 The statistics for the messages are shown in Table 5 below.  Each message has an 
average of 172 tokens (words).  This number is somewhat misleading due to the stripping 
of all punctuation (emoticons, for example) tokens, and numeric tokens and message 
lengths may be artificially inflated due to the signatures found in the bottom of many 
messages.  Most noticeable is the relatively few number of errors for each message, 
errors only account for ~4% of the total tokens. The number of spelling mistakes is even 
smaller due to the fact that foreign language terms were counted as “errors” leading to 
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.8% spelling error rate, if only spelling errors, slang, compound and unknown words are 
taken into account.   
Table	   5:	   Total	   and	   average	   number	   of	   tokens	   and	   types	   of	   tokens	   found	   in	  
analyzed	  messages.	  	   Tokens Drugs  Errors Names Medical  
Total 86,105 145 3,546 2,672 404 
Average 172.21 .29 7.09 5.34 .81 
 
 The distribution of error types is listed below.  The classification of error types 
was done manually except for foreign language tokens which utilized freely available 
lexicon from spelling checkers.  After it was noted that many tokens appeared in different 
languages, the use of these lexicons was utilized to reduce classification time while also 
increasing accuracy due to the lack of knowledge of several languages.   
Table	  6:	  Tokens	  not	   in	  English,	  medical,	  drug,	  disease,	  or	  slang	   lexicons	   that	  
were	  manually	  classified	  by	  type.	  
Error Type Total Unique 
Foreign Language 1925 1213 
Names 592 386 
Spelling Errors 376 314 
Compound Words 140 117 
Slang 109 80 
Abbreviations 107 47 
Web 107 41 
Unknown Words 92 76 
Numbers 68 50 
Garbage 11 11 
 
Not surprisingly the second most abundant type of “error” was names because 
dictionaries cannot capture names of all people, places, or products.  The total of column 
two from Table 2 does not equal the total number of errors listed in table one because the 
dictionary utilized was not comprehensive and missed some common English terms that 
	  
 
 50	  
should have been in it or common variations such as British spelling on terms like favour 
or colour.    
The incidence of medical terminology misspellings seems somewhat higher than 
that of normal words.  Medical terminology makes up approximately .637% of the total 
number of terms within the text, yet makes up approximately 14% of the total spelling 
mistakes (not including compound words).  This seems somewhat intuitive since medical 
terminology is often used less often than other terms and people are less familiar with it.  
Similarly, spell checkers on computers often lack medical dictionaries containing 
terminology or drugs.   
Table	  7:	  Spelling	  error	  breakdown,	  medical	  vs.	  non-­medical	  terms. 
 Total Unique 
Medical Terms 53 48 
Non-Medical Terms 323 267 
 
Upon inspection several messages are in a foreign language, including Indonesian 
and Spanish.  It is not known whether the message board started in English and 
progressed towards the other language or if the board was mis-labeled as English 
speaking.  Terms in other languages are used as slang or as a term of endearment, “my 
beautiful lochie….your sweet little lochie,” and often are interspersed within English 
messages.  Some messages are in English but include foreign language signature blocks 
at the end or the message text is written in a foreign language with a news release or other 
form of information in English in lined within the message.  The distribution of 
languages is listed below. However, this may not be an accurate representation.  Many 
words exist in multiple languages, and a single term within another language may 
indicate that the term was not in the true language’s dictionary but denoted as another 
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language, ie. a single word in French, Norwegian or Pampanga.  For example a message 
contained the word “mahu”, which exists in Hawaiian but was not included in the 
Indonesian dictionary, but upon further inspection the entire message where mahu was 
found was in Indonesian.  Foreign language lexicons, like English, are not comprehensive 
and do not contain new terminology or slang which makes the identification of language 
difficult.   
Table	  8:	  Breakdown	  of	  foreign	  language	  tokens	  by	  language. 
Language Total Unique 
Afrikaans 3 3 
Arabic 3 2 
Croatian 4 4 
Czech 4 3 
Dutch 48 38 
Finnish 21 20 
French 1 1 
Galician 12 9 
German 4 4 
Icelandic 2 1 
Indonesian 1085 604 
Italian 50 48 
Macedonian 3 3 
Malay 54 40 
Norwegian 1 1 
Pampanga 1 1 
Persian 4 1 
Polish 56 47 
Portuguese 142 114 
Russian 1 1 
Serbian 6 5 
Spanish 179 138 
Swedish 34 30 
Tagalog 49 30 
Turkish (Kurdish) 59 47 
Unknown 99 18 
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The results of this study demonstrate that spelling errors are not as problematic as 
previously thought, this presumably in part due to the prevalence of spell checking 
software in email clients and increased amount of medical terminology misspelled.   
Foreign language is by far more problematic and a worthwhile goal is to look at 
automated foreign language classifiers.  Not surprisingly new names or previously unseen 
tokens are a challenging problem.   
 The task of Named Entity Recognition relies on identifying tokens as certain 
entities. For this dissertation I focus on drugs and drug effects.  Drugs are a relatively 
closed class of nominals; however, as evidenced by this experiment many foreign and 
non-FDA approved as well as non-drug labeled biologicals such as herbs or other 
chemicals are not available in a comprehensive list.  It remains to be seen if dictionary 
based approaches are good for the identification of drug outcomes as this is a more open 
bounded problem and people may use slang terms such as one labeled in our data, 
“itchers.”  However, the implications of this work demonstrate that spelling problems are 
not as problematic as I previously thought, comprising a relatively small amount of total 
tokens, indicating that dictionary identification approaches are feasible leading to high 
precision with lower recall.  While this is not ideal, high precision approaches are useful 
for certain tasks.   
 I have demonstrated corpus statistics of a small sample of the Yahoo! health 
corpus that will be used in the rest of the dissertation.  Here I have developed semi-
automated techniques for manual annotation of statistics regarding the prevalence of 
names, spelling errors and foreign language tokens.  While errors are not as prevalent as I 
had previously believed this does highlight the open ended nature of NER and the 
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difficulty in creating a pre-calculated dictionary of proper nouns including people and 
companies.  
3.3 General Vocabulary 
While all words in messages concerning drugs can be utilized in feature vector 
generation, this is not necessary and can lead to poorer results due to added noise as well 
as slower running times due to additional computational overhead.  For instance the 
running time to train linear SVMs is dependent on the number of training instances (n) 
times the number of features k leading to a running time of O(kn).  Many text 
classification tasks utilize feature vectors of single words taking the “bag of words” 
approach where the ordering of words does not matter.  However, it is intuitive that the 
ordering of words is important; for instance the series of three words - good, bad, not - 
have very different meanings depending on their orderings “good not bad” is different 
from “bad not good.”  Additionally, certain drugs or medical procedures are composed of 
multiple words where the meaning of the phrase is different from its constituent 
components, for example “vitamin a” is different from “vitamin” and “a” occurring 
within a message.  Here word-grams can capture the importance of certain word 
orderings. For our text classification task we utilize unigrams, bi-grams and tri-grams.   
A common approach utilizes the top k-most frequently occurring words.  
However if no initial stop word removal was performed many of the most frequently 
occurring words are ones that contain little information such as the, and, a, or.  Luhn’s 
(1957) work proposed that the most informative words in a work are the mid-frequently 
occurring ones.  In this dissertation I utilize this feature selection approach.  While other 
feature selection approaches exist such as Information Gain (IG) or Bi-Normal 
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Separation (BNS) these utilize binary counts, whether features exist or not and if they 
exist within one class versus another.  These feature selection criterions would penalize 
terms occurring within both classes, including many of the specialized medical 
terminology, drugs names, diseases, or sentiment words.  Instead we would like to see 
these words included but look at the differences in number of occurrences in vocabulary 
between the two groups.  We take the approach of taking the top k-n most frequently 
occurring terms where k is the top number of terms minus n to account for function 
words like a, or, and the.   
3.4 Specialized Lexicon 
An alternative to using specialized lexicon is taking a subset of the general 
vocabulary and performing feature selection on it.  In this case the feature selection 
criterion is world knowledge preferencing words that are more related to the specific 
health domain.  I aim to utilize combinations of the set of lexicon since using a small 
subset of the entire lexicon can lead to over-fitting.  For example the drug lexicon is 
relatively small and each example will have specific drug mentions over represented (the 
instance’s drug).  The presence of the watchlist drug will then map to a drug being 
classified as watchlist or not.  While it can have a high degree of accuracy for the training 
set instances it is not generalizable to unseen drugs.  As mentioned before the specialized 
lexicons used are: drug lists from drugs.com, medical terminology from MedicineNet, 
Sentiment Lexicon from SentiWordNet and LIWC, MedDRA lexicon from AERS reports 
and disease lists from Wikipedia. From the five different lexicons we can generate 
different feature sets combining various combinations of the lexicon.  This leads to 29 
different datasets with each lexicon a separate dataset, pairs of lexicons, and so on and 
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the last including all of the combined lexicon terms.  The feature vector is then the subset 
of the generalized lexicon terms contained within the combinations of specialized 
lexicon; for example if a two combination consisting of sentiment and drug lexicon, the 
resulting feature vector dimensions would consist of all drug and sentiment terms.    
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4 Data Preprocessing 
4.1 Language Identification 	   Due to the significant amounts of messages in foreign languages, it is necessary to 
identify and remove these messages from the corpus.  This chapter focuses on techniques 
for processing the Yahoo! data to reduce the noise and improve classification 
performance.  A major focus of this preprocessing is foreign language identification and 
removal of those messages.  While the text processing techniques are language agnostic, 
messages in foreign languages would increase the size of feature vectors for each drug in 
the machine learning experiments.  Larger feature vectors increase the amount of storage 
space and processing requirements and possibly negatively affect classification if 
sufficient numbers of messages for each language do not occur (data sparsity problems).   
 Foreign language terms are also problematic for visualizations where the 
projected audience is English speaking.  Drug comparisons depicting features that 
indicate similarity in languages other than English are difficult for English-only speakers 
to interpret and evaluate.   	   An initial first pass over the data is performed utilizing Unicode language 
detection to remove messages that contain non-romanized text.  For example messages 
written in Japanese alphabets or Kanji, Chinese characters, Arabic abjad, or Cyrillic were 
eliminated.   
 Differentiating between English and non-English messages written in Romanized 
alphabets is more difficult.  A variety of methods have been used to identify different 
languages; among them are the “common words” approach, character n-grams and 
dictionary based approaches.  The common words approach utilizes function or stop 
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words in a language; for example in English some words include: a, and, be, but, than, 
the, you (Ingle, 1976).  These words carry little information but make up large portions of 
the content in written text.  Later work by Dunning (1994) utilized character n-grams or 
series of characters (20 characters in one example: e pruebas bioquimica; man 
immunodeficiency; faits se sont produi) based upon the observation that humans need 
little amounts of text to correctly identify a language.   Dunning’s approach requires the 
use of training data (albeit small amounts – several kilobytes worth) for statistical 
classifiers.  Later work by Rehurek and Kolkus (2009) utilizes dictionaries derived from 
nine European Wikipedia datasets.  Dunning (1994) dismisses the use of dictionaries, 
however the dictionaries discussed only consist of function word lists.  Rehurek and 
Kolkus (2009) determined 97.16% accuracy on 1,000 documents and 49,943 words.   
Rehurek and Kolkus (2009) the authors go on to discuss the advantages of 
dictionary word based language modeling versus character n-grams.  Character n-grams 
are not reliable when building statistics of web corpus documents that include the 
character distribution is skewed towards repetitious words or phrases such as “In reply 
to:” in the case of our Yahoo! Health message corpus.   Many web pages (and our input 
data as well) consist of multiple languages due to logical structure (Yahoo! Signatures at 
the end of a message) but also the nature of the body text itself.   
dear	  all,	  semalam	  'terlepak'	  sama	  ustaz	  abdul	  rahman	  (ABU).	  dia	  ada	  cerita	  sikit2	  about	  his	  'struggle',	  hmm,	  i	  don't	  actually	  know	  where	  to	  start!	  hahaha...	  anyway,	  dia	  ada	  plans	  to	  establish	  an	  orphanage	  in	  tawau	  -­‐	  he	  went	  there	  a	  few	  weeks	  ago,	  on	  his	  friend's	  invitation,	  according	  to	  his	  friend,	  in	  tawau	  tak	  ada	  orphanage.	  dia	  ada	  plans	  to	  go	  there	  lagi	  sekali,	  this	  time	  nak	  survey	  tempat,	  etc.	  risma,	  if	  you're	  free,	  maybe	  you	  can	  meet-­‐up	  with	  this	  ustaz	  or	  mintak	  tolong	  your	  brother,	  jusri,	  hehehe	  (kawan	  baik	  &	  housemate	  john	  masa	  study	  kat	  upm!).	  maybe	  can	  bring	  him	  around,	  etc.	  
Figure	  2:	  Example	  of	  a	  multilingual	  message	  from	  the	  Yahoo!	  corpus.	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Character n-grams also have difficulty in dealing with similar languages. For 
example Slavic languages such as Slovenian, Slovakian, Czech and Polish have 
significant grammatical and lexical overlap.  
Due to the web nature of our input data, I used dictionary-based methods of 
language identification; the goal of this identification is a simpler problem than 
traditional language identification.   We have a binary problem, determining if a message 
is predominantly English or not.  While the identification task is simpler in some regard, 
in others it is more difficult.  As observed previously the messages are a mix of English 
and foreign words, a lot of names, medical terminology, and other erroneous tokens such 
as ascii are often found in signatures, emoticons or punctuation based delimiters.  Luckily 
spelling errors are not as frequent as previously thought; however the unseen word 
problem is significant.  Rehurek and Kolkus (2009) method relies on building language 
models utilizing large amounts of text (several gigabytes for each language).  Such 
training data does not exist for foreign language (and English) health message board text.   
Instead I used dictionaries of commonly found words for various languages 
available through the OpenOffice project, an open source freely distributable office 
software suite (www.openoffice.org).  In addition medical dictionaries, drug and disease 
lexicon, as well as lists of names as described previously are utilized.  The foreign 
language dictionaries contain many more words than just function words. While they are 
not as extensive as language modeling based approaches containing domain specific or 
esoteric words, they capture many words found in everyday use. Instead of using a 
statistical scoring function, an inequality of two linear combinations of word counts was 
utilized: 
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Equation	  2:	  Linear	  inequality	  for	  scoring	  a	  message	  as	  English	  or	  not.	  4*foreign	  +	  unknown	  +	  ignore	  >	  english	  +	  drugs	  +	  medical	  	  	   The constant in front of the number of foreign tokens is greater than one, 
increasing the amount a foreign token counts for, indicating that fewer foreign tokens are 
needed than English ones to count the message as non-English – an English message 
should contain approximately < 25% foreign words.   Each token or word in the message 
is compared to a set of dictionaries to derive word type counts.  The word counts are 
calculated in the following way: 	  
If ((word in Ignore List) OR (word length < 2) OR (word contains "@")) 
Ignore Count++ 
Else if (word in English List) 
English Count++ 
Else if (word in Drug List) 
Drug Count++ 
Else if (word in Medical List) 
Medical Count++ 
Else if (word in Name List) 
Name Count++ 
Else if (word in Foreign List) 
Foreign Count++ 
Else 
Unknown Count++ 
 
Figure	  3:	  Pseudo	  code	  for	  scoring	  a	  word	  token.	  	  
Pre-processing of tokens incurs removing web addresses (URLs) and punctuation 
only tokens (such as emoticons like ;) or :-( ).  Short words, email addresses, or tokens 
that are on an ignore list are filtered out.  Then each token is progressively compared to 
another dictionary.  The counting function is conservative erring on the side of English 
rather than foreign words, tagging a token as English rather than foreign if it occurs in 
both lists.  This is based on the assumption that having a foreign language message is 
better than removing an English language message.  Unknown counts include spelling 
errors, names, slang, expletives or other words not in any list.   
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However allowing some foreign language words can lead to problems with short 
message text in a foreign language followed by a longer English signature block like the 
message below: 
Pidu	  toimub	  ja	  Liisa	  koju	  ei	  l?he	  :)	  On	  	  ,	  Dmitri	  Somov	  <dimsgen@	  >	  wrote:	  ei	  tea	  mis	  ?ldse	  tuleb,	  aga	  kolmanda	  kursuse	  tudengid	  on	  oma	  ?ppemisega	  nii	  mures,	  et	  mingi	  pidu	  ei	  mahu	  nende	  plaanidesse:(	  -­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐	  Yahoo!	  Groups	  Sponsor	  -­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐~-­‐-­‐>	  Affected	  by	  disease?	  Support	  health	  awareness	  efforts	  at	  Network	  for	  Good.	  -­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐~-­‐>	  Yahoo!	  Groups	  Links	  <*>	  To	  visit	  your	  group	  on	  the	  web,	  go	  to:	  <*>	  To	  unsubscribe	  from	  this	  group,	  send	  an	  email	  to:	  ehyljuhatus-­‐unsubscribe@	  <*>	  Your	  use	  of	  Yahoo!	  Groups	  is	  subject	  to:>	  
Figure	   4:	   Example	   of	   a	   non-­English	   message	   from	   the	   Yahoo!	   corpus	  
containing	  an	  English	  signature	  block.	  	  	  	   Utilizing the sampled original text from the previous section, the linear inequality 
and coefficients were optimized.  This resulted in a smaller corpus consisting of 
10,178,710 messages with 20,417,209 unique terms from the original 12,520,438 
messages with 31,124,146 terms reducing the number of unique terms per a message 
from ~2.5 to ~2.   	   This	  chapter	  demonstrates	  the	  data	  preprocessing	  and	  cleansing	  techniques	  employed	  on	  the	  data	  used	  in	  this	  dissertation.	   	  The	  number	  of	  messages	  has	  been	  substantially	   reduced	  although	   it	   is	   still	   unknown	  how	  much	  noise	   is	   still	   present	  and	  to	  what	  extent	  it	  will	  affect	  classification	  performance;	  however	  it	  is	  possible	  to	  extrapolate	  these	  numbers	  based	  upon	  the	  sampling	  performed	  in	  the	  last	  chapter.	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5 Experimental Design 
 This dissertation focuses on generating a classification system for drugs based 
upon the way people talk about them.  The diagram below depicts the architecture of the 
system.  Here a set of cleaned messages from the Yahoo! corpus was organized by the 
drug mentions in them.  For safety alert or watchlist drugs, only messages up to the date 
the safety alert was released were used.  I aim to build a predictive classifier and want to 
determine if the way people talk about safety alert drugs are different from non safety 
alert ones. 
	  
Figure	   5:	   	   Depiction	   of	   the	   iterative	   process	   involved	   in	   building	   a	  machine	  
learning	  classifier.	  	  
 Messages containing drug mentions are divided into two sets, a testing and 
training set.  These messages are then converted into feature vectors, which are run 
through classification algorithms, in this case Naive Bayesian, and Support Vector 
Machines.  The parameters for each algorithm are tuned and the results against the test set 
are generated to rate their performance.   
 This dissertation uses two different feature vector compositions as illustrated in 
the diagram below: 
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T1 T2 T3 T4 T5 ... Tn 
 
Word Features 
T1 T2 … Tn F1 ... Fn 
Word and Special Features 
 
 
The first type of feature vector consists entirely of words or phrases.   Feature 
vectors do not preserve any of the word ordering that exists in a message.  To incorporate 
some of the ordering word phrases (N-Grams) are utilized.  Word ordering is especially 
important for things like negations; “not good” is very different from “not” and “good”.  
These features consist of words selected from the message corpus themselves that tend to 
differentiate the classes of messages, for example, preferencing words pairs that exist in 
watchlist messages but not in non-watchlist ones.  Other types of word features include 
specialty lexicons such as the AERS lexicons, disease names from Wikipedia or drug 
names from drugs.com.  By selecting these lexicon a priori we are imparting our 
knowledge and intuition that these words are good discriminators between the two 
classes.   
The second type of feature vector combines word features as previously discussed 
along with “specialty” features.  These specialty features consist of counts over the 
number of instances of specialty lexicon; for example, number of disease mentions, 
number of drug mentions, number of positive sentiment containing words, and number of 
negative sentiment containing words.   
Figure	  6:	  Depiction	  of	  the	  feature	  vectors	  used	  by	  the	  classification	  algorithms. 
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The identification of drug names and sentiment containing words rely on Named 
Entity Recognition (NER) of drug names and sentiment analysis tracking.  Both 
approaches are dictionary based but raise validation concerns.  Can we reliably extract 
these entities and are they meaningful?  The next sections describe experiments detailing 
dictionary NER techniques for drug and drug effect detection followed by experiments on 
tracking sentiment.   
However before any machine learning experiments or NER and sentiment 
tracking experiments are run, one must determine if the two classes are separable by 
examining the language use of watchlist messages versus ones that are non-watchlist. 
5.1 Kullback–Leibler Divergence 
As an initial experiment I first looked at the word distributions of the watchlist 
drug messages and the non-watchlist drug messages.  If there is a large difference 
between the distributions it is indicative that people talk about these two classes of drugs 
in differing ways.   If people talk about the watchlist drugs differently from non-watchlist 
drugs it demonstrates the tractability of utilizing machine learning classification to 
separate the two classes of drugs.  If there is a metric of distance or difference it should 
also indicate the ease or difficulty in separating the two classes and building a predictive 
classifier.  In this dissertation I utilize Kullback–Leibler divergence (KL divergence) to 
quantify the difference in word frequency distributions between watchlist and non-
watchlist drug containing messages.   KL divergence is a non-symmetric measure of the 
difference between two probability distributions P and Q.  It is often used in the area of 
information theory and probability theory. While often alluded to as a distance metric, it 
is not a true distance metric since it does not satisfy the triangle inequality in that the 
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“distance” from P to Q is different from the “distance” from Q to P.  In information 
theory, KL divergence is the expected number of extra bits needed to encode samples 
from P when using a code based on Q, rather than using a code based on P.   Formally 
KL divergence is specified as: 
 
 
Within the context of this dissertation I create a probability distribution from a 
frequency distribution over words utilizing smoothing.  Smoothing is necessary because 
when utilizing KL divergence if for some i (in this case i represents a word or phrase) 
exists in P but not in Q this leads to an infinite KL divergence indicating the distribution 
P predicts an event that is possible while Q predicts it is impossible.    This is intuitively 
incorrect, though a word i not existing in one distribution does not mean it is impossible 
in the other, it was simply not present in the data the distribution was generated over and 
may not have been seen yet.  So a small probability is ascribed to each value in one 
distribution that is not present in the other. 
While KL divergence gives us a measure, it is somewhat meaningless without a 
point of reference.  I compared the KL divergence between watchlist and non watchlist 
drug containing messages to the Google Web 1T 5-gram corpus and the Reuters Corpus.   
The Google corpus is composed of English word n-grams ranging in size from one to five 
words.  The corpus was generated from approximately 1 trillion words from publicly 
accessible web pages.  However, I utilized only the single words and compared them to 
the single words in the drug corpus due to memory constraints.  The Reuters corpus 
 
Equation	  3:	  Kullback-­Leibler	  Divergence	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consists of 810,000 Reuters English language news stories from August 20, 1997 to 
August 19, 1997.  
The Reuters corpus is more formal in nature leading to fewer spelling mistakes, 
slang, swear words, etc.  The Google corpus, however, is rife with spelling mistakes and 
swear words and has many more brand names, slang, proper nouns, etc.  Due to the 
colloquial nature of the Yahoo! messages I hypothesize that the KL divergence between 
them and the Google corpus is smaller than the KL divergence between the Yahoo! 
messages and the Reuters corpus. 
5.2 Dictionary NER Exploration 
The next two sections detail special features; drug entities and sentiment scores 
that will be employed by the machine learning classifiers.  These features are different 
from those found in general text classification tasks.  However, it is important to 
understand these features individually, both how easy they are to identify as well as how 
accurate they are and what information they contribute.    
This section details experiments of dictionary named entity recognition from the 
Yahoo! corpus.  A dictionary approach is employed due to the lack of training data as 
well as other NLP tools that are necessary if one uses a statistical classification approach.    
The drug lexicon used to identify drug named entities is derived from the FDA 
and the drug taxonomy available at Drugs.com.  The taxonomy enables the grouping of 
name brand and generic drugs by function. The following is a branch from the taxonomy: 
Central Nervous System Agents > Antiemetic/antivertigo Agents > 5HT3 Receptor Antagonists 
Figure	  7:	  Branch	  of	  a	  drug	  taxonomy	  from	  Drugs.com.	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The taxonomic structure enables the ability to group drugs in a semantically 
meaningful way.  Grouping drugs could be used to look for trends within a class, for 
example generalizing and hypothesizing that a group of drugs might exhibit a particular 
adverse reaction if it is found that all sub classes of drugs exhibit the same adverse 
reaction.  Taxonomic structure also facilitates the analysis of drugs within the same class 
and chemical structure if there is not enough data – it can help to alleviate the data 
poverty problem.     
The Adverse Event Reporting System (AERS) uses the Medical Dictionary for 
Regulatory Activities (MedDRA).  It is a lexicon that is applicable to all phases of drug 
development excluding animal toxicology and includes the effects, operation and 
malfunction of medical devices. It is used to report adverse event data from clinical trials 
and for post-marketing reports and pharmacovigilance.  MedDRA was developed by the 
International Conference on Harmonisation (ICH) and is owned by the International 
Federation of Pharmaceutical Manufacturers and Associations (IFPMA). 16    
A Lucene (an Open Source Java Information Retrieval package17) index was 
created over the approximately 10 million (12.5 million originally with 2.5 million 
messages removed) messages.  The AERS and drug lexicons were then used to generate 
phrase searches, which were run against the Lucene index.   The index is a structure 
enabling fast retrieval of message text and ease of locating relevant information.   There 
are drawbacks to using an information retrieval (IR) system to look for instances of drugs 
or medical terminology.  I currently use a lowercase filter with stemming; this creates a 
lower case representation of a term within the inverted index: “Commit”, “commit”, 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
16 Taken from: http://www.meddramsso.com/public_about_meddra.asp 
17 Available at: http://lucene.apache.org/java/docs/ 
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“COMMit” are all mapped to the same lexical entry “commit”.  Similarly “committing” 
and “commit” are also mapped to the same lexical entry “commit”.  These two filters 
have implications in precision and recall for IR.    
Precision is the number of relevant documents retrieved by a search divided by 
the total number of documents retrieved by that search, and recall is the number of 
relevant documents retrieved by a search divided by the total number of existing relevant 
documents.  While precision and recall do not necessarily have to be trade offs, ie 
optimizing for precision at the expense of recall or vice versa, in practice this is generally 
the case.  Utilizing a lowercase filter will generally retrieve more documents leading to 
(generally) greater recall, whereas without it will generally lead to greater precision.  For 
example, if someone wanted to retrieve instances of “COMMit” since it is a brand name a 
lower case filter will return all instances of “commit” leading to many documents not 
referring to the item but the verb (for example, the act of giving trust or act of consigning 
someone) leading to a lower precision.  On the other hand the lowercase filter would 
enable the retrieval of all instances of “commit” including instances where the noun is not 
properly capitalized such as “COMmit” leading to greater recall.  This is important 
because some drug names consist of common words that are capitalized. Some drugs in 
the lexicon that utilize common words include: Commit, Control, Duration, Perfect 
Choice, Sleep, Hold, SF, RID, Maternity, Bright Beginnings, and Definity.  “Definity” is 
not a common word and therefore people commonly mistype “definity” as “definitely”.  
This leads to the second problem with using IR for NER, the lack of contextual clues or 
other information such as part of speech (POS) tags.     
Utilizing a dictionary approach does not make use of contextual information, 
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though it leverages the inverted index nature of an IR system matching index terms to 
lexicon terms.    However, an IR system could be augmented to use context such as fuzzy 
searches requiring “drug” or “taking” or other keywords indicating a drug along with the 
drug name.  Other contextual information such as POS tags might be useful at 
differentiating drug names.  In the case of the drug “Commit” verb instances could be 
ignored such as “commit a crime”.  These rules, however, are not absolute, since the text 
is colloquial in nature, instead of the fragment, “starting to take Commit” one might 
instead say, “starting Commit” dropping the verb phrase “to take”.  Similarly people in 
colloquial text are not careful about proper capitalization.   
For the purpose of this dissertation and the following experiments, drug names 
with common words were replaced by the generic (chemical) name. For each of the 
lexicons phrase searches were constructed and run against the index. 
5.3 Drug Mentions in Messages 	  
I performed an analysis on messages looking at the distance between unique drug 
messages with more than one drug mention.  The goal is to determine the separation 
between drug mentions in messages.  If drugs are close together it is harder to segment 
the message around a drug to determine the sentiment towards a particular drug as well as 
attributing a particular effect to drug.  Given prior work it is expected that drug mentions 
would be close together.  For example, people often list drugs they are on – their current 
regimen - or ask for opinions between two drugs of the same class to determine which is 
better or how to differentiate between the two.   
To confirm this hypothesis pairs of unique drug mentions within the same 
messages were extracted and the distance (number of characters) between the first 
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mention was calculated.  This method has some drawbacks such as messages containing 
more than two unique drugs; to eliminate some of this I only look at messages with two 
mentions.  Looking at messages where there are frequent co-occurrences between 
different drugs highlights how the drugs are talked about. The variance in distance 
illustrates that drugs are usually talked about in the same way.  Similarly, a large 
difference between the median and mean is also indicative of the variability of the data. 
 
 
 
 
 
Figure	   8:	   Pseudo	   code	   describing	   how	   average	   distance	   between	   drug	  
mentions	  is	  calculated.	  
 
Mutual information is used to score pairs of unique drugs within the same 
message to look for highly co-occuring drugs. Mutual information measures the 
information that two variables X and Y share.  It quantifies the extent of knowing one of 
the variables X or Y reduces uncertainty about the other.   If X and Y are independent, 
then information about X does not provide any information about Y and vice versa, 
therefore their mutual information is zero.  If X and Y are identical, information about X 
is also applicable to Y.   
Equation	  4:	  Formula	   for	  calculating	  Mutual	   Information	  between	  variables	  X	  
and	  Y.	  
 
I (X;Y ) =
￿
y∈Y
￿
x∈X
p (x, y) log
￿
p (x, y)
p1 (x) p2 (y)
￿
|  for each N pairs of highly overlaping drugs 
|    for each message containing drug1 and drug2 mentions:  
|    |  find first mention of drug 1  
|    |   find first mention of drug 2 
|    |  distance = absolute value of (drug 1 first mention – drug 2 first mention) 
|    | end  
|    calculate mean, standard deviation, median, minimum and maximum distances 
| return statistics for each N 
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Mutual information was used as a scoring function instead of cosine similarity.  
Cosine similarity, which is the cosine between two vectors A and B, where the vectors 
represent drugs and the dimensions are messages the drugs occur in.  As seen by the 
formula below, cosine is the intersection of vectors A and B divided by the size of the 
two vectors multiplied together.  Cosine biases towards exact matching of vectors, such 
that if two drugs only occur in one message each but occur together this would rank 
higher than drugs that each occur in 100 messages each and occur together 90 times.   
Equation	  5:	  Formula	  for	  calculating	  the	  Cos	  between	  vectors	  A	  and	  B.	  	  
5.4 Measuring Sentiment Tracking Drug Outcomes 
5.4.1 Introduction 
Sentiment is the next type of special feature.  Two dimensions are added to the 
word feature vector, number of positive sentiment containing terms and the number of 
negative sentiment containing terms.  I equate drug opinions within forum messages to 
product reviews.  However, the question arises, if a message contains a drug and also 
sentiment containing terms, does the sentiment reflect the author’s opinion of the drug?   
Due to the lack of labeled training data, I instead look at aggregate sentiment of messages 
with drug mentions over time.  It is then possible to look at the changes in sentiment to 
see if they correspond to significant news items such as FDA announcements or 
manufacturer announcements about the drug.   Ideally drug mentions should be 
statistically different from messages without drug mentions utilizing a sentiment scoring 
metric.  
cos (θ) =
A ·B
￿ A ￿￿ B ￿
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I believe that sentiment analysis, determining the positive or negative valence, is 
another way in which we can determine drug satisfaction. A drug may have many serious 
side effects, yet people may still have a positive attitude towards it, especially if they 
believe it helps them in some way (Silver, 2002).   
Opinion mining and sentiment analysis is a commonly accepted area within 
natural language processing.  It is commonly used to aggregate and evaluate product 
reviews.  In this dissertation I consider drugs analogous to other products.  We value 
others’ opinions in our own decision-making processes for purchasing products (Pang 
and Lee, 2008). Widespread dissatisfaction with a drug is not only alarming to others 
potentially taking the drug but also to oversight organizations such as the FDA.  
Widespread unease may be indicative of problems associated with the drug, ranging from 
adverse effects to concerns over pricing or efficacy; it can indicate to others that further 
investigation into the drug is warranted.   
5.4.2 Methods Using Personal Health Messages 
Within the Yahoo! forums, patients seek others’ support, advice and information 
about treatment options. Below is an excerpt from a message from a neurological group 
that has been anonymized. I interpret these responses that a patient writes as a “review.”  
Traditional sentiment analysis techniques are applied to these texts.   
…when I gave up coffee and sugar in earnest and stopped the amitrptyline I 
was taking I am feeling much better still especially depression wise and the 
heavyness and sluggishnes that was in my legs is leaving. I am also getting 
back into a more normal sleep pattern of getting sleepy by normal time in 
evening and waking up in the morning more normally.  I believe the years of 
amitriptyline for muscle relaxant were doing more damage than good and am 
doing pretty good controlling my night time bladder spasms by no coffee, 
magnesium and the diet… 
Figure	   9:	   	   Excerpt	   of	   a	  message	   from	   a	   neurological	   group	   from	   the	   Yahoo!	  
corpus.	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My method utilizes portions of the lexicon in the Linguistic Inquiry and Word 
Count (LIWC) when calculating sentiment scores for messages (Pennebaker, Francis and 
Booth, 2007).  Previous work utilized LIWC to demonstrate variations in language usage 
between depressed and depression-vulnerable students (Rude, Gortner and Pennebaker, 
2004).  Further, it is known that the words people use correlate with their physical and 
mental health (Pennebaker and Campbell, 2000).   
Specifically, I use the words in LIWC corresponding to the following categories: 
positive emotion, negative emotion, anxiety, anger and sadness.  I have augmented the 
LIWC lexicon to include a wide range of emoticons such as :),  :( , :P, ^__^ , LOL ROFL.   
The messages from the Yahoo groups were parsed to extract just the textual 
information and to remove noise such as replies that are often included in messages.  
While replies help understand the context, a message’s emotional context should not be 
based on what other people write, only on the author’s text. 
The resulting messages were matched against the LIWC lexicon categories and 
emoticons discussed previously.  Counts containing number of positive emotion words, 
and negative ones, and total number of words were recorded.  It was found that the ratio 
of negative emotion words to total words was the most helpful in determining negative 
valence. The following methods and results use a negative ratio of negative emotion 
words to total words in a message so that when graphing results, the positive y-axis 
represents less negative messages.   
5.5 Machine Learning Experiments 
The crux of this dissertation depends on the assumption that people talk about 
FDA watchlist drugs differently from non-watchlist drugs.  While the difference might be 
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difficult for humans to readily discern, I depend on machine learning algorithms to 
differentiate the two.  The inputs into these algorithms are feature vectors generated over 
the words people use to talk about these drugs.  Feature selection is an important part of 
all machine-learning tasks. The goal is to utilize sufficient numbers of features to enable 
an algorithm to differentiate between instances both in the training set as well as 
unforeseen instances while limiting the amount of noise introduced.    
This dissertation focuses on generating features using two approaches.  In the first 
approach the feature vector is generated over general vocabulary terms and “meta 
features”.   In this approach all terms within messages are considered and then filtered 
using heuristics such as frequency cutoffs.  These general terms are combined with other 
“meta features” these meta-features impart world knowledge in the form of counts over 
specialized lexicons for example the number of drug mentions or positive or negative 
sentiment words.  The second approach focuses on using the specialized lexicons 
exclusively.  An example feature vector might consist of only medical terminology, 
drugs, diseases, and sentiment containing words or some subset of them.  The specialized 
lexicons include drugs, medical terminology, sentiment, adverse drug event lexicon from 
MedDRA, and lists of diseases as mentioned previously.   
 Classification utilizing machine learning algorithms typically require large 
amounts of training data, and the performance of classifiers are often commensurate with 
the amount of training data available.  However, due to the nature of the data available 
relatively few positive (watchlist drugs) are available with sufficient amount of data.  
There are only 435 drugs with more than 500 unique messages mentioning them; of these 
there are 63 watchlist drugs.  Similarly if drugs with more than 250 unique mentions are 
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used, there are only 575 drugs and 77 watchlist drugs.  Approximately 90% of instances 
are non-watchlist drugs.  This is somewhat comforting in terms of health and drug safety; 
only 10% of drugs are watchlist and are demonstrated to possibly cause adverse effects.  
However, in terms of machine learning experiments this leads to problems with bias and 
data scarcity.  This is problematic due to the few numbers of examples a classifier can 
learn and generalize over.   
 To help alleviate some of the data sparsity problems, cross-fold validation is 
utilized. Multiple runs utilize the datasets for comparison: watchlist drugs versus non-
watchlist drugs.  In stratified K-fold cross-validation, the original data is partitioned into 
K subsections (in this case 10).  One of the subsections is withheld as testing data and the 
other K-1 ones are used for training.  The cross validation process is then repeated K 
times (folds).  The folds are selected such that the same proportion of positive and 
negative classes is chosen.   The K results are then averaged to produce a single estimate.  
All observations are used for training and testing and each one is used for testing once 
(McLachlan, Do and Ambrose, 2004).  Cost weighting is another technique that is used.  
Two common forms of cost weighting exist:  weighting instances or introducing penalties 
for misclassification.  Instance weighting involves weighting instances of a particular 
class more than others, for example weighting or counting positive instances double what 
a negative one counts for.  Misclassification penalties involve training a model and 
classifying instances.  Instances misclassified by the model depending if they are positive 
or negative impact the updating of the model in different ways.  
 Instead of weighting instances one may build balanced datasets, where the 
number of positive examples is near the number of negative examples using sampling 
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techniques.  Machine learning classification tasks frequently have many training 
examples available and usually in the binary classification application, approximately 
equal numbers of positive and negative instances.  The dataset consists of only 13.4% 
positive instances.  This leads to an imbalanced dataset where most examples are 
negative.  A variety of sampling techniques are used to generate a balanced dataset, 
among these are: random undersampling (RUS), random oversampling (ROS), ons-sided 
selection (OSS), cluster-based oversampling (CBOS), Wilson’s editing (WE), 
SMOTE(SM) and borderline-SMOTE (BSM), see Van Hulse, Khoshgoftaar, and 
Napolitano (2007) for an overview of various methods.   This dissertation focuses on 
RUS in which instances of the majority class are randomly discarded.  RUS resulted in 
the best performance in empirical tests of 2340 datasets (Van Hulse, Khoshgoftaar and 
Napolitano, 2007).  However in the same work it was demonstrated that sampling does 
not significantly improve the area under the curve (AUC which is discussed in more 
detail below) for Naïve Bayesian classifiers and the performance measurement (AUC, 
true positive rate, accuracy) dictates the performance of the sampling method.   
5.5.1 Decision Making 
The building of machine learning classifiers depends on making many choices 
from a broad decision space as discussed previously. Aside from choosing specific 
algorithms, in this case SVM and Naïve Bayes, there are also associated parameter space 
decisions for SVM such as the type of kernel and the parameters for each kernel.  
Furthermore, there are feature selection problems for choosing the types of features as 
input into the classification algorithms; the features in this case are word grams.   
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Another consideration when dealing with feature selection and associated feature 
vectors is to utilize scaling of individual dimensions.  One of the advantages of scaling is 
to avoid attributes in greater numeric ranges dominating those in smaller numeric ranges.  
One can imagine that common dimensions such as words like “drug” or “pain” might 
then dominate the classification and overwhelm less frequently occurring but more 
informative dimensions like “dying”.  A common approach is to use term frequency-
inverse document frequency (tf-idf) to weight a word according to its importance based 
upon the number of appearances; see Manning (1999) for an in depth discussion on tf-idf 
weighting.  Scaling further helps to avoid numerical difficulties during calculations when 
using SVMs because kernel values usually depend on the inner products of feature 
vectors, and large attribute values can cause numerical problems such as number 
overflows. 
Yet another choice is in how to divide the testing and training data.  Many times 
one wants to use as many examples as possible to train a model and 90/10 splits are 
common where 90% of the total number of instances are used for training a model and 
10% are used for testing.  However, in this case if only 10% of the instances are utilized 
for testing, this leaves 58 testing instances or 16 testing instances with a balanced test set.   
 For these experiments I chose to utilize drugs with more than 250 messages, 
leading to an overall example set of 575 drugs of which, 77 are watchlist drugs.  
Separating examples into two different datasets, one with 500 or more messages and 
between 250 and 500 messages, leads to the question of generalizability.  Will a classifier 
trained on more data (500 messages/drug) work on instances with sparser data (250 
messages/drug) or vice versa, and would the results be fair?  Instead both types of 
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instances are mixed and a subset of the total is used for testing while the rest is used for 
training.  
5.5.2 Training and Testing Dataset Size Experiment 
 An initial experiment aimed at satisfying some of the dataset construction 
questions was implemented and run.  This first experiment was designed to choose 
between scaling dimensions in feature vectors or not in addition to choosing the ratio of 
negative to positive training examples for both testing and training datasets.  For example 
a 1:1 ratio for testing would indicate the same number of positive (watchlist) drugs as 
non-watchlist ones, 2:1 would indicate 2 times the number of non-watchlist drugs to 
watchlist drugs. There are many more instances of non-watchlist drugs available.  I 
decided on a 80/20 data split due to the fact that if a 90/10 split was used and 1:1 ratio of 
negative to positive examples were used, the resulting testing set would only have 15 
instances, hardly enough for a statistically significant result.  The word features utilized 
for the early test were comprised of the combined special lexicons.  The preliminary 
experiments were performed using SVMs with a RBF kernel and using grid search with 
10-fold cross validation for building models.  The test dataset was then run against the 
resulting model and ROC curves and AUC numbers were generated from the resulting 
output.   
5.5.3 Classification Experiments 
For the specialty lexicon experiments and the general lexicon experiments, the 
total set of instances are divided into a test and training set as shown in the Figure 7. Due 
to the inconclusive nature of the training and testing dataset size experiments presented 
earlier, the commonly accepted stratified sampling approach is utilized where the test and 
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training sets are sampled with the same distribution as the original data.  The data is 
divided into a 90/10 split with 90% of examples being used to train and 10% being used 
for testing and are sampled such that the splits are representative of the original 
distribution of positive and negative instances.  Several types of experiments are run.  
The first is 10-fold stratified cross validation on the 90% of training data.   Several cross 
validation experiments are run on the 90% of the data, the first a general classification 
experiment with now cost weighting, another is a cost weighting experiment where the 
costs of the positive and negative examples are adjusted to make the cost distributions 
approximately equal.  In the case of the cost weighting experiment, a greater penalty is 
imposed for incorrectly classifying a positive example then a negative one.  
 
Figure	   10:	   Figure	   demonstration	   how	   the	   instance	   data	  was	   divided	   for	   the	  
various	  experiments.	  	  
The types of classification experiments performed include: Un-normalized Naïve 
Bayes (UNB), Un-normalized Naïve Bayes with cost weighting (UNBC), Normalized 
Naïve Bayes (NNB), Normalized Naïve Bayes with cost weighting (NNBC), Un-
normalized SVM (SVM), Un-normalized SVM with cost weighting (SVMC), 
Normalized SVM (NSVM), and Normalized SVM with cost weighting (NSVMC).  For 
the case of cross fold SVM experiments, grid search was performed for each fold.  
All Data 
Test 
Train Cross Validation 
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I believe that the cross fold validation experiments offer a more accurate picture 
of the classification performance because cross fold validation is the average over 
multiple runs with multiple divisions of the data. I utilize the smaller subset of data for 
these initial cross fold validation experiments because similar sized data is used in the 
feature selection experiments and to make the results comparable over differing 
experiments.  There is no test data for the feature selection experiments, and instead I use 
the 10% of the full dataset to select word features over utilizing BNS.  In this way the 
feature selection does not preference the watchlist drugs a priori and thus reduces the 
chances of overfitting. 
5.5.3.1 Specialty Lexicon Experiments 
An initial experiment of the 5 various combinations of the specialty lexicon 
(medical, disease names, drug names, sentiment, reaction lexicon) was used to identify 
the best combination of lexicon that provides the top classification performance.   This 
leads to a total of 30 combinations of lexicons ranging from each individual lexicon to all 
of them together.  Two hundred forty (240) experiments with various parameters were 
run.  Accuracy, F1 (a combination of precision and recall) and area under the ROC curve 
are chosen as evaluation metrics.   
5.5.3.2 BNS Lexicon Experiments 	   The BNS lexicon experiments as stated previously use the test subset of data to 
choose the most salient word gram features using Bi-Normal Separation which 
preferences word-grams that are differentially expressed between watchlist and non-
watchlist messages.  The top 15,000, 10,000, and 5,000 word grams were chosen from 
the test subset.  Utilizing word grams from the entire message set would artificially 
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inflate the classification scores since often times classifiers do not have complete 
knowledge about the entire lexicon apriori.   
5.5.3.3 Watchlist Predictions 
As with any predictive work it is difficult to quantify the results except basing it 
upon past performance.  This is usually but not necessarily indicative of future 
performance. I provide predictions of future watchlist or recalled drugs; however these 
predictions are validated with evidence of past performance cases drugs, which are 
removed from market. 
The previous section’s results are used to choose the highest performing 
classifiers for accuracy, F1 and AUC scores. Utilizing the feature set and classification 
algorithms, numerous cross validation runs across all of the data are performed multiple 
times.  The output from these classification runs provides insight into future watchlist 
drug predictions.  
Multiple top performing classifiers from each category are combined in an 
ensemble like approach taking their combination of features and different classification 
algorithms to produce a meta classifier where the false positives from each category are 
combined using a linear combination resulting in a score.   
I look at the false positives, drugs that are non-watchlist but are classified as 
watchlist by a classifier. A false positive occurs when a negative instance is incorrectly 
identified as a positive one.  For SVMs this means that the instance falls on the same side 
of the hyperplane as the positive instances and is usually close to the boundary.  For 
Naïve Bayes, the maximum likelihood estimate is such that the likelihood of the instance 
being a watchlist drug is greater than a non-watchlist drug.   
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I am interested in drugs that are consistently marked as false positives.  I 
hypothesize that drugs consistently labeled as watchlist are more likely to be “real” or 
future watchlist or removed from market drugs in the future.   In being labeled as a false 
positive the consistency provides confidence in the prediction.  This prediction is based 
solely on the word features people use to talk about these drugs. Drugs that are false 
positives could be real watchlist drugs in the future given third party confirmation such as 
from the FDA.   
Figure	   11:	   Depiction	   of	   ensemble	   classification	   method	   using	   a	   divided	  
dataset. 
	  
 
 82	  
Given a 90/10 split where 10% of drugs are used to evaluate a classifier, 10 runs 
should ensure each drug is tested at least once and 50 runs statistically speaking, should 
allow each drug to be classified 5 times against 5 different classifiers.  For these 
experiments each set of features was used to build a hundred classifiers, test and training 
sets.   
Here outputs from classifiers are utilized because different types of classifiers 
were found to perform the best and their output cannot be directly compared. It does not 
make sense to compare a likelihood estimate to a distance to a hyperplane.  Multiple 
rounds of classification with mixed training data increase the confidence in a prediction, 
as does the use of multiple classifiers.   
 A weighted ratio is created to score the false positives including the ratio of false 
positives to number of tests, the number of false positives and the number of classifiers 
that predicted a false positive: Number of False Positives / Number of occurrences (tests) 
* Number of False Positives * Number of classifier types.  This was done because it is 
intuitive that a weighted average over the number of false positives is important, a ratio 
of .5 given 1 false positive to 2 occurrences is different from 100 false positives to 200 
occurrences.  The number of different classifiers is also important, which classified it as a 
watchlist drug giving credence to the other classifications. 	   Two	   runs	   were	   made	   with	   drugs	   withdrawn	   from	   the	   market.	   	   Firstly	  withdrawn	  drugs	  were	  labeled	  as	  non-­‐watchlist	  to	  determine	  if	  the	  classifiers	  would	  accurately	   identify	   the	  withdrawn	  drugs.	   	  This	  procedure	  validates	   this	  method	  of	  watchlist	   drug	   identification.	   	   Secondly,	   it	   demonstrates	   the	   robustness	   of	   the	  method	   for	   watchlist	   drug	   identification.	   	   The	   second	   run	   removed	   the	   watchlist	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drugs	  and	  classifies	  them	  after	  the	  classifier	  has	  been	  built	  for	  each	  fold	  of	  the	  cross-­‐validation	  run.	  	  This	  second	  method	  should	  more	  accurately	  identify	  the	  withdrawn	  drugs	  with	  greater	  confidence	  because	  their	  data	   is	  not	  mixed	  with	  the	  other	  non-­‐watchlist	  drugs	  possibly,	  reducing	  the	  accuracy	  of	  the	  classifiers.	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6 Results 
6.1 KL Divergence 
KL Divergence demonstrates differences in distributions.  Here we are interested 
in the differences in word distributions between messages with watchlist drug mentions 
compared to those without mentions.  Table 9 describes the divergence between the two 
distributions; Because KL Divergence is non symmetric, both scores (for example 
Watchlist compared to Non-Watchlist and Non-Watchlist compared to Watchlist 
distributions) are reported.   
 
Table	  9:	  KL-­Divergence	  scores	   for	   the	  word	  distributions	   from	  watchlist	  and	  
non-­watchlist	   messages	   versus	   the	   Google	   1-­Tera	   gram	   corpus	   and	   the	  
Reuters	  News	  corpus.	  
P Q Score 
Watchlist Non-Watchlist 0.1684 
Non-Watchlist Watchlist 0.1778 
Watchlist Google 1.4178 
Non-Watchlist Google 1.1804 
Watchlist Reuters 1.3279 
Non-Watchlist Reuters 1.0815 
Reuters Google 1.2534 	  
Table 9 compares the differences between the watchlist and non-watchlist 
distributions and between the Google and Reuters distributions.  Interestingly the Reuters 
distribution is closer to the Google distribution than the watchlist drug message.  Some of 
the differences might be attributable to the watchlist distribution generated over less data 
than the non-watchlist.  It was generated from approximately 15.5% of the amount of 
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data from which the non-watchlist distribution generated.  In addition some of the 
differences in the watchlist and non-watchlist distributions could also be attributed to the 
drug mentions themselves.   
We can look at the terms within each distribution that were attributed to the 
greatest differences between the distributions.  In some sense this shows the “over 
expressed” terms, ones that proportionately occur more in one distribution than in the 
other.  
Table	  10:	  Terms	  with	  the	  most	  contribution	  to	  the	  KL-­Divergence	  between	  the	  
term	  distributions	  from	  the	  wachlist	  and	  non-­watchlist	  message	  corpora.	  
DKL(Watchlist||Non) DKL(Non||Watchlist) 
Term Score Term Score 
br 0.015891 the 0.004037 
gt 0.011768 nbsp 0.002699 
i 0.007875 of 0.002254 
lt 0.003781 in 0.00207 
my 0.003018 vaccin 0.002002 
br&gt 0.0029 oil 0.001032 
me 0.002256 fat 0.001032 
have 0.001763 by 7.92E-04 
you 0.001712 as 7.60E-04 
yahoo 0.001395 is 7.56E-04 
it 0.001326 or 7.40E-04 
take 0.001311 food 7.30E-04 
amp 0.001303 use 6.67E-04 
sevofluran 0.00123 diet 6.25E-04 
u 0.001157 hiv 5.95E-04 
med 0.001122 natur 5.75E-04 
am 0.001098 autism 5.74E-04 
drug 0.001091 product 5.71E-04 
was 0.001043 cream 5.53E-04 
get 0.001041 ribavirin 5.43E-04 
about 0.001026 contain 5.18E-04 
i'm 9.64E-04 are 5.12E-04 
feel 9.44E-04 acid 4.95E-04 
so 8.80E-04 skin 4.87E-04 
migrain 8.69E-04 magnesium 4.87E-04 	  	  
	  
 
 86	  
There are marked differences between the two lists of the 25 top terms contributing to 
differences between the distributions.  The first thing that comes to mind are the 
differences in “garbage” or conversion artifacts of html stripping such as npbsp, br, gt, 
br&gt, and amp.  These exist in both lists indicating that messages in both distributions 
were written in html though they are more prevalent in the watchlist drug messages.   
Ribavirin and Sevofluran are two drugs in the top 25 terms.  While drug mentions 
are not the most prevalent type of term, they do exist.  Similarly conditions such as HIV 
and Autism are mentioned. Drug names and conditions might be mentioned together if 
drugs to treat serious conditions are more likely to cause side effects or if they occur 
often with names of watchlist drugs since people are describing the problematic drug.     
Furthermore there are differences in the expression of determiners and 
prepositions such as the, am, you, it, I’m, is, or.   This is not surprising as previous work 
has shown that such features are used to determine authorship between genders.  These 
functional words are also indicative of emotional writing, which one would expect from 
adverse effect causing drugs.  This is also helpful because these types of words are 
general in nature and likely to occur frequently.  General features are preferred since the 
classifier will not learn on rare words or features that can lead to overfitting, especially 
with small amounts of data.    
6.2 Dictionary NER 
The KL Divergence results are encouraging indications that the two word list 
distributions are separable utilizing machine learning techniques.  However, to aid in the 
classification task identification of drug and effect entities are necessary.  This section 
details results of experiments on identifying and extracting drug and effect entities from 
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within messages. 
For the purpose of this dissertation and the following experiments, drug names 
with common words were removed and instead the generic (chemical name) was left. 
Each of the lexicons phrase searches was constructed and run against the index.  A total 
of 13,794,445 AERS instances and	   2,228,588 drug instances were found. These are 
numbers of messages containing a mention.   However messages can contain multiple 
drug and AERS mentions. The differences in the number of instances between numbers 
of AERS versus drug mentions are clearly delineated in Figure 10.  Figure 9 depicts the 
number of different drug mentions per message.  Many messages have relatively few 
mentions with >96% of messages that contain a drug having 5 or fewer distinct drugs.  
However, several messages have many different drug mentions with one containing >700 
distinct drugs.  Messages having many mentions are often lists of drugs people post on 
groups or SPAM.  Messages having more than 5 unique drugs in them are removed.  A 
potential side effect is that this will remove some messages from people with very large 
drug regimens such as those with CHF or HIV.   
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Figure	   12:	   Graph	   depicting	   the	   number	   of	   unique	   drug	   mentions	   versus	  
numbers	  of	  messages	  that	  contain	  that	  number	  of	  mentions	  in	  a	  log/log	  scale.	  	  
The	   graph	   follows	   a	   Zipf	   distribution	   with	   many	   messages	   containing	   few	  
unique	  drug	  mentions.	   	  	  
	  
Figure	  13:	  Graph	  depicting	  the	  number	  of	  messages	  with	  unique	  AERS	  or	  drug	  
lexicon	  mentions	  per	  a	  message	  versus	  term	  length.	   	  For	  example	  "Benadryl"	  
would	  have	  a	  term	  length	  of	  one	  and	  "abdominal	  cramps"	  would	  have	  a	  length	  
of	  two.	  	  The	  distributions	  are	  exponentially	  decaying.	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Figure 10 demonstrates the differences in the number of instances of AERS 
lexicon found versus drug lexicon.  Note that many more side effects are mentioned than 
drugs.  Further analysis is warranted to determine if previous mentions of a drug in an 
earlier post negates the need of mentioning it again and the drug mention becomes 
implicit, or perhaps people are complaining or listing adverse effects without attributing 
them to a particular drug, or it is a common symptom of their treatment or illness.  For 
example headaches or migrains are both symptoms of certain illnesses and a side effect of 
drugs.   
The drug lexicon consists of multi-word phrases.  However the distribution of 
phrase decays exponentially as seen in Figures 13 and 14, with most drug and AERS 
phrases found being of length 1.  These results are not surprising as people are more 
likely to use a brand name of a drug rather than a multi-term generic active ingredient 
name.  Multi-term phrases are often longer than single term ones, increasing the 
likelihood of a spelling mistake or typo.   
	  
Figure	  14:	  Graph	  similar	  to	  the	  one	  in	  Figure	  13	  but	  depicting	  the	  percentages	  
of	  messages	  with	  AERS	  or	  drug	  lexicons	  by	  term	  length.	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6.3 Drug mentions in messages 
Appendix C has a list of the mean, standard deviation, minimum, maximum and 
median distances for occurences of the top 25 co-occuring drugs.  This distance is hard to 
quantify since English words have an average length of 5.1 characters (7.1 including 
spaces before and after a word). However many messages contain other text such as 
signatures, ascii art, emoticons and various amounts of spacing and formatting characters.  
As seen from the averages of the statistics mentioned for the 25 top scoring drugs, the 
standard deviation is quite large indicating that people talk about these drugs in very 
different ways and not only in lists as previously mentioned.   Due to the large variance 
and large differences between the minimum and maximum distances, the median gives a 
more accurate picture of the data than just the average. The median and average are quite 
different with the average of the 25 scores ~215 or ~30 words and the median average 
~51 or 7 words. 
 Looking at the number one correlated drug pair, both Viagra and Cialis are used 
to treat Erectile Dysfunction.  The two drugs overlapped in 9,406 messages where they 
were the only drugs mentioned.   Looking at Appendix C, the mean distance between the 
two drugs is ~90 characters with a standard deviation of 296 characters.  The median is 
11 and the minimum distance is 7 characters and the maximum distance was 1265.  
Looking at the distribution of distances between mentions of Viagra and Cialis, Figure 12 
demonstrates that the distribution in distance is heavily skewed towards small differences 
in distances.    
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Figure	   15:	   Character	   distance	   between	   mentions	   of	   drugs	   plotted	   against	  
frequency	  of	  occurrence	  demonstrates	  a	  Zipfian	  distribution.	  	  
With this skewed distribution, looking at average distance does not give an accurate 
picture of what most distances between mentions are like. Upon further inspection the 
method of calculating distance is biased.  The first mention of each drug is not 
necessarily close to the other.  Inspecting the longest distance between messages 
demonstrated that the first drug (Viagra) was mentioned in the beginning of the message 
and Cialis was first mentioned near the bottom.  However Viagra was re-iterated in the 
sentence Cialis was first mentioned.   Similar results were found in randomly sampled 
messages with distances that were average, mean, minimum and median cases.  In each 
case both drugs were mentioned either within the same sentence or the following 
sentence.  This makes segmentation of the messages difficult as it becomes hard to 
discern which adverse effect is attributable to which drug.  Therefore for the analysis, 
attribute effects to all drugs within the messages.  The idea is that the varied patterns of 
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effects and messages combined with the law of large numbers lead to discernable 
differences by the machine learning classifiers. 
 This chapter explores dictionary named entity recognition and drug effect 
mentions and looks at the distribution of drugs within messages. Within the Yahoo! 
corpus 13,794,445 AERS instances and 2,228,588 drug instances were identified.  A 
SPAM heuristic of >5 different drug mentions in a message was developed.  Results also 
indicate that segmentation  of messages is difficult when multiple drugs and effects are 
mentioned since they are both close in the number characters separating them so it is 
difficult to attribute an effect to a particular drug.  
6.4 Sentiment  
The other feature used by the classifiers is sentiment.  I believe that sentiment is 
important in the classification process due to the similarities with product reviews.  The 
sentiment of messages that contain drug mentions are similar to product reviews.  People 
make qualitative and emotional statements about drugs. In order to demonstrate that 
sentiment can be measured with meaningful results, sentiment of messages with drug 
mentions are tracked over time. Here we look for a correlation between news articles and 
changes in aggregate sentiment of drug containing messages.   
I hypothesize that sentiment scores increase or decrease following a positive or 
negative news item.  As a control the sentiment scores of drug containing messages are 
compared to those within the same forums that do not have drug mentions. Two case 
studies for the drugs Tyysabri and Vioxx are presented. 
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6.4.1 Tysabri 
Tysabri is a recently introduced prescription medication approved for patients 
with relapsing forms of Multiple Sclerosis (MS).  It was originally approved by the FDA 
in November 2004, and then was subsequently withdrawn by the manufacturer, Biogen-
Idec in February 2005.  In June 2006 it was then approved for resumed marketing (FDA, 
2006). The use of this drug is narrow, specifically for MS.   
We demonstrate the ability to track changes in sentiment within a specific group 
for a limited use drug. Two MS groups that contained more than 500 instances of Tysabri 
were selected.  The messages were evaluated using our augmented LIWC lexicon.  A one 
way ANOVA was run to determine if there was a statistically significant difference 
between the scores of messages in the following groups: messages containing Tysabri 
references pre-recall, during recall, and after the recall, and messages not containing 
Tysabri references pre-recall, during recall, and after the recall.  We found that the results 
were statistically significant with p < .001.   We plotted the outlier corrected means of the 
messages containing Tysabri references versus control (messages with no Tysabri 
references).  See Figure 16 for this graph.  Data was binned by quarters to improve the 
number of samples per a data point.   
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Figure	  16:	  Sentiment	  of	  messages	  mentioning	  Tysabri	  versus	  those	  that	  do	  not	  
for	  two	  MS	  groups.	   	  Vertical	  bars	   indicate	  dates	   for	  FDA	  approval	  of	  Tysabri,	  
voluntary	  withdrawal,	  and	  remarketing.	  
 
Tysabri first appears shortly after it was approved by the FDA in the 
November/December timeframe as seen by the first data point.  After its introduction the 
sentiment initially improved then got increasingly negative during the time period 
Biogen-Idec removed it from the market.  After the drug’s re-introduction to the market 
the sentiment was extremely positive compared to the time period before and during its’ 
recall.  Now that the drug was back on the market, the sentiment has seemed to stabilize 
at a more slightly negative point than at its reintroduction.  We conjecture that the highly 
positive sentiment was due to people’s hope for the drug but the actual effect on the 
population lagged later and can be seen by the stabilized sentiment.   
6.4.2 Vioxx  
We looked for groups that contained 100 more instances of Vioxx or Celebrex.  
Our data was spread over more than 25,000 news groups spanning 7 years.  This 
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selection process was used to weed out news groups that did not contain any references to 
either of the drugs and ensure there were similar numbers of drug messages as compared 
to control ones.  We only consider the sentiment of control messages of groups that 
mention either of the drugs.  The pruning resulted in 40 groups, 681,516 people (we 
consider an email address a proxy for a person), containing 867,659 messages of which 
had an average message length of 1,513 characters.   We were interested in determining if 
our system was able to accurately determine effects for large groups as well as for a 
broad coverage drug.  Vioxx and Celebrex are commonly used pain relievers.  Vioxx was 
first marketed in 1999 and subsequently withdrawn in 2004 (FDA, 2004a). We tracked 
the sentiment of these two drugs over time.  See Figure 10 for data points and dates.   
	  
Figure	  17:	  Sentiment	  of	  two	  drugs,	  Vioxx	  and	  Celebrex	  tracked	  over	  time.	  	  See	  
Figure	  16	  for	  data	  points	  and	  dates.	  
 
The messages were evaluated using our augmented LIWC lexicon.  A one way 
ANOVA was performed to determine if there was a statistically significant difference 
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between the scores of messages in the following groups: messages containing Vioxx pre 
and post recall; messages containing Celebrex pre and post recall; and messages not 
Vioxx or Celebrex pre and post recall.  The results are statistically significant with p < 
.001.  The outlier corrected message means containing Vioxx references, Celebrex and 
control (messages with no Vioxx or Celebrex references) are plotted in Figure 10.  Data 
is binned by quarters to improve number of samples. 
 1) Sentiment sharply increases for Celebrex and similarly decreases for Vioxx.  On 
October 30, 2003 the Wall Street Journal published an article from a medical conference 
that was funded by Merck, the maker of Vioxx, which found “an increased risk of heart 
attack…compared with patients taking a competing painkiller, Celebrex, from Pfizer Inc” 
(Burton and Callahan, 2003).  
 2) The Celebrex sentiment graph increases again and decreases for Vioxx.  On 
April 14, 2004, in study sponsored by Merck, researchers found an elevated risk of acute 
myocardial infarction associated with Vioxx but not with Celebrex (Solomon et al., 
2004). A similar study was published in May 2004 showing that rates of admission for 
congestive heart failure were higher for patients on Vioxx and non-selective NSAIDs 
(Mamdani et al., 2004). 
 3) On September 30, 2004 Merck voluntarily pulled Vioxx from the market (FDA, 
2004a). Intuitively one would expect that sentiment towards the drug decreases, however 
one can imagine that sentiment might increase due to the relief people would have since 
they are no longer on the drug and that it is no longer available. 
 4) Sentiment for Celebrex declined, whereas Vioxx sentiment looks somewhat 
static. On December 17, 2004 the FDA released a statement that the National Cancer 
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Institute and Pfizer had stopped a clinical trial for Celebrex after determining: “Patients 
in the clinical trial taking 400 mg. of Celebrex twice daily had a 3.4 times greater risk of 
CV [cardiovascular] events compared to placebo. For patients taking 200 mg. of 
Celebrex, the risk was 2.5 times greater” (FDA, 2004b).   
 5) Again, sentiment for Celebrex declined.    On April 7, 2005 the FDA ordered 
Pfizer, the maker of Celebrex to remove a related drug Bextra (FDA, 2006).  However, 
Celebrex was allowed to remain on the market with a boxed warning about potential 
cardiovascular events and life-threatening gastrointestinal bleeding (FDA, 2006). 
	  
6.5 Lexicon Experiments 
6.5.1 Specialty Lexicon Experiments 
An initial experiment of the 5 various combinations of the specialty lexicon 
(medical, disease names, drug names, sentiment, reaction lexicon) were used to identify 
the best combination of lexicon that provide the top classification performance.   This 
results in a total of 30 combinations of lexicon ranging from each individual lexicon to all 
of them together.  A total of 240 experiments with various parameters were run.  
Accuracy, F1 (a combination of precision and recall) and area under the ROC curve are 
chosen as evaluation metrics.  Below we sort the experiments into three main categories, 
Cross Validation, Test, and Test with Cost Weighting.  The results are labeled as follows: 
lexicon + classification type with dis = disease lexicon, react = AERS reaction lexicon, 
drugs = drug lexicon, sent = sentiment lexicon and med = medical lexicon.  Graphs of all 
of the runs for Accuracy, F1 and Area Under the ROC Curve are in the appendix.  Below 
are the results of the top 10 performing classification algorithm with the corresponding 
feature set for each of the evaluation metrics.   
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Table	  11:	  Table	  depicting	  the	  accuracy	  of	  the	  various	  classification	  algorithms	  
with	   different	   feature	   sets	   with	   the	   lower	   and	   upper	   bounds	   with	   a	   95%	  
confidence	  interval.	  
Experiment Accuracy Lower Bound Upper Bound 
Cross Validation 	   	   	  
dis_react_NSVM 0.903288201 0.793206235 0.957882075 
drugs_dis_sent_react_NSVM 0.901353965 0.790801818 0.956684149 
drugs_sent_react_NSVM 0.901353965 0.790801818 0.956684149 
dis_sent_react_NSVM 0.901353965 0.790801818 0.956684149 
react_NSVM 0.901353965 0.790801818 0.956684149 
sent_react_NSVM 0.901353965 0.790801818 0.956684149 
drugs_dis_sent_NSVM 0.899419729 0.788404626 0.955478999 
all_NSVM 0.899419729 0.788404626 0.955478999 
drugs_dis_NSVM 0.899419729 0.788404626 0.955478999 
drugs_NSVM 0.899419729 0.788404626 0.955478999 
Test 	   	   	  
drugs_dis_sent_react_UNB 0.879310345 0.771204077 0.940291098 
drugs_sent_react_UNB 0.879310345 0.771204077 0.940291098 
dis_sent_react_UNB 0.879310345 0.771204077 0.940291098 
drugs_dis_NSVM 0.879310345 0.771204077 0.940291098 
sent_react_UNB 0.879310345 0.771204077 0.940291098 
dis_SVM 0.877192982 0.768668117 0.938855394 
dis_NSVM 0.877192982 0.768668117 0.938855394 
dis_NNB 0.877192982 0.768668117 0.938855394 
drugs_sent_SVM 0.862068966 0.750738501 0.928415984 
drugs_sent_NSVM 0.862068966 0.750738501 0.928415984 
Test  With Cost Weighting 	   	   	  
drugs_dis_NSVMC 0.879310345 0.771204077 0.940291098 
drugs_sent_SVMC 0.862068966 0.750738501 0.928415984 
drugs_sent_NSVMC 0.862068966 0.750738501 0.928415984 
drugs_dis_sent_react_SVMC 0.862068966 0.750738501 0.928415984 
drugs_dis_sent_react_NSVMC 0.862068966 0.750738501 0.928415984 
med_dis_sent_SVMC 0.862068966 0.750738501 0.928415984 
med_dis_sent_NSVMC 0.862068966 0.750738501 0.928415984 
med_drugs_dis_sent_SVMC 0.862068966 0.750738501 0.928415984 
med_drugs_dis_sent_NSVMC 0.862068966 0.750738501 0.928415984 
drugs_sent_react_SVMC 0.862068966 0.750738501 0.928415984 	  
We initially utilize accuracy to provide some basis of differentiation from the baseline 
classifier that would label all instances as negative.  Labeling all instances as negative 
would lead to an accuracy of 86.7%.  For all three of the experiments, cross fold 
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validation, simple classification and classification with cost weighting, the top 
performing system is more accurate than the naïve baseline classifier.  However, once we 
calculate the error bounds utilizing a binomial distribution (since the classifier is binary 
in nature so each trial is a Bernoulli trial) the lower confidence level is less than the naïve 
accuracy rate, leading to uncertainty in determining if the classifiers are more accurate 
than the naïve one.  
Table	  12:	  Table	  depicting	  the	  F1	  score	  of	  the	  various	  classification	  algorithms	  
with	  different	  feature	  sets.	  
Experiment F1 
Cross Validation 
drugs_dis_react_NSVM 0.476190476 
drugs_dis_react_UNB 0.472527473 
drugs_UNB 0.469879518 
drugs_react_UNB 0.463276836 
dis_sent_react_NSVM 0.463157895 
sent_react_NSVM 0.463157895 
sent_react_UNB 0.460431655 
dis_react_NSVM 0.456521739 
dis_sent_react_UNB 0.453900709 
drugs_sent_UNB 0.452054795 
Test 
drugs_UNB 0.470588235 
drugs_dis_UNB 0.444444444 
drugs_dis_sent_react_UNB 0.363636364 
drugs_sent_react_UNB 0.363636364 
dis_sent_react_UNB 0.363636364 
sent_react_UNB 0.363636364 
dis_UNB 0.358974359 
med_dis_NNB 0.333333333 
drugs_dis_NNB 0.333333333 
drugs_NNB 0.333333333 
Test With Cost Weighting 
drugs_dis_SVMC 0.444444444 
drugs_UNBC 0.444444444 
drugs_react_SVMC 0.384615385 
drugs_dis_react_SVMC 0.384615385 
drugs_dis_UNBC 0.357142857 
drugs_SVMC 0.352941176 
sent_react_UNBC 0.307692308 
dis_sent_UNBC 0.266666667 
sent_UNBC 0.266666667 
med_dis_sent_NNBC 0.25 
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The accuracy results of classifiers using cost weighting are less than classifiers not using 
cost weighting.  This makes some sense as the training and test distributions are biased. 
However what is not apparent from the accuracy score itself is the number of positive 
(watchlist drugs) each classifier has predicted (either correctly or not).   The F1 and AUC 
(area under the ROC curve) scores provide additional insight into the classifier 
performance.	  
The F1 score is the harmonic mean of precision and recall and can be thought of 
as their weighted average.  F1 = 2* precision * recall / (precision + recall).  Precision 
(measure of exactness) and recall (measure of completeness) are common metrics used in 
information retrieval.  An inverse relationship is often seen where optimizing for one 
leads to a decline in the other.  This is particularly apparent in a plot of precision versus 
recall graph of the classifiers shown in Figure 18 below. 
	  
Figure	  18:	  Graph	  plotting	  precision	  versus	  recall	  for	  the	  various	  classification	  
algorithms	  and	   feature	   sets	   for	   cross	  validation	  experiments	  with	   classifiers	  
with	  the	  highest	  recall	  and	  precision	  labeled.	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Here we see that in the cross validation graph there seem to be two main clusters where 
the classifiers lay, one cluster with more mass near 1.0 for precision (perfect precision) 
but relatively low recall (0.3) whereas the other cluster has a mass near 0.45 for recall and 
0.4 for precision.  Here we see that the classifier with the highest precision uses the 
disease lexicon using an un-normalized naïve bayes algorithm. The precision is relatively 
low at approximately 0.18 but has a relatively high recall at 0.73.   However, both points 
are not in the list of top 10 F1 score list because they only optimize one component of the 
F1 score.     
 
Figure	  19:	  Graph	  plotting	  precision	  versus	  recall	  for	  the	  various	  classification	  
algorithms	   and	   feature	   sets	   for	   separate	   test	   and	   evaluation	   instance	  
experiments	  with	  classifiers	  with	  the	  highest	  recall	  and	  precision	  labeled.	  	  	   Like the accuracy scores, the F1 scores were lower for the experiments with cost 
weighting and the cross validation scores were the greatest by a small amount.  The 
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patterns of scores for the precision versus recall plots differed significantly from the cross 
validation ones with overall masses with lower precision and recall with few outliers.   
	  
Figure	  20:	  Graph	  plotting	  precision	  versus	  recall	  for	  the	  various	  classification	  
algorithms	  and	  feature	  sets	  for	  cost	  weighted	  classification	  experiments	  with	  
classifiers	  with	  the	  highest	  recall	  and	  precision	  labeled.	  	  
Surprisingly the AUC score is the only metric where cost weighting scores higher than 
non-weighted scores.  However, only one score is greater than the non-weighted scores 
and it is unclear whether or not the difference is statistically significant. 
Looking at AUC for non-weighted classifiers, Naïve Bayes dominates. Similar 
results occur for F1 whereas for accuracy, SVM dominates.  The results are more even 
for the classifiers using cost weighting for F1 and AUC.  Looking at the lexicon that 
occurs in the top performing systems no one set of lexicon dominates.  However, drugs 
and disease lexicon occur most often in the top performing classifiers.  The occurrence of 
each lexicon in the top 10 scoring systems for accuracy, F1 and AUC are shown in Figure 
14. 
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Table	  13:	  Table	  depicting	  the	  F1	  score	  of	  the	  various	  classification	  algorithms	  
with	  different	  feature	  sets.	  
Experiment AUC	  
Cross Validation 
drugs_UNB 0.7592 
drugs_dis_UNB 0.7564 
med_drugs_NNB 0.7545 
med_drugs_dis_NNB 0.7545 
med_drugs_dis_react_NNB 0.7536 
med_drug_react_NNB 0.7536 
sent_UNB 0.7441 
drugs_react_UNB 0.7427 
all_NNB 0.7406 
med_drugs_dis_sent_NNB 0.7405 
Test 
dis_UNB 0.7514 
drugs_dis_UNB 0.6850 
dis_sent_react_UNB 0.6675 
drugs_UNB 0.6675 
sent_react_UNB 0.6675 
drugs_sent_UNB 0.6550 
drugs_dis_sent_UNB 0.6300 
sent_UNB 0.6300 
dis_sent_UNB 0.6250 
med_dis_NNB 0.6100 
Test With Cost Weighting 
drugs_UNBC 0.7825 
drugs_dis_UNBC 0.7075 
drugs_dis_SVMC 0.6900 
drugs_react_SVMC 0.6825 
drugs_dis_react_SVMC 0.6825 
dis_UNBC 0.6514 
sent_react_UNBC 0.6325 
drugs_SVMC 0.6275 
dis_sent_react_UNBC 0.6238 
dis_NNBC 0.6200 	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Table	  14:	  Table	  demonstrating	  the	  number	  of	  occurrences	  of	  each	  of	  the	  five	  
lexicon	   occurring	   in	   the	   10	   best	   performing	   classifiers	   for	   the	   F1,	   AUC	   and	  
accuracy	  scores.	  The	   table	  on	   the	   top	   is	   for	  non-­weighted	  classifiers	  and	   the	  
one	  below	  is	  for	  cost	  weighted	  classifiers.	  
Non-Weighted Classifiers 
Drugs 33 
Disease 32 
Sentiment 28 
Reactions 27 
Medical 7 
 
Weighted Classifiers 
Drugs 20 
Disease 18 
Sentiment 15 
Reactions 10 
Medical 5 
 	  
Of the 5 lexicons the medical lexicon seems to be the least useful in building top 
performing classifiers leading one to believe that people do not use medical terminology 
frequently or it is used similarly within the two groups.  It is surprising that the AERS 
lexicon is the second least performing lexicon indicating also that the reactions are talked 
about in similar ways or the lexicon does not capture the way people discuss their adverse 
events that is plausible.   It is expected if not somewhat disappointing that the drug and 
disease lexicons do well.  However, as stated previously this leads to overfitting due to 
classification learning on drug names or the diseases associated with the watchlist drugs.   
6.5.2 BNS Lexicon Experiments 	   The BNS lexicon experiments as stated previously use the test subset of data to 
choose the most salient word gram features using Bi-Normal Separation which 
preferences word-grams that are differentially expressed between watchlist and non-
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watchlist messages.  Here we choose the top 15,000, 10,000, and 5,000 word grams from 
the test subset.  Utilizing word grams from the entire message set would artificially 
inflate the classification scores since often times classifiers do not have complete 
knowledge about the entire lexicon a priori.   
 Listed below are the top terms ranked by the BNS score.   There are many 
unlikely terms that are ranked the highest including “26” and “as to”.  Many of these are 
due to the relatively small sample size (58 drugs, 8 of which are watchlist).   Terms in the 
top 10,000 list include names “rita tx_genesis7” and “romero” but also general medical 
terms that seem related to adverse effects such as “root cause” or “risk[s] are” and 
include adverse effects “rosacea …”   
The BNS lexicon features were combined with the top scoring special lexicon in 
decreasing scoring order so drugs, diseases, and sentiment were one group followed by 
drugs and diseases and finally drugs.  Along with the lexicon items special features 
including the counts of numbers of disease mentions, drug mentions, medical 
terminology, sentiment containing terms and AERS terminology were used.  It was 
hypothesized that the most BNS features along with the specialty lexicon and numerical 
features utilizing normalized SVM would yield the best results. 
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Table	  15:	  Table	  demonstrating	  the	  top	  25	  word	  grams	  using	  BNS	  as	  a	  scoring	  
metric	  for	  the	  various	  feature	  cutoff	  sizes.	  	  All	  feature	  sizes	  (15k,	  10k	  and	  5k)	  
contain	   “All”	   of	   the	   word	   grams.	   	   Only	   the	   15,000	   and	   10,00	   feature	   sizes	  
contain	  the	  terms	  in	  the	  “Top	  5,000	  Terms”	  and	  only	  the	  15,000	  feature	  sizes	  
contain	  the	  terms	  in	  the	  “Top	  10,000	  Terms”.	  
All Top 5,000 Terms Top 10,000 Terms 
they were culinari right med to 
claim culprit i also right now for 
26 culprit of right now in 
time the culprit that right now this 
lab cumul dose right reserv republ 
not onli cup oliv right where 
out that cup oliv oil risk are 
research and cure rosacea risk patient 
pre cure was rita that 
find that current i take rita tx_genesis7 tx_genesis7 
upon current math river 
as to current math requir rn and 
brand current research road for 
day of current topic romero 
decid to current topic that roof then 
indic that current undergo roof then the 
pattern curti room temperatur away 
that some cut into root caus 
uniqu cut it and rosacea although 
assum cuti rosacea and other 
is my cvd rosacea bump 
suspect cycl and then rosacea can 
brown cytokin that rosacea can be 
correl cytokin tnf rosacea dr 
infant d sinc rosacea flush 	  
 
 Again the various feature combinations were combined with the Naïve Bayes and 
SVM classification algorithms with and without both normalization, and with and 
without cost penalties.  Due to the numerous combinations of options in classification and 
feature selection it was necessary to divide the output in some way to demonstrate 
meaningful results.  However, the way data is presented leads to bias such that some 
features are preferred over others.  Here we present results divided into three categories 
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based upon the most salient feature of this experiment, which is the number of BNS 
features used.   
 Table 16 below lists the top ten highest scoring (in accuracy) feature set 
combinations with their associated classification algorithms.   The associated lower and 
upper bounds for error are also listed.  None of the scores is significantly higher than a 
naïve classifier that labels all instances as non-watch list.   It is also disappointing that 
these accuracy scores are lower than the highest scores for cross validation in the last set 
of experiments. 
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Table	  16:	  Table	  depicting	  the	  accuracy	  of	  the	  various	  classification	  algorithms	  
with	   different	   feature	   sets	   with	   the	   lower	   and	   upper	   bounds	   with	   a	   95%	  
confidence	  interval.	  
 Accuracy Lower Bound Upper Bound 
All Features 
bns drugs diseases sentiment NNB 0.8762 0.7602 0.9405 
bns drugs diseases sentiment NNBC 0.8762 0.7602 0.9405 
bns drugs diseases sentiment NSVM 0.8762 0.7602 0.9405 
bns drugs diseases sentiment NSVMC 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NNB 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NNBC 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NSVM 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NSVMC 0.8762 0.7602 0.9405 
bns drugs diseases NNB 0.8762 0.7602 0.9405 
bns drugs diseases NNBC 0.8762 0.7602 0.9405 
Five Thousand Features 
bns drugs diseases sentiment NNB 0.8762 0.7602 0.9405 
bns drugs diseases sentiment NNBC 0.8762 0.7602 0.9405 
bns drugs diseases sentiment NSVM 0.8762 0.7602 0.9405 
bns drugs diseases sentiment NSVMC 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NNB 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NNBC 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NSVM 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NSVMC 0.8762 0.7602 0.9405 
bns drugs diseases NNB 0.8762 0.7602 0.9405 
bns drugs diseases NNBC 0.8762 0.7602 0.9405 
Ten Thousand Features 
bns drugs diseases sentiment NNB 0.8762 0.7602 0.9405 
bns drugs diseases sentiment NNBC 0.8762 0.7602 0.9405 
bns drugs diseases sentiment NSVM 0.8762 0.7602 0.9405 
bns drugs diseases sentiment NSVMC 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NNB 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NNBC 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NSVM 0.8762 0.7602 0.9405 
bns drugs diseases sentiment no features NSVMC 0.8762 0.7602 0.9405 
bns drugs diseases NNB 0.8762 0.7602 0.9405 
bns drugs diseases NNBC 0.8762 0.7602 0.9405 
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The most accurate classifiers for each of the three BNS feature sets are ones that utilize 
the specialty lexicon; the highest-ranking ones feature all the specialty lexicon, drugs, 
diseases and sentiment whereas the lower ranking ones contain drugs and diseases.  The 
number of BNS features does not change the overall accuracy indicating that they have 
little effect on the classifiers.  Similarly, it appears that the numerical features – counts 
over the number of disease mentions, number of drug mentions, etc. also have little effect 
on the classification performance. 
  The cross fold validation scores also coalesce since many of the scores tend to be 
close to one another.  This can be seen through the similar accuracy scores as well as the 
following precision recall graphs and F1 score tables. 
	  
Figure	  21:	  Graph	  plotting	  precision	  versus	  recall	  for	  the	  various	  classification	  
algorithms	  utilizing	  all	  15,000	  BNS	  word	  features.	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The high recall and precision scores were not highlighted because many of the feature set 
combinations had the same performance.  The similarities among the three graphs further 
emphasize the fact that the differences in BNS feature sizes have little impact on the 
classification performance. 
 
Figure	  22:	  Graph	  plotting	  precision	  versus	  recall	  for	  the	  various	  classification	  
algorithms	  utilizing	  10,000	  BNS	  word	  features.	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Figure	  23:	  Graph	  plotting	  precision	  versus	  recall	  for	  the	  various	  classification	  
algorithms	  utilizing	  5,000	  BNS	  word	  features.	  	  
Like accuracy, the F1 scores are very similar. However there is some differentiation in 
the top ten.  Interestingly, non-normalized Naïve Bayes performs best, outperforming the 
other classification algorithms despite different feature set combinations.  However, there 
are no bounds on the error for the F1 scores so the differences may not be statistically 
significant.  This is markedly different from the other set of experiments where there was 
no clear indication that one algorithm performed better than another.  In the previous 
cross validation experiments non-normalized Naïve Bayes and normalized SVM 
performed best, disappointingly the previous scores greater than the top F1 scores for all 
feature sets and algorithms in these experiments.   
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Table	  17:	  Table	  depicting	  the	  F1	  score	  of	  the	  various	  classification	  algorithms	  
with	  different	  feature	  sets.	  
Experiment F1	  
All Features 
bns drugs diseases sentiment UNB 0.4394 
bns drugs diseases sentiment no features UNB 0.4394 
bns drugs diseases UNB 0.4394 
bns drugs diseases no features UNB 0.4394 
bns drugs UNB 0.4394 
bns drugs no features UNB 0.4394 
bns UNB 0.4394 
bns no features UNB 0.4394 
bns drugs diseases sentiment UNBC 0.3889 
bns drugs diseases sentiment no features UNBC 0.3889 
Five Thousand Features 
bns drugs diseases sentiment UNB 0.4394 
bns drugs diseases sentiment no features UNB 0.4394 
bns drugs diseases UNB 0.4394 
bns drugs diseases no features UNB 0.4394 
bns drugs UNB 0.4394 
bns drugs no features UNB 0.4394 
bns UNB 0.4394 
bns no features UNB 0.4394 
bns drugs diseases sentiment UNBC 0.3889 
bns drugs diseases sentiment no features UNBC 0.3889 
Ten Thousand Features 
bns drugs diseases sentiment UNB 0.4394 
bns drugs diseases sentiment no features UNB 0.4394 
bns drugs diseases UNB 0.4394 
bns drugs diseases no features UNB 0.4394 
bns drugs UNB 0.4394 
bns drugs no features UNB 0.4394 
bns UNB 0.4394 
bns drugs diseases sentiment UNBC 0.3889 
bns drugs diseases sentiment no features UNBC 0.3889 
bns drugs diseases UNBC 0.3889 	  	  
The AUC scores provide additional insight into the classification performance.  The 
results of the AUC scores show similar results to the F1 scores in that the best forming 
algorithm is un-normalized Naïve Bayes. However, un-normalized Naïve Bayes with cost 
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weighting also is in the top scoring algorithms.  Unfortunately, similar to the F1 scores, 
the performance of the BNS feature experiments in AUC scores are less than those in the 
previous set of experiments.   
Table	   18:	   Table	   depicting	   the	   AUC	   score	   of	   the	   various	   classification	  
algorithms	  with	  different	  feature	  sets.	  
Exepriment AUC	  
All Features 
bns drugs diseases sentiment UNB 0.7028 
bns drugs diseases sentiment no features UNB 0.7028 
bns drugs diseases UNB 0.7028 
bns drugs diseases no features UNB 0.7028 
bns drugs UNB 0.7028 
bns drugs no features UNB 0.7028 
bns UNB 0.7028 
bns no features UNB 0.7028 
bns drugs diseases sentiment UNBC 0.7006 
bns drugs diseases sentiment no features UNBC 0.7006 
Five Thousand Features 
bns drugs diseases sentiment UNB 0.7028 
bns drugs diseases sentiment no features UNB 0.7028 
bns drugs diseases UNB 0.7028 
bns drugs diseases no features UNB 0.7028 
bns drugs UNB 0.7028 
bns drugs no features UNB 0.7028 
bns UNB 0.7028 
bns no features UNB 0.7028 
bns drugs diseases sentiment UNBC 0.7006 
bns drugs diseases sentiment no features UNBC 0.7006 
Ten Thousand Features 
bns drugs diseases sentiment UNB 0.7028 
bns drugs diseases sentiment no features UNB 0.7028 
bns drugs diseases UNB 0.7028 
bns drugs diseases no features UNB 0.7028 
bns drugs UNB 0.7028 
bns drugs no features UNB 0.7028 
bns UNB 0.7028 
bns drugs diseases sentiment UNBC 0.7006 
bns drugs diseases sentiment no features UNBC 0.7006 
bns drugs diseases UNBC 0.7006 	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The pattern of similar classification performance between the BNS feature sets indicates 
that the BNS features do not factor into classification performance or that more than 
5,000 features do not help.   
 The BNS feature performance overall is poorer than the specialty lexicon 
experiments.  This may be partly due to the poor feature selection, which is a side effect 
of the few numbers of messages from which the BNS features were selected.  This task, 
like many other machine learning and data mining tasks are data driven, requiring large 
amounts of annotated data to learn and generalize over.   
 Quantitative analysis of the classifiers is performed on various combinations of 
feature sets and algorithms in this chapter.  The knowledge rich features, diseases and 
drug names seemed to perform best overall.  However, these numbers without some 
comparison or task to perform, give no idea of how well this task is performed.  What is 
85% accuracy? What is good enough when predicting drug safety?  How accurate does a 
predictive classifier need to be in order to be useful?  If even one dangerous drug is found 
before it harms, is it worthwhile?  
6.5.3 Watchlist Predictions 
The previous section’s results were used to choose the highest performing 
classifiers for accuracy, F1 and AUC scores. Examining the top performing classifiers, a 
normalized SVM using the disease and AERS lexicon yields 90.33% accuracy.  A 
normalized SVM using drugs, disease and AERS lexicon yields a F1 score of 0.4762 and 
an un-normalized Naïve Bayes classifier yields an AUC score of 0.7592.   
We are interested in drugs that are consistently marked as false positives.  We 
hypothesize that drugs that are consistently labeled as watchlist are more likely to be 
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“real” or future watchlist or removed from market drugs in the future.   The consistency 
in being labeled as a false positive provides confidence in the prediction. The prediction 
is based solely based on word features.  Drugs that are discussed in similar ways will be 
labeled alike.  Drugs that are false positives could be real watchlist drugs in the future 
given third party confirmation such as from the FDA.   
 Two runs were made with drugs withdrawn from the market.  Firstly withdrawn 
drugs were labeled as non-watchlist to determine if the classifiers would accurately 
identify the withdrawn drugs.  This procedure validates this method of watchlist drug 
identification.  Secondly it demonstrates the robustness of the method for watchlist drug 
identification.  The second run removes the watchlist drugs and classifies them after the 
classifier has been built for each fold of the cross-validation run.  This second method 
should more accurately identify the withdrawn drugs with greater confidence because 
their data is not mixed with the other non-watchlist drugs possibly reducing the accuracy 
of the classifiers.   
For the first run, four drugs that were withdrawn from market were identified, Vioxx, 
Trovan, Baycol, and hydromorphone.  The following demonstrates the top scoring results 
from the first run.  All drugs with a score > 0 are in Appendix J.  
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Table	  19:	  Top	   scoring	   false	  positive	  generating	  drugs	  with	  withdrawn	  drugs	  
mixed	  in	  and	  labeled	  as	  non-­watchlist.	  	  Next	  to	  the	  drug	  name,	  the	  Pos	  column	  
denotes	  the	  number	  of	  times	  a	  classifier	  marked	  the	  drug	  as	  a	  false	  positive.	  	  
Occ	   indicates	   the	   number	   of	   occurrences,	   or	   number	   of	   times	   the	   drug	  was	  
classified.	   	   Class	   indicates	   the	   number	   of	   different	   types	   of	   classifiers	   (1-­3)	  
that	   predicted	   a	   false	   positive	   for	   a	   drug.	   	   Score	   indicates	   the	   linear	  
combination	   of	   Pos,	   Occ,	   and	   Class	   resulting	   in	   a	   score	   of	   the	   confidence	   in	  
prediction.	  	  Drugs	  are	  arranged	  in	  descending	  order.	  
Drug Pos Occ Class Score 
clozapine OR Clozaril OR FazaClo 31 64 3 45.047 
fludarabine OR Fludara OR Oforta 29 61 3 41.361 
methylphenidate OR Concerta OR Daytrana OR Metadate CD 
OR Metadate ER OR Methylin OR Methylin ER OR Ritalin 
OR Ritalin LA OR Ritalin-SR 25 50 3 37.500 
morphine OR Astramorph PF OR Avinza OR Duramorph OR 
Infumorph OR Kadian OR MS Contin OR MSIR OR 
Morphine IR OR Oramorph SR OR RMS OR Roxanol 14 38 3 15.474 
meloxicam OR Mobic 15 50 3 13.500 
Extraneal 10 36 3 8.333 
aripiprazole OR Abilify OR Abilify Discmelt 9 30 3 8.100 
evening primrose OR Evening Primrose Oil OR Primrose Oil 17 56 1 5.161 
quetiapine OR Seroquel OR Seroquel XR 15 52 1 4.327 
trazodone OR Desyrel OR Desyrel Dividose OR Oleptro 14 46 1 4.261 
(acetaminophen AND diphenhydramine) OR Anacin P.M. 
Aspirin Free OR Coricidin Night Time Cold Relief OR 
Excedrin PM OR Headache Relief PM OR Legatrin PM OR 
Mapap PM OR Midol PM OR Percogesic Extra Strength OR 
Sominex Pain Relief Formula OR Tylenol PM OR Tylenol 
Severe Allergy OR Tylenol Sore Throat Nighttime OR 
Unisom with Pain Relief 12 34 1 4.235 
thalidomide OR Thalomid 13 44 1 3.841 
 
Hydromorphone is a narcotic.  It is a semi-synthetic opiod derived from 
morphine.  An extended-release version of hydromorphone called Palladone was 
available in the United States before it was voluntarily withdrawn after a July 2005 FDA 
advisory warned of a high overdose potential when taken with alcohol (FDA, 2005). 
However, as of March 2007, it is still available in many European countries. 
Cerivastatin (Baycol) is a synthetic statin introduced in 1997 and used to lower 
cholesterol and prevent cardiovascular disease.  Statins work by inhibiting the enzyme 
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HMG-CoA reductase, which is important in the production of cholesterol.  It was 
voluntarily withdrawn in 2001 due to reports of fatal rhabdomyolysis, which is the 
breakdown of skeletal muscle that can lead to kidney failure.  At the time of withdrawal 
the FDA had reports of 31 deaths due to rhabdomyolysis (USA Today, 2001).   
Trovafloxacin (Trovan) is a broad spectrum antibiotic that was withdrawn from 
market due to the risk of heptatoxicity - causing liver damage and failure.  In 1996, Pfizer 
violated international law during an epidemic by testing the unproven drug on 100 
children and infants with brain infections (Stephens, 2006).  Currently the FDA is aware 
of 14 cases of liver failure linked to Trovan and over 100 cases of liver toxicity (FDA, 
1999).   
Rofecoxib (Vioxx) is a nonsteroidal anti-inflammatory drug (NSAID) first 
marketed in 1999 as a safer alternative to drugs such as Tylenol or Aleve.  It was 
subsequently withdrawn in 2004 due to a significant increased risk of acute myocardial 
infarction (heart attack) (FDA, 2004a).  Rofecoxib was one of the most widely used drugs 
to be withdrawn from market.  Merck, the maker of Vioxx, reported revenue of $2.5 
billion the year before it was withdrawn (Reuters, 2006).   
 Thalidomide was also flagged as a high-scoring false positive. Thalidomide was 
used as an anesthetic but was withdrawn from market in the 1960’s after it was found to 
cause birth defects resulting in babies having no limbs or limbs with finger or toes fused 
together.  However, thalidomide has been remarketed with narrow focus and strong 
labeling. 
Temazepam is an intermediate acting benzodiazepine prescribed as a short term 
sleeping aid and is sometimes used as an anti-anxiety, anticonvulsant, and muscle 
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relaxant. Sweden and Norway withdrew the drug from market in 1999 due to diversion, 
abuse, and high rate of overdose deaths in comparison to other drugs of its group.  It is 
still available in the US with strong warnings for severe anaphylactic and anaphylactoid 
reactions and cautions about complex behavior such as “sleep driving” - driving while 
not fully awake and having amnesia about the event (FDA, 2009). 
Primrose oil is derived from Oenothera biennis and is sometimes used to treat 
eczema, rheumatoid arthritis, menopausal symptoms, premenstrual syndrome, cancer and 
diabetes.  This supplement had an unusually high score given that it is a supplement.  
However, the broad range of uses and associations with other diseases and medications 
could lead to misclassification especially since one of the classifiers is based solely upon 
other drug mentions.  This misclassification could also apply to acetaminophen, vitamin 
e, fish oil and Metamucil.   
The most striking find was Sibutramine (Meridia), which is an appetite 
suppressant and is used to treat obesity.  It is currently still available in the US but has 
been removed from market in the United Kingdom and European Union.  Currently the 
drug is under review but is not considered a watchlist drug.  A FDA early communication 
about the drug was posted on 11/20/2009 and a subsequent follow-up on 1/21/2010 
indicating an increased risk of heart attack and stroke in patients with a history of 
cardiovascular disease (FDA, 2010b).  This drug was repeatedly marked as a false 
positive.  The latest dated Yahoo! messages mentioning Sibutramine were from 
12/11/2008, almost year before FDA advisories and a little over a year before the UK 
withdrawal (BBC, 2010).   Table 20 contains example messages about adverse events 
attributed to Sibutramine from the Yahoo! corpus.   These are two examples of the 
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numbers of messages that exist and contain serious effects including heart arrhythmia, 
high blood pressure, confusion, etc.   
Table	  20:	  Example	  messages	  about	  Sibutramine	  highlighting	  side	  effects.	  Date:	  4/20/2003	  Subject:	  I	  will	  be	  leaving	  the	  group	  Hello	  to	  All	  I	  have	  been	  on	  Meridia	  for	  a	  year	  and	  have	  lost	  about	  45	  pounds	  but	  now	  I	  am	  going	  off	  it	  due	  to	  health	  problems	  which	  my	  doctor	  feels	  was	  caused	  by	  it.	  I	  had	  high	  ,	  very	  high	  blood	  pressure,	  the	  doctor	  was	  going	  to	  try	  me	  on	  a	  blood	  pressure	  medication	  but	  felt	  I	  should	  stop	  Meridia	  first	  to	  see	  if	  it	  could	  be	  the	  possible	  trigger.	  i	  stopped	  Meridia	  two	  weeks	  ago	  and	  my	  blood	  pressure	  is	  back	  to	  normal.	  I	  was	  also	  having	  hair	  loss	  and	  mental	  confusions,	  unless	  I	  wrote	  things	  down	  I	  would	  forget	  all	  the	  time.	  I	  am	  so	  frustrated	  as	  I	  have	  lots	  more	  weight	  to	  lose	  and	  am	  scarred	  that	  I	  will	  gain	  all	  my	  other	  weight	  back	  but	  I	  don't	  want	  to	  die	  from	  high	  blood	  pressure.	  I	  guess	  I	  will	  just	  have	  to	  deal	  with	  being	  over	  weight	  and	  learn	  to	  love	  myself.	  My	  finance	  was	  very	  upset	  by	  the	  article	  below	  and	  told	  me	  to	  stop	  taking	  the	  drug	  also.	  I	  also	  read	  the	  following	  on	  line.	  Take	  care	  everyone	  kimberly	  	  Date:	  2/9/2006	  Subject:	  Re:[Meridia	  Forum]	  Hi,	  I'm	  new!	  I	  was	  on	  Meridia	  and	  lost	  over	  27	  pounds,	  all	  of	  which	  I	  have	  kept	  off.	  However,	  I	  had	  alarming	  heart	  rhythm	  problems	  so	  I	  stopped	  the	  Meridia	  after	  1	  month.	  Please	  keep	  in	  mind	  that	  Meridia	  WAS	  listed	  in	  Consumer	  Reports	  as	  a	  potentially	  unsafe	  drug.	  I	  am	  living	  testimony	  that	  it	  was	  dangerous	  for	  	  me.	  I	  have	  lost	  the	  rest	  of	  the	  weight	  by	  sheer	  willpower.	  The	  Meridia	  was	  a	  wonder	  drug	  but	  do	  weigh	  the	  risks	  of	  obesity	  with	  the	  risks	  of	  the	  drug.	  Just	  my	  opinion	  -­‐ 	  	  
In the second run, results of which are in Appendix K, a re-ordering of the drugs 
is seen.  Below is a list of the top twelve scoring drugs to compare against the first run.  If 
we take the identification of European Union drugs with higher scores then the second 
run performs better.  Sibutramine is ranked higher, 5th in the list of predictions.  However 
looking at the overall score including the withdrawn drugs, disappointingly Baycol has an 
overall lower score.   
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Table	  21:	  Top	   scoring	   false	  positive	  generating	  drugs	  with	  withdrawn	  drugs	  
removed	   from	   the	   cross	   validation	   data.	   	   Next	   to	   the	   drug	   name,	   the	   Pos	  
column	  denotes	   the	  number	  of	   times	  a	   classifier	  marked	   the	  drug	  as	   a	   false	  
positive.	   	   Occ	   indicates	   the	   number	   of	   occurrences,	   or	   number	   of	   times	   the	  
drug	  was	  classified.	  	  Class	  indicates	  the	  number	  of	  different	  types	  of	  classifiers	  
(1-­3)	   that	   predicted	   a	   false	   positive	   for	   a	   drug.	   	   Score	   indicates	   the	   linear	  
combination	   of	   Pos,	   Occ,	   and	   Class	   resulting	   in	   a	   score	   of	   the	   confidence	   in	  
prediction.	  	  Drugs	  are	  arranged	  in	  descending	  order.	  
Drug Pos Occ Class Score 
methylphenidate OR Concerta OR Daytrana OR Metadate CD 
OR Metadate ER OR Methylin OR Methylin ER OR Ritalin 
OR Ritalin LA OR Ritalin-SR 30 34 3 79.412 
morphine OR Astramorph PF OR Avinza OR Duramorph OR 
Infumorph OR Kadian OR MS Contin OR MSIR OR Morphine 
IR OR Oramorph SR OR RMS OR Roxanol 13 38 3 13.342 
quetiapine OR Seroquel OR Seroquel XR 14 31 2 12.645 
indomethacin OR Indocin OR Indocin IV OR Indocin SR 19 37 1 9.757 
sibutramine OR Meridia 17 34 1 8.500 
meloxicam OR Mobic 17 35 1 8.257 
vigabatrin OR Sabril 14 31 1 6.323 
losartan OR Cozaar 13 28 1 6.036 
oxycodone OR ETH-Oxydose OR OxyContin OR OxyIR OR 
Oxyfast OR Percolone OR Roxicodone OR Roxicodone 
Intensol 13 30 1 5.633 
doxepin OR Adapin OR Prudoxin OR Silenor OR Sinequan OR 
Zonalon 14 37 1 5.297 
aripiprazole OR Abilify OR Abilify Discmelt 13 32 1 5.281 
guaifenesin OR Altarussin OR Amibid LA OR Drituss G OR 
Duratuss G OR GG 200 NR OR Ganidin NR OR Guaifenesin 
LA OR Guaifenex G OR Guaifenex LA OR Hytuss OR 
Liquibid OR Mucinex OR Mucinex for Kids OR Muco-Fen 
1200 OR Organidin NR OR Q-Bid LA OR Robitussin Chest 
Congestion OR Scot-Tussin Expectorant OR Tussin 13 34 1 4.971 	  	  
In both cases we see strong psychiatric drugs such as Ritalin and Clozapine 
ranked near the top as well as strong painkillers (opiates) such as morphine, Mobic and 
Oxycodone.  This might indicate intuitively that these classes of drugs are more 
dangerous or likely to cause more serious effects than other types of drugs.   
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 As stated earlier the prevalence of vitamins or over the counter painkillers that 
seem innocuous abound on both lists.  This might be attributed to their wide spread use 
among many conditions and used in combination with many different drugs.  Both runs 
demonstrate a relatively high score for acetaminophen and acetaminophen containing 
products. However, the causality of scores is not established.  Like many other machine 
learning and classification tasks, even if the features used by a classifier are known, there 
is no established causation, only the correlation between feature and class.  It remains to 
be seen if the outcome is corroborating the recent allegations over the safety of 
acetaminophen with regard to overdosing and safety of children products (FDA, 2010a) 
or due to the their widespread use and association with many different drugs and 
diseases.   	   Both	   watchlist	   and	   drugs	   withdrawn	   from	   market	   have	   been	   successfully	  identified	  using	  multiple	  machine	   learning	  classifiers.	   	  These	  drugs	  were	  correctly	  identified	   even	   when	   incorrectly	   labeled.	   	   Other	   non-­‐watchlist	   drugs	   were	   also	  identified.	   	  These	  drugs	  are	   false	  positives	   in	   the	  sense	  that	   they	  are	  not	  currently	  watchlist	  or	  recalled	  drugs.	  	  However,	  these	  drugs,	  at	  some	  point	  in	  the	  future	  could	  become	   watchlist	   or	   withdrawn	   drugs.	   	   A	   list	   of	   potential	   watchlist	   drugs	   was	  produced;	  the	  most	  significant	  of	  these	  is	  a	  weight	  loss	  drug	  Sibutramine	  (Meridia).	  	  Sibutramine	   was	   withdrawn	   from	   the	   US	   market	   in	   October	   2010	   following	   the	  removal	  from	  the	  European	  Union	  and	  United	  Kingdom	  drug	  markets	  earlier	  in	  the	  year.	   	   The	   Yahoo!	   data	   only	   contained	  messages	   three	   years	   prior	   to	   the	   removal	  from	  US	  and	  European	  markets.	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7 Conclusions 
This dissertation explores the use health forum data as a possible data source for 
pharmacovigilance tasks.  The major contribution of this work is methods used explore 
the identification of drugs for further drug safety study.  Further contributions include 
methods for analyzing this dataset for prevalence of drug entities, drug misspellings and 
other lexical attributes. 
The methods presented here are able to accurately identify drugs withdrawn from 
market as well as drugs that have been put on the FDA’s watchlist.  The way in which 
people discussed drugs before the drugs were placed on the watchlist was used to classify 
them.  A drug withdrawn from market was accurately identified based on data prior to its 
withdrawal.  
7.1 KL Divergence 
Table 9 compares the differences between the watchlist and non-watchlist 
distributions and between the Google and Reuter’s distributions.  The differences in the 
distributions are smaller than when compared to Google or Reuters, which is expected.  
However, it is still difficult to quantify the amount of difference between the 
distributions.  This is a limitation of this metric.  Future work might include other 
distributions to compare against or the same distribution with perturbations to 
demonstrate how these differences impact the KL divergence scores.    
Most of the differences between the distributions are due to common words, 
which is useful for machine learning classifiers.  It is more useful to have classifiers 
trained on common words since they are more likely to exist in more messages leading to 
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classifiers that work on a greater number of messages.  While the “distance” between the 
two distributions is difficult to quantify it is encouraging to see that the differences are 
attributable to non-drug or disease specific terminology. 
7.2 Sentiment 
 We demonstrate the ability to track sentiment of messages containing drug 
mentions over time.  There are statistically significant lexical differences between the 
word distributions of watchlist and non-watchlist messages within the same forum.  
These differences tend to track news items about drugs showing.  While the differences 
are demonstrated numerically, a numerical result can hide some of the complexity in the 
language distributions.   
A similar numerical result can be obtained from very different word distribution 
pairs, for example in one case the differences can occur in common words like 
determiners or pronouns that occur in both word distributions, whereas in another most of 
the differences are attributable to unique or rare words.  It appears that there are 
differences in general word features that exist in both sets, which are helpful since the 
classifiers will hopefully be able to discern patterns based upon these common features, 
and are generalizable to previously unseen examples.  These results agree with results in 
the KL divergence section leading to the conclusion that classifiers can be built over 
general/common word features.   
7.3 Machine Learning Experiments 
 Quantitative analysis of the classifiers is performed on various combinations of 
feature sets and algorithms.  The knowledge rich features, disease and drug names 
seemed to perform the best overall.  However, these numbers without some comparison 
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or task to perform, give no idea of how well this task is performed.  What is 85% 
accuracy? What is “good enough” when predicting drug safety?  How accurately does a 
predictive classifier need to be in order to be useful?  
 Implementations of machine learning classifiers have real world costs and 
consequences.  Costs are involved in building classifiers and annotating data.  Similar 
costs in human capital are involved in evaluating the results of these classifiers.   
  7.3.1 Watchlist Predictions 
 Chapter 6 provided a quantitative analysis of classification results.  The raw 
numbers look somewhat disappointing due to the small performance difference between a 
machine learning classifier and always labeling a drug as non-watchlist.  However, we 
now look for more interesting qualitative results of the data.  The low performance scores 
is an indicator that many drugs are boundary cases, that a classifier has a hard time 
differentiating between the watchlist and non-watchlist drugs and are close together in n-
dimensional space because the features do not adequately separate the instances.   
 There are several reasons for the low performance scores: the instances are nearly 
indistinguishable; the algorithm does not efficiently combine or utilize features; the 
features were poorly chosen and therefore the instances look similar within the feature 
speace (for example trying to distinguish between a sphere and a conical object from a 2-
d representation looking downward at the objects); instances are mislabeled.  This third 
reason is what we are after; a watchlist drug is a non-watchlist drug that has been 
declared so by some outside entity (the FDA).  Drugs can cause potentially serious 
adverse effects but until the FDA puts them on a watchlist they are not watchlist drug.  
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Here, we look at boundary drugs to hopefully identify drugs that are not considered 
watchlist ones but are adverse effect causing relative to other watchlist drugs. 
 Future withdrawal or watch list drugs are predicted based upon multiple false 
positives from many different classifiers.  These drugs are false positives in the sense that 
they are not currently watchlist or recalled drugs.  However, these drugs at some point in 
the future could become watchlist or withdrawn drugs.  The most significant outcome 
was the identification of Sibutramine or Meridia, a weight loss drug.  Our dataset only 
has posts up to a year before it was put on a watchlist then subsequently withdrawn from 
the European market.  Further this drug has been recently voluntarily withdrawn from the 
market by its manufacturer, almost three years beyond the data we currently have.  
Further work is necessary to determine if predictions are accurate and further refinement 
of the methods discussed in this dissertation may give further confidence in the other 
predictions. 
Table	   22:	   Table	   of	   drugs	   withdrawn	   from	   the	  market	   with	   their	   associated	  
scores	   for	   the	   two	   experiments.	   	   The	   first	   two	   columns	   are	   the	   scores	  
associated	  with	   each	   experiment.	   The	   following	   columns	   are	   the	   position	   of	  
each	  drug	  within	  the	  list	  of	  results	  for	  each	  experiment.	  	  	  
Drug Score Exp 1 Score Exp 2 Rank Exp 1 Rank Exp 2 
Palladone 1.929 10.89 33 4 
Trovan 1.761 10.89 40 5 
Vioxx 1.62 10.24 50 6 
Baycol 0.03 0.04 117 107 	  
These scores indicate the classifiers were better at identifying the drugs withdrawn from 
market in the second run.  The raw scores of Palladone, Trovan and Vioxx were almost a 
magnitude of order higher and similarly ranked almost a magnitude higher in the list.  
Disappointingly Baycol’s score did not improve much and its relative rank while higher 
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was not significantly higher.  However, all drugs withdrawn from market had a score and 
were identified in both runs leading indicating that this method is promising in detecting 
adverse event causing drugs. 
 Drug safety is not black and white, but a gradient.  Some of the decisions made in 
this dissertation were almost arbitrary, for example choosing to differentiate between 
active safety alert drugs versus non-current safety alert drugs. For instance one might 
choose all drugs that were not relabeled, or alternatively only drugs recalled from market.   
These drug divisions give different quantities of positive and negative examples and one 
must balance the sensitivity of the resulting classifier with available data.  If one chooses 
drugs withdrawn from market, there would be fewer than 15 positive examples, not 
enough to build a classifier.  This dissertation demonstrates that patient derived data is 
useful in building classifiers for this particular division of data.   We cannot predict that 
online health forum posts would be useful for other classification tasks or that other types 
of online health forum posts from other sources would similarly be appropriate.  Other 
forums may be narrower in scope and have skewed or otherwise biased information. 
Machine learning classifiers make decisions based upon previously seen 
examples.  While the previous decisions might be biased, future decisions using machine 
learning will be biased in the same way, giving consistency to the decisions made. We 
present methods using machine learning classifiers in hopes of providing information to 
people based upon precedent; to forum contributors as well as agencies or groups to 
guide their individual decision-making processes.    
The machine learning classifiers developed perform better than a naive classifier 
predicting all drugs as non-watchlist ones.  A naïve classifier would obtain 86.54% 
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accuracy; however the F1 score would be 0 and the AUC score would be 0.5.  Looking at 
the top performing classifiers, a normalized SVM using the disease and AERS lexicon 
yields 90.33% accuracy.  A normalized SVM using drugs, disease and AERS lexicon 
yields a F1 score of 0.4762 and an un-normalized Naïve Bayes classifier yields an AUC 
score of 0.7592.  Contrary to earlier work demonstrating that group sentiment concerning 
a particular drug can be tracked, the sentiment word features themselves seemed not to 
improve classification performance regarding identification of watchlist or potential 
watchlist drugs.   However, words associated with negative sentiment such as pain are 
contained within the AERS lexicon.  
The performance of these classifiers is better than a naïve always non-watchlist 
classifier because the machine learning ones are able to actually predict positive 
(watchlist) instances.   While predicting positives also leads to generating false positives, 
false positives with regard to the pharmacovigilance task are preferred over false 
negatives.  A positive (even false positive) instance will generate a hypothesis or at least 
participate in the information gathering and evaluation process for a drug, whereas a false 
negative will incorrectly add credence about a drug’s safety.   
Further work is needed in looking into the “false positives” generated by our 
system.  We demonstrate a watchlist prediction model utilizing false positives on current 
data and have successfully predicted a drug that is currently undergoing FDA review and 
has been pulled from the EU and UK markets with data that predates these events by a 
year.   
 We are able to demonstrate effective identification of these watchlist and potential 
watchlist drugs based upon people’s mentions within online health forum messages.  This 
	  
 
 128	  
dissertation serves as an exploration in the use of health forum messages for datamining 
tasks.  Obvious hurdles we have dealt with include the lack of suitable amounts of 
training data as well as nascent tools to work with this type of data. 
 The contributions of this work include the exploration and annotation of health 
forum data, providing statistics over the incidence of disease, drug, medical and adverse 
effect terminology mentions.  We have developed algorithms to identify and differentiate 
spelling mistakes from foreign language words.  We have also provided statistics over the 
provenance of foreign language containing messages and spelling errors within a online 
health forum corpus.  
 We demonstrate that specialty lexicons such as drug and disease names perform 
better than word features using BNS indicating that world knowledge imparted through 
the specialty lexicon is important.  While it is disappointing that drug and disease names 
are the most salient features in identifying possibly harmful drugs it is intuitive that drugs 
used to treat certain diseases are more likely to cause harmful effects.  For example drugs 
to treat life threatening conditions such as AIDS or cancer are more taxing on the body 
and therefore are likely to cause more harmful effects.  This effect is seen in the 
prediction of potential watchlist drugs.  Psychiatric medications, strong pain relievers as 
well as broad-spectrum items such including over the counter pain relievers or vitamins 
and supplements are often flagged as potentially harmful.   
 We contribute a new methodology and toolset to aid in the pharmacovigilance 
task.  We demonstrate that patient derived data can be used to differentiate and 
predictively classify drug safety leading to hypothesis generation about potential drug 
safety for future drugs.   
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 As stated earlier, drug safety is relative and is determined in part by people’s 
choices about drug benefits compared to their drawbacks.  With any drug there are 
potential side effects and society deems if those side effects are sufficiently bad to label a 
drug or remove it from market.  There are many differing views across many societies 
with drugs that are available in the United States but not available elsewhere and vice-
versa.  This dissertation makes no ethical or moral consideration of any drug.  Who is to 
determine drug safety if a drug can potentially save a life but also has the potential to kill 
a small percentage of the persons taking it?  Would the same drug be better if it only had 
that side effect on a smaller percentage of the people taking it?  Is there a point in which 
the likelihood of dying from a drug is small enough it outweighs its potential for good?   
This dissertation constructs predictive classifiers for drug safety based upon the 
societal norms that have judged past drugs – the norms and judgments that created the 
training data we use.  I aim to provide hypothesis and information not only to drug safety 
organizations or companies, but also to individuals who ultimately have to make the 
decision to put a drug in their body and want to enable them to make informed decisions.  
7.4 Limitations 
The method presented identifies 127 candidate drugs with scores ranging from 
79.4 to 0.02.  The 127 candidates are a relatively small number of drugs compared to the 
11,706 prescription drugs, 390 over the counter drugs, and numerous herbal remedies that 
exist.  However, it is a larger percentage of the 575 total drugs we had data for, 
illustrating that we have data for relatively few drugs compared to the total numbers of 
existing drugs.  This type of system requires large amounts of data, a weakness of many 
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machine-learning techniques.   However, we have demonstrated that this methodology 
could be useful in identifying drugs for further study. 
This technique assesses which drugs are discussed in similar ways; like 
comparing a drug to its peers.  This may not be a fair assessment of a drug and may 
inaccurately predict a drug for safety warning or withdrawal based upon its perception.  
Perception of a drug is different from its actual effects.  Many people may like their drug 
despite low efficacy or serious side effects.   
A current drawback of this method is that we aggregate all messages across all 
disease groups.  Drugs have different audiences and certain segments of the population 
are at greater risk for specific diseases.  For example women are more likely to suffer 
from multiple sclerosis than men, therefore the question remains is it valid to group drugs 
together that are targeted to different segments of the population?  It is unknown whether 
or not it is correct to group all drugs and messages together.    
The number of messages for each drug is not evenly distributed, for example the 
numbers of drugs mentioning nonsteroidal anti-inflammatory drugs (NSAIDs) are much 
greater than those mentioning Tysabri (a multiple sclerosis drug).  Many NSAIDs such as 
Aleve are available over the counter and have multiple applications.  This differs 
significantly from a narrow purpose drug used by a smaller population. As stated 
previously the prevalence of vitamins or over the counter painkillers that seem innocuous 
abound on both lists.  This might be attributed to their wide spread use among many 
conditions and in combination with many different drugs.  Both experiments demonstrate 
a relatively high score for acetaminophen and acetaminophen containing products. 
However the causality of scores is not established.  Like many other machine learning 
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and classification tasks, even if the features used by a classifier are known, there is no 
established causation, only the correlation between feature and class.  It remains to be 
seen if the outcome is corroborating the recent allegations over the safety of 
acetaminophen with regard to overdosing and safety of children products or due to the 
their widespread use and association with many different drugs and diseases. 
The filtering of false positives is outside of the scope of this dissertation.  
However one could imagine using this approach as a signal detection method and 
combining the resulting signals with signals generated from other sources.  Currently the 
FDA generates signals over medical claims data from the Mini-Sentinal initiative, 
spontaneous reporting systems (AERS/VAERS), as well as clinical trials.  This data 
source and technique represents just one tool out of many to generate signals of possible 
adverse effect correlated drugs.    
We rely on words and groups of words as features. Spelling errors introduce 
problems.  Misspelled words are not correctly attributed to their correct word or phrase 
resulting in lower classification accuracy.  Greater numbers of messages help to mitigate 
this problem but the problem is more pronounced for drugs with fewer mentions or that 
exist in disease communities with cognitive impairment.   Drugs that are discussed in 
ways that are different from most of the training set will also be misclassified. Drugs 
causing rare but serious effects, or effects that are different from the other watchlist drugs 
is a possible cause that Baycol score was so low.   
This method will classify drugs that are discussed in similar ways.  However there 
are no controls for volume of messages.  Intuitively messages that have greater volumes 
of negative sentiment or adverse effects than other drugs should have a higher score.  An 
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implementation of reporting ratios which rank drugs with greater proportions of negative 
sentiment containing messages compared to it’s peers will score higher.  
The language processing techniques used were coarse grained; no spelling 
correction was performed or more sophisticated syntactic parsing or anaphora resolution.  
Threading was also not utilized so “me too” messages did not provide any additional 
information.  Both messages were not counted or used if a message stating a dislike of a 
drug or containing an adverse effect was followed by another person in the forum saying, 
“same here” or “me too”.   Ideally we would want to attach some score or weight to these 
types of messages.   
This method is a black box; the inputs are groups of messages with drug mentions 
and the output a single score.  This output is lacking in explanation.  If one used a single 
Naïve Bayesian classifier the sets of words or word groups that contributed most to the 
groups classification could be examined.  However this approach is unfeasible when 
using multiple classifiers and multiple methods.  A justification or explanation for a 
prediction might be more satisfying.  
 A limitation of this work is that crowd intelligence can fail due to emotional 
factors.  People want to belong and succumb to peer pressure. Discussing ones’ health is 
a highly personal and emotional subject.  The media or other events could also influence 
people's perceptions of drugs and cause them to talk about things in similar ways.   
7.5 Future Work 
This dissertation explores the online health message data from a purely technical 
standpoint and does not look at the societal connections and impacts of such information 
and technology.   
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Furthermore, we ignore much of the sociological data that could provide useful 
information to improve prediction performance merely because we do not currently 
understand how to extract and utilize such information.  Understanding people’s 
interpersonal relationships within these online forums as well as this implicit social 
hierarchy could provide useful information on data provenance – providing data quality 
metrics that might be used to filter SPAM or unhelpful or derogatory messages.   We all 
implicitly evaluate data quality, for example giving more credence to advice given by a 
good friend with a background in the problem situation than perhaps an acquaintance 
with a background in a different discipline.  Many online message boards try to make 
such information explicit; for example depicting the number of posts by a user, the 
number of helpful responses, the length of forum membership, etc.  All of these factors 
need exploration to possibly develop a data provenance or quality metric. 
This dissertation did not explore many of the aspects of message data that exist.  
For example, times beyond pre and post watchlist warnings were not explored.  The way 
people discuss a drug could change over time.  For example, an avalanche effect could 
occur right before a watchlist report is released due to information cascades.  A more 
ideal situation would be to identify a watchlist drug candidate before an avalanche 
occurred, decreasing the amount of time to detect a watchlist drug, though an avalanche 
effect could provide more confidence in a prediction. 
I also believe that colloquial tools for natural language processing would also help 
to improve classification performance.  To date few tools are trained on colloquial data 
and medical data.  Currently there are no tools trained on colloquial medical text like 
those found in online health forum data.  Further compounding this is the lack of  
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annotated corpora for this task.  As such, regular NLP tools such as part of speech 
taggers, syntactic parsers and other tools work poorly on such data.  Spelling errors, 
capitalization issues, non-grammatical sentences and html and java script tags within this 
text make it difficult for even simple part of speech tagging.  It is reasonable to believe 
that such tools would provide helpful information since they have proved useful in many 
other classification tasks.   
However, each of these improvements in NLP is a milestone in and of 
themselves.  At first glance spelling correction would appear to be easy. However 
without knowing the prior distribution of drug names compared to other common words, 
it is difficult to use tools such as edit distance or approximate string matching.  There is a 
drug named Drize. Instances where people talk about driving to a hospital would 
incorrectly be corrected to Drize. There are similar problems for Doctar and doctor, 
Blistex and blister, etc.    
While there are relatively few polysemous drug names, they do exist. Some 
examples include: Amen, Commit, Compete, Control, Cope, Liberate and Muse.  While 
these drugs did not exist in our corpus, a comprehensive drug safety system would need 
to account for drug names like these.  In this case, word sense disambiguation or some 
sort of statistical named entity recognizer using part of speech tags and other features is 
necessary.   
Currently we are also using general-purpose lexicon for sentiment analysis.  
Trained sentiment classifiers or weighted lexicon should similarly improve sentiment 
scoring for this task.  It is apparent that sentiment is domain specific.  For example in the 
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Rotten Tomato lexicon, “explosion” scores high in the sentiment lexicon; however 
explosions are generally thought of negatively.   
Further study into the specifics of disease communities is also necessary.  Each 
community such as Multiple Sclerosis or Diabetes has disease specific terminology as 
well as colloquial terms, for example dx for diagnosis, TSH for Thyroid-stimulating 
hormone or Thyrotropin a test to help diagnosis thyroid disorders or to monitor 
hyperthyroidism.  While different terminology exists for each of these disease groups it is 
unclear whether or not the way in which people discuss drugs differs enough to build 
different watchlist classifiers for each of the disease groups.   
Many of these problems are due to one of two things, lack of sufficient data or 
lack of hand labeled training data.  The development of NLP tools such as part of speech 
taggers or sentiment classifiers depends on having annotated data.  
In conclusion, I have demonstrated a scalable technique that needs little manually 
annotated training data, which is a limitation of the application of machine learning for 
many tasks.  I believe that this method can be generalized to different types of data 
sources such as twitter or blogs with little augmentation due to the lack of custom 
features or advanced natural language processing techniques such as full syntactic 
parsing.  I have demonstrated that our method was able to identify drugs removed from 
market both when the data was intentionally mislabeled and trained upon as well as when 
it was used only for testing.  I propose that this method could be used as a coarse signal 
detection technique that can augment existing SRS data and methods using unstructured 
information directly found in online sources. 
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Appendix A: FDA Drug List with Important Information 
 
"Advair Diskus" OR ("fluticasone propionate" AND "salmeterol xinafoate") 
"Alosetron hydrochloride"  
"Ciprofloxacin Extended Release" 
"Fentanyl buccal" 
"Fluticasone propionate" 
"Levothyroxine sodium" 
"Plan B" OR levonorgestrel 
"Salmeterol xinafoate" 
"Serevent Diskus" OR "salmeterol xinafoate" 
"Testosterone gel" 
Abilify OR aripiprazole 
Accolate OR zafirlukast 
Alimta OR pemetrexed 
Ambien OR "zolpidem tartrate" 
AndroGel 
Aranesp OR "darbepoetin alpha" 
Aspirin 
Avandamet OR rosiglitazone OR Avandaryl OR Avandia OR  
Avastin OR bevacizumab 
Bupivicaine 
Buprenorphine 
Butisol sodium 
Carbrital OR "pentobarbital and carbromall" 
Cerebyx 
Cerezyme OR imiglucerase 
Chlorprocaine 
Cialis OR tadalafil 
Clozaril OR clozapine 
Coly-Mycin M OR colistimethate 
Creon OR pancrelipase 
Dalmane OR flurazepam 
Dilantin 
Doral OR quazepam 
Drotrecogin alfa activated 
Elidel OR pimecrolimus 
Eloxatin OR oxaliplatin 
Endrate OR "edetate disodium" 
Epogen OR "epoetin alfa" 
Eprex OR "epoetin alfa" 
Erbitux OR cetuximab 
Erythromycin 
Exjade OR deferasirox 
Foradil OR "formoterol fumarate" 
Fosphenytoin 
Gadolinium 
Gemifloxacin mesylate 
Geodon OR ziprasidone 
Gleevec OR "imatinib mesylate" 
Halcion OR triazolam 
Heparin 
Ibuprofen 
Innohep OR tinzaparin 
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Invirase  OR saquinavir 
Iplex 
Kepivance OR palifermin 
Ketek OR telithromycin 
Lenalidomide 
Levitra OR vardenafil 
Lidocaine 
Lindane 
Lotronex OR "alosetron hydrochloride" 
Lunesta OR eszopiclone 
Magnivist OR "gadopentetate dimeglumine" 
Maxipime OR cefepime 
Mecasermin rinfabate recombinant 
Mepiivicaine 
Meridia OR "sibutramine hydrochloride" 
Methadone OR dolophine 
Multihance OR "gadobenate dimeglumine" 
Naratriptan 
Natalizumab 
NeutroSpec OR technetium-99m 
Nexium OR esomeprazole 
Nimotop OR nimodipine 
Norelgestromin 
Omniscan OR gadodiamide 
Onsolis OR "fentanyl buccal soluble film" 
OptimarkM OR gasoversetamide 
Ortho Evra OR ("norelgestromin" AND "ethinyl estradiol") 
Pallodone OR hydromorphone 
Pentobarbital and carbromal 
Peramivir  
Permax OR pergolide 
Phenytek 
Phenytoin 
Placidyl OR ethchlorvynol 
Plavix OR "clopidogrel bisulfate" 
Prilosec OR omeprazole 
Procaine 
Procrit OR "epoetin alfa" 
Prohance  OR gadoteridol 
Propoxyphene 
Prosom OR estazolam 
Protopic OR tacrolimus 
Raptiva OR efalizumab 
Regranex OR becaplermin 
Relenza OR zanamivir 
Restoril OR temazepam 
Revatio OR sildenafil 
Revlimid OR lenalidomide 
Risperdal OR risperidone 
Ropivicaine 
Rozerem OR ramelteon 
Seconal OR secobarbital 
Seroquel OR quetiapine 
Singulair OR montelukast 
Sonata OR zaleplon 
Spiriva OR "tiotropium bromide" 
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Suboxone 
Subutex 
Tamiflu OR "oseltamivir phosphate" 
Testim 
Thalomid OR thalidomide 
Trasylol OR aprotinin 
Unithroid OR "levothyroxine sodium" 
Valproate 
Velcade OR bortezomib 
Viagra OR "sildenafil citrate" 
Victoza OR liraglutide 
Videx OR didanosine 
Vioxx OR rofecoxib 
Xigris OR "drotrecogin alfa" 
Zarfirlukast 
Zelnorm OR "tegaserod maleate" 
Zetia OR ezetimibe 
Zicam 
Zocor OR simvastatin 
Zyflo and "Zyflo CR" OR zileuton 
Zyprexa OR olanzapine 
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Appendix B: FDA Watch List Drugs 
 
"Diastat AcuDial" 
"Diazepam rectal gel" 
"Fentanyl buccal" 
"Fentanyl transdermal system" 
"Fleet Accu-Prep" OR "sodium phosphate" 
"Fleet Phospho-Soda" OR "sodium phosphate" 
"Mitoxantrone hydrochloride" 
"Proquin XR" OR "ciprofloxacin extended release" OR "Proquin" OR "ciprofloxacin" 
"Sodium phosphates" 
Accupril OR quinapril 
Accutane OR isotretinoin 
Aceon OR perindopril 
Actimmune OR "interferon gamma-1b" 
Actonel OR risedronate 
Actoplus OR pioglitazone OR Actos 
Adderall OR "amphetamine salts" 
Aleve OR "naproxen sodium" OR Anaprox 
Alli OR orlistat Or Xenical 
Altace OR ramipril 
Amerge OR naratriptan 
Amiodarone AND Simvastatin 
Amnesteem OR isotretinoin or Accutane OR Claravis OR Sotret 
Aredia OR pamidronate 
Avelox OR moxifloxacin 
Axert OR "almotriptan malate" 
Bextra OR valdecoxib 
Biaxin OR clarithromycin 
Boniva OR ibandronate 
Botox OR OnabotulinumtoxinA 
Botulinium Type A and B 
Brovana OR "arformoterol tartrate" 
Budesonide 
Byetta OR exenatide 
Campath OR alemtuzumab 
Capoten OR captopril 
Carbatrol OR carbamazepine 
Celebrex OR celecoxib 
Celexa OR "citalopram hydrobromide" 
CellCept OR "mycophenolate mofetil" 
Chantix OR varenicline 
Cimzia OR "certolizumab pergol" 
Cipro OR ciprofloxacin 
Cipro XR OR "ciprofloxacin extended release" 
Citalopram 
Codeine 
Colcrys OR colchicine 
Colistimethate 
Compazine OR prochlorperazine 
Cordarone OR amiodarone 
Crestor OR "rosuvastatin calcium" 
Cylert OR pemoline 
Cymbalta OR duloxetine 
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Cytotec OR misoprostol 
Depacon OR valproate 
Depakene OR valproate OR Depakene 
Didronel OR etidronate 
Diprivan OR propofol 
Duragesic OR "fentanyl" 
Dysport OR abobotulinumtoxinA 
Effexor OR venlafaxine 
Enalapril AND Enalaprilat 
Enbrel OR etanercept 
Equetro OR carbamazepine 
Ezetimibe AND simvastatin 
Factive OR gemifloxacin 
Felbatol OR felbamate 
Fentora OR "fentanyl buccal tablets" 
Floxin OR ofloxacin 
Fluvoxamine 
Fosamax OR alendronate 
Frova OR "frovatriptan succinate" 
Gabitril OR tiagabine 
Haldol OR haloperidol 
Humira OR adalimumab 
Imitrex OR sumatriptan 
Iressa OR gefitinib 
Januvia  OR "sitagliptin " 
Keppra OR levetiracetam 
Lamictal OR lamotrigine 
Levaquin OR levofloxacin 
Lexapro OR escitalopram 
Lotensin OR benazepril 
Loxitane OR loxapine 
Lyrica OR pregabalin 
Mavik OR trandolapril 
Maxalt 
Mellaril OR thioridazine 
Mifeprex OR mifepristone 
Minirin OR desmopressin OR DDAVP 
Moban OR molindone 
Monopril OR fosinopril 
Myfortic OR "mycophenolate acid" 
Myobloc 
Naprosyn OR naproxen 
Navane OR thiothixene 
Neoral OR cyclosporine OR Sandimmune 
Neurontin OR gabapentin 
Noroxin OR norfloxacin 
Novantrone OR "mitoxantrone hydrochloride" 
Ofloxacin 
Optison OR "perflutren protein-type A microspheres" OR perflutren OR Definity  
Orap OR pimozide 
Osmoprep OR "sodium phosphate" 
Pacerone OR amiodarone 
Paxil OR paroxetine 
Performist OR "formoterol fumarate" 
Phenergan OR promethazine 
Prezista OR darunavir 
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Prinivil OR lisinopril OR Zestril 
Prolixin OR fluphenazine 
Propylthiouracil 
Prozac OR fluoxetine 
Rapamune OR sirolimus 
Razadyne OR galantamine 
Reclast OR "zoledronic acid" 
Relpax OR eletriptan 
Remeron OR mirtazapine 
Remicade OR infliximab 
RimabotulinumtoxinB 
Rituxan 
Rituximab 
Rizatriptan 
Rocephin OR ceftriaxone 
Rosuvastatin 
Serzone OR nefazodone 
Simponi OR golimumab 
Simvastatin OR Amiodarone 
Skelid OR tiludronate 
Stelazine OR trifluoperazine 
Stimate Nasal Spray OR desmopressin 
Strattera OR atomoxetine 
Symbicort OR ("budensonide" AND "formoterol fumarate") 
Symbyax OR (olanzapine AND fluoxetine) 
Tegretol OR carbamazepine 
Tequin OR gatifloxacin 
Thorazine OR chlorpromazine 
Topamax OR topiramate 
Trilafon OR perphenazine 
Trileptal OR oxcarbazepine 
Tussionex OR hydrocodone 
Tysabri OR natalizumab 
Univasc OR moexipril 
Vasotec OR (enalapril AND enalaprilat) 
Visicol OR "sodium phosphate" 
Vivitrol OR naltrexone 
Vytorin OR (ezetimibeANDsimvastatin) 
Wellbutrin OR bupropion 
Xolair OR omalizumab 
Ziagen OR "abacavir sulfate" 
Zoloft OR sertraline 
Zometa OR "zoledronic acid" 
Zomig OR zolmitriptan 
Zonegran OR zonisamide 
Zyban OR "bupropion hydrochloride" 
Zyvox OR linezolid 
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Appendix C: String Distance Between Drug Mentions 	  The	  data	  is	  in	  the	  format:	  Drug	  Name	  1	  Drug	  Name	  2	  Average	   Standard	  Deviation	   Median	  	   Minimum	   Maximum	  	  
message:("sildenafil" OR "Revatio" OR "Viagra") 
message:("tadalafil" OR "Adcirca" OR "Cialis") 
9.67425 296.0729 11.0 7.0 12165.0 
 
message:("tadalafil" OR "Adcirca" OR "Cialis") 
message:("vardenafil" OR "Levitra") 
28.476190476190474 85.36018922637123 10.0 8.0 401.0 
 
message:("carisoprodol" OR "Soma" OR "Vanadom") 
message:("tramadol" OR "Ryzolt" OR "Ultram" OR "Ultram ER") 
106.48780487804878 147.9179032354129 26.0 5.0 484.0 
 
message:("sildenafil" OR "Revatio" OR "Viagra") 
message:("vardenafil" OR "Levitra") 
76.85082872928177 101.62253064857481 42.0 8.0 699.0 
 
message:("ascorbic acid" OR "Acerola" OR "Ascor L 500" OR "Ascorbic Acid Quick 
Melts" OR "Ascot" OR "Betac" OR "C-Time" OR "C/Rose Hips" OR "Cecon" OR 
"Cemill" OR "Cemill 1000" OR "Cemill 500" OR "Cenolate" OR "Centrum Singles-
Vitamin C" OR "Cevi-Bid" OR "Ester-C" OR "N Ice with Vitamin C" OR 
"Protexin" OR "Sunkist Vitamin C" OR "Vicks Vitamin C Drops" OR "Vitamin C" 
OR "Vitamin C TR" OR "Vitamin C with Rose Hips") 
message:("vitamin e" OR "Alpha E" OR "Amino-Opti-E" OR "Aquasol E" OR 
"Aquavite-E" OR "Centrum Singles-Vitamin E" OR "E Pherol" OR "E-400 Clear" 
OR "Nutr-E-Sol") 
217.0563829787234 844.3520141274772 21.0 10.0 19301.0 
 
message:("alprazolam" OR "Alprazolam Intensol" OR "Niravam" OR "Xanax" OR 
"Xanax XR") 
message:("diazepam" OR "Diastat" OR "Diastat AcuDial" OR "Diastat Pediatric" OR 
"Diazepam Intensol" OR "Valium" OR "Valrelease") 
163.68214285714285 552.1191780555655 10.0 6.0 6112.0 
 
message:("fluoxetine" OR "Prozac" OR "Prozac Weekly" OR "Rapiflux" OR "Sarafem" 
OR "Selfemra") 
message:("sertraline" OR "Zoloft") 
483.3007246376812 1135.2676128879045 86.0 8.0 10377.0 
 
message:("diazepam" OR "Diastat" OR "Diastat AcuDial" OR "Diastat Pediatric" OR 
"Diazepam Intensol" OR "Valium" OR "Valrelease") 
message:("sildenafil" OR "Revatio" OR "Viagra") 
23.142857142857142 33.64054712916879 11.0 8.0 206.0 
 
message:("fluoxetine" OR "Prozac" OR "Prozac Weekly" OR "Rapiflux" OR "Sarafem" 
OR "Selfemra") 
message:("paroxetine" OR "Paxil" OR "Paxil CR" OR "Pexeva") 
595.9365750528541 1122.2559869325905 151.0 7.0 9644.0 
 
message:("acetaminophen" OR "Acephen" OR "Actamin" OR "Adprin B" OR "Anacin 
Aspirin Free" OR "Apra" OR "Atasol" OR "Bromo Seltzer" OR "Children's 
ElixSure" OR "Children's Silapap" OR "Children's Tylenol" OR "Dolono" OR 
"Ed-APAP" OR "Elixsure Fever/Pain" OR "Febrol Solution" OR "Feverall" OR 
"Genapap" OR "Genebs" OR "Infants' Tylenol" OR "Jr. Tylenol" OR "Mapap" OR 
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"Mapap Arthritis Pain" OR "Mapap Children's" OR "Mapap Infant Drops" OR 
"Mapap Meltaway" OR "Mapap Rapid Release Gelcaps" OR "Mapap Rapid Tabs" OR 
"Pain-Eze" OR "Q-Pap" OR "Q-Pap Extra Strength" OR "Silapap Childrens" OR 
"Silapap Infants" OR "St. Joseph Aspirin-Free" OR "Tactinal" OR "Tempra" OR 
"Tempra Quicklets" OR "Tycolene" OR "Tylenol" OR "Tylenol 8 Hour" OR 
"Tylenol Arthritis Pain" OR "Tylenol Extra Strength" OR "Tylenol GoTabs" OR 
"Tylenol Sore Throat Daytime" OR "Tylophen" OR "Uniserts" OR "Vitapap") 
message:("ibuprofen" OR "Advil" OR "Advil Children's" OR "Advil Junior 
Strength" OR "Advil Liqui-Gels" OR "Advil Migraine" OR "Caldolor" OR 
"Children's Motrin" OR "Childrens Ibuprofen Berry" OR "Genpril" OR "Haltran" 
OR "IBU" OR "IBU-200" OR "Midol IB" OR "Midol Maximum Strength Cramp 
Formula" OR "Motrin" OR "Motrin Childrens" OR "Motrin IB" OR "Motrin Infant 
Drops" OR "Motrin Junior Strength" OR "Motrin Migraine Pain" OR "NeoProfen" 
OR "Nuprin" OR "Q-Profen") 
141.33816863100634 431.6383666324089 14.0 6.0 6402.0 
 
message:("ascorbic acid" OR "Acerola" OR "Ascor L 500" OR "Ascorbic Acid Quick 
Melts" OR "Ascot" OR "Betac" OR "C-Time" OR "C/Rose Hips" OR "Cecon" OR 
"Cemill" OR "Cemill 1000" OR "Cemill 500" OR "Cenolate" OR "Centrum Singles-
Vitamin C" OR "Cevi-Bid" OR "Ester-C" OR "N Ice with Vitamin C" OR 
"Protexin" OR "Sunkist Vitamin C" OR "Vicks Vitamin C Drops" OR "Vitamin C" 
OR "Vitamin C TR" OR "Vitamin C with Rose Hips") 
message:("vitamin a" OR "A-25" OR "A/Fish Oil" OR "Aquasol A") 
169.63956639566396 722.1454430073155 16.0 10.0 15420.0 
 
message:("paroxetine" OR "Paxil" OR "Paxil CR" OR "Pexeva") 
message:("sertraline" OR "Zoloft") 
379.21270718232046 825.3031116495735 89.0 7.0 6691.0 
 
message:("carisoprodol" OR "Soma" OR "Vanadom") 
message:("sildenafil" OR "Revatio" OR "Viagra") 
146.26315789473685 159.7243714095961 94.0 6.0 580.0 
 
message:("diazepam" OR "Diastat" OR "Diastat AcuDial" OR "Diastat Pediatric" OR 
"Diazepam Intensol" OR "Valium" OR "Valrelease") 
message:("tadalafil" OR "Adcirca" OR "Cialis") 
24.25 14.174507634012077 25.5 7.0 39.0 
 
message:("sibutramine" OR "Meridia") 
message:("tadalafil" OR "Adcirca" OR "Cialis") 
69.66666666666667 37.18960428220051 67.5 17.0 77.0 
 
message:("vitamin a" OR "A-25" OR "A/Fish Oil" OR "Aquasol A") 
message:("vitamin e" OR "Alpha E" OR "Amino-Opti-E" OR "Aquasol E" OR 
"Aquavite-E" OR "Centrum Singles-Vitamin E" OR "E Pherol" OR "E-400 Clear" 
OR "Nutr-E-Sol") 
243.67532467532467 389.09838605122957 73.5 10.0 2701.0 
 
message:("diazepam" OR "Diastat" OR "Diastat AcuDial" OR "Diastat Pediatric" OR 
"Diazepam Intensol" OR "Valium" OR "Valrelease") 
message:("zolpidem" OR "Ambien" OR "Ambien CR" OR "Edluar" OR "Zolpimist") 
713.9166666666666 1212.4585126624072 95.5 8.0 3597.0 
 
message:("carisoprodol" OR "Soma" OR "Vanadom") 
message:("vardenafil" OR "Levitra") 
25.5 6.363961030678928 25.5 21.0 0.0 
 
message:("alprazolam" OR "Alprazolam Intensol" OR "Niravam" OR "Xanax" OR 
"Xanax XR") 
message:("tadalafil" OR "Adcirca" OR "Cialis") 
253.57142857142858 334.0248778872901 69.0 8.0 734.0 
 
message:("phentermine" OR "Adipex-P" OR "Ionamin" OR "Obenix" OR "Oby-Cap" OR 
"Pro-Fast SA" OR "Teramine" OR "Zantryl") 
message:("sildenafil" OR "Revatio" OR "Viagra") 
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239.73809523809524 301.42264788780886 171.0 7.0 1338.0 
 
message:("finasteride" OR "Propecia" OR "Proscar") 
message:("sildenafil" OR "Revatio" OR "Viagra") 
103.11111111111111 147.36048015363926 28.0 21.0 391.0 
 
message:("ascorbic acid" OR "Acerola" OR "Ascor L 500" OR "Ascorbic Acid Quick 
Melts" OR "Ascot" OR "Betac" OR "C-Time" OR "C/Rose Hips" OR "Cecon" OR 
"Cemill" OR "Cemill 1000" OR "Cemill 500" OR "Cenolate" OR "Centrum Singles-
Vitamin C" OR "Cevi-Bid" OR "Ester-C" OR "N Ice with Vitamin C" OR 
"Protexin" OR "Sunkist Vitamin C" OR "Vicks Vitamin C Drops" OR "Vitamin C" 
OR "Vitamin C TR" OR "Vitamin C with Rose Hips") 
message:("selenium" OR "Selepen") 
256.8776758409786 654.7162245462931 44.0 10.0 6588.0 
 
message:("alprazolam" OR "Alprazolam Intensol" OR "Niravam" OR "Xanax" OR 
"Xanax XR") 
message:("sildenafil" OR "Revatio" OR "Viagra") 
244.88235294117646 313.10219624607817 28.0 7.0 607.0 
 
message:("carisoprodol" OR "Soma" OR "Vanadom") 
message:("diazepam" OR "Diastat" OR "Diastat AcuDial" OR "Diastat Pediatric" OR 
"Diazepam Intensol" OR "Valium" OR "Valrelease") 
168.12 306.9787343340469 28.0 8.0 1105.0 
 
message:("aspirin" OR "Arthritis Pain" OR "Aspergum" OR "Aspir 81" OR "Aspir-
Low" OR "Aspirin Lite Coat" OR "Aspirin Low Strength" OR "Aspiritab" OR 
"Bayer Aspirin" OR "Bayer Aspirin Extra Strength Plus" OR "Bayer Aspirin 
Regimen" OR "Bayer Children's Aspirin" OR "Bayer Women's Aspirin With 
Calcium" OR "Buffered Aspirin" OR "Bufferin" OR "Bufferin Arthritis 
Strength" OR "Bufferin Extra Strength" OR "Easprin" OR "Ecotrin" OR "Ecotrin 
Adult Low Strength" OR "Ecotrin Maximum Strength" OR "Empirin" OR "Fasprin" 
OR "Genacote" OR "Halfprin" OR "Litecoat Aspirin" OR "Medi-Seltzer" OR 
"Norwich Aspirin" OR "St. Joseph 81 mg Aspirin Enteric Safety-Coated" OR 
"St. Joseph 81 mg Chewable Aspirin" OR "St. Joseph Aspirin" OR "Stanback 
Analgesic" OR "Tri-Buffered Aspirin" OR "YSP Aspirin" OR "ZORprin") 
message:("ibuprofen" OR "Advil" OR "Advil Children's" OR "Advil Junior 
Strength" OR "Advil Liqui-Gels" OR "Advil Migraine" OR "Caldolor" OR 
"Children's Motrin" OR "Childrens Ibuprofen Berry" OR "Genpril" OR "Haltran" 
OR "IBU" OR "IBU-200" OR "Midol IB" OR "Midol Maximum Strength Cramp 
Formula" OR "Motrin" OR "Motrin Childrens" OR "Motrin IB" OR "Motrin Infant 
Drops" OR "Motrin Junior Strength" OR "Motrin Migraine Pain" OR "NeoProfen" 
OR "Nuprin" OR "Q-Profen") 
425.72280701754386 1165.0117618667502 32.0 6.0 13985.0 
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Appendix D: Accuracy Graphs The	  graph	  on	  the	  left	  depicts	  the	  cross	  validation	  experiments	  and	  classification	  with	  separate	  test	  instances	  on	  the	  right.	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The	  graph	  below	  depicts	  the	  accuracy	  experiments	  for	  cost	  weighted	  classification	  algorithms.	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Appendix E: F1 Graphs The	  graph	  on	  the	  left	  depicts	  the	  cross	  validation	  experiments	  and	  classification	  with	  separate	  test	  instances	  on	  the	  right.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
 
 160	  
The	  graph	  below	  depicts	  the	  F1	  experiments	  for	  cost	  weighted	  classification	  algorithms.	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Appendix F: AUC Graphs The	  graph	  on	  the	  left	  depicts	  the	  cross	  validation	  experiments	  and	  classification	  with	  separate	  test	  instances	  on	  the	  right.	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The	  graph	  below	  depicts	  the	  AUC	  experiments	  for	  cost	  weighted	  classification	  algorithms.	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Appendix G: Accuracy Graphs The	  graph	  below	  depicts	  the	  accuracy	  over	  all	  15,000	  word	  features	  selected	  from	  the	  sampled	  lexicon.	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The	  graph	  below	  depicts	  the	  accuracy	  over	  all	  10,000	  word	  features	  selected	  from	  the	  sampled	  lexicon.	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The	  graph	  below	  depicts	  the	  accuracy	  over	  all	  5,000	  word	  features	  selected	  from	  the	  sampled	  lexicon.	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Appendix H: F1 Graphs The	  graph	  below	  depicts	  the	  F1	  scores	  over	  all	  15,000	  word	  features	  selected	  from	  the	  sampled	  lexicon.	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The	  graph	  below	  depicts	  the	  F1	  scores	  over	  all	  10,000	  word	  features	  selected	  from	  the	  sampled	  lexicon.	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The	  graph	  below	  depicts	  the	  F1	  scores	  over	  all	  5,000	  word	  features	  selected	  from	  the	  sampled	  lexicon.	  	  
	  	  
	  
 
 169	  
Appendix I: AUC Graphs The	  graph	  below	  depicts	  the	  AUC	  scores	  over	  all	  15,000	  word	  features	  selected	  from	  the	  sampled	  lexicon.	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The	  graph	  below	  depicts	  the	  AUC	  scores	  over	  all	  10,000	  word	  features	  selected	  from	  the	  sampled	  lexicon.	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The	  graph	  below	  depicts	  the	  AUC	  scores	  over	  all	  5,000	  word	  features	  selected	  from	  the	  sampled	  lexicon.	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Appendix J:  Potential Problematic Drug List from False 
Positives Below	  are	  the	  drugs	  and	  the	  associated	  scores	  of	  drugs	  identified	  as	  false	  positives	  from	  the	  three	  top-­‐performing	  classifiers.	  	  Next	  to	  the	  drug	  name,	  the	  Pos	  column	  denotes	  the	  number	  of	  times	  a	  classifier	  marked	  the	  drug	  as	  a	  false	  positive.	  	  Occ	  indicates	  the	  number	  of	  occurrences,	  or	  number	  of	  times	  the	  drug	  was	  classified.	  	  Class	  indicates	  the	  number	  of	  different	  types	  of	  classifiers	  (1-­‐3)	  that	  predicted	  a	  false	  positive	  for	  a	  drug.	  	  Score	  indicates	  the	  linear	  combination	  of	  Pos,	  Occ,	  and	  Class	  resulting	  in	  a	  score	  of	  the	  confidence	  in	  prediction.	  	  Drugs	  withdrawn	  from	  market	  are	  highlighted	  in	  yellow.	  	  Interesting	  results	  are	  highlighted	  in	  green.	  	  
Drug Pos Occ Class Score 
clozapine OR Clozaril OR FazaClo 31 64 3 45.047 
fludarabine OR Fludara OR Oforta 29 61 3 41.361 
methylphenidate OR Concerta OR Daytrana OR 
Metadate CD OR Metadate ER OR Methylin OR 
Methylin ER OR Ritalin OR Ritalin LA OR Ritalin-SR 25 50 3 37.500 
morphine OR Astramorph PF OR Avinza OR 
Duramorph OR Infumorph OR Kadian OR MS 
Contin OR MSIR OR Morphine IR OR Oramorph SR 
OR RMS OR Roxanol 14 38 3 15.474 
meloxicam OR Mobic 15 50 3 13.500 
Extraneal 10 36 3 8.333 
aripiprazole OR Abilify OR Abilify Discmelt 9 30 3 8.100 
evening primrose OR Evening Primrose Oil OR 
Primrose Oil 17 56 1 5.161 
quetiapine OR Seroquel OR Seroquel XR 15 52 1 4.327 
trazodone OR Desyrel OR Desyrel Dividose OR 
Oleptro 14 46 1 4.261 
(acetaminophen AND diphenhydramine) OR 
Anacin P.M. Aspirin Free OR Coricidin Night Time 
Cold Relief OR Excedrin PM OR Headache Relief 
PM OR Legatrin PM OR Mapap PM OR Midol PM OR 
Percogesic Extra Strength OR Sominex Pain Relief 
Formula OR Tylenol PM OR Tylenol Severe Allergy 
OR Tylenol Sore Throat Nighttime OR Unisom with 
Pain Relief 12 34 1 4.235 
thalidomide OR Thalomid 13 44 1 3.841 
clomipramine OR Anafranil 13 44 1 3.841 
vigabatrin OR Sabril 13 50 1 3.380 
risperidone OR Risperdal OR Risperdal Consta OR 
Risperdal M-Tab 11 36 1 3.361 
eszopiclone OR Lunesta 11 36 1 3.361 
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omega-3 polyunsaturated fatty acids OR Animi-3 
OR EPA Fish Oil OR Fish Oil OR Icar Prenatal 
Essential Omega-3 OR Lovaza OR Marine Lipid 
Concentrate OR MaxEPA OR MaxiTears Dry Eye 
Formula OR MaxiVision Omega-3 Formula OR Mi-
Omega OR Mi-Omega NF OR Omacor OR Omega-
500 OR Proepa OR Sea-Omega OR Sea-Omega 30 
OR Sea-Omega 70 OR TheraTears Nutrition 13 52 1 3.250 
influenza virus vaccine, live, trivalent OR FluMist 10 31 1 3.226 
verapamil OR Calan OR Calan SR OR Covera-HS 
OR Isoptin OR Isoptin SR OR Verelan OR Verelan 
PM 12 46 1 3.130 
acetazolamide OR Diamox OR Diamox Sequels 12 47 1 3.064 
(conjugated estrogens AND 
medroxyprogesterone) OR Premphase OR 
Prempro 11 46 1 2.630 
methylprednisolone OR A-methapred OR Depo-
Medrol OR Medrol OR Medrol Dosepak OR 
MethylPREDNISolone Dose Pack OR Solu-Medrol 11 47 1 2.574 
nifedipine OR Adalat OR Adalat CC OR Afeditab 
CR OR Nifediac CC OR Nifedical XL OR Procardia 
OR Procardia XL 10 41 1 2.439 
temazepam OR Restoril 11 50 1 2.420 
sulindac OR Clinoril 10 42 1 2.381 
calcipotriene OR Dovonex 6 32 2 2.250 
vancomycin OR Lyphocin OR Vancocin OR 
Vancocin HCl OR Vancocin HCl Pulvules 10 45 1 2.222 
insulin lispro OR Humalog OR Humalog KwikPen 
OR Humalog Pen 9 38 1 2.132 
albuterol OR AccuNeb OR Airet OR ProAir HFA OR 
Proventil OR Proventil HFA OR Ventolin OR 
Ventolin HFA OR Volmax OR Vospire ER 9 39 1 2.077 
amlodipine OR Norvasc 9 40 1 2.025 
dronabinol OR Marinol 5 38 3 1.974 
nicardipine OR Cardene OR Cardene IV OR 
Cardene SR 8 33 1 1.939 
hydromorphone OR Dilaudid OR Dilaudid-HP OR 
Exalgo OR Palladone 9 42 1 1.929 
losartan OR Cozaar 7 26 1 1.885 
irinotecan OR Camptosar 9 43 1 1.884 
(dyphylline AND guaifenesin) OR COPD OR Difil G 
OR Dilex-G OR Dy-G OR Dyfilin GG OR Dyflex-G 
OR Dyphylline GG OR Jay-Phyl OR Lufyllin-GG OR 
Panfil G 8 34 1 1.882 
doxepin OR Adapin OR Prudoxin OR Silenor OR 
Sinequan OR Zonalon 9 44 1 1.841 
filgrastim OR Neupogen 8 36 1 1.778 
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(acetaminophen AND butalbital AND caffeine) OR 
Alagesic OR Alagesic LQ OR Anolor 300 OR Dolgic 
LQ OR Dolgic Plus OR Esgic OR Esgic-Plus OR 
Fioricet OR Geone OR Margesic OR Medigesic OR 
Repan OR Zebutal 9 46 1 1.761 
trovafloxacin OR Trovan 9 46 1 1.761 
ziprasidone OR Geodon 8 38 1 1.684 
oxycodone OR ETH-Oxydose OR OxyContin OR 
OxyIR OR Oxyfast OR Percolone OR Roxicodone 
OR Roxicodone Intensol 8 38 1 1.684 
clonazepam OR Klonopin OR Klonopin Wafer 7 30 1 1.633 
rofecoxib OR Vioxx 9 50 1 1.620 
flecainide OR Tambocor 8 40 1 1.600 
methotrexate OR Rheumatrex Dose Pack OR 
Trexall 7 31 1 1.581 
hydroxyzine OR Atarax OR Hyzine OR Vistaril 7 31 1 1.581 
lorazepam OR Ativan 6 24 1 1.500 
guaifenesin OR Altarussin OR Amibid LA OR 
Drituss G OR Duratuss G OR GG 200 NR OR 
Ganidin NR OR Guaifenesin LA OR Guaifenex G 
OR Guaifenex LA OR Hytuss OR Liquibid OR 
Mucinex OR Mucinex for Kids OR Muco-Fen 1200 
OR Organidin NR OR Q-Bid LA OR Robitussin 
Chest Congestion OR Scot-Tussin Expectorant OR 
Tussin 8 43 1 1.488 
pneumococcal 7-valent vaccine OR Prevnar 8 43 1 1.488 
pramipexole OR Mirapex 8 44 1 1.455 
selegiline OR Eldepryl OR Emsam OR Zelapar 6 26 1 1.385 
glyburide OR DiaBeta OR Glycron OR Glynase OR 
Glynase PresTab OR Micronase 6 27 1 1.333 
nortriptyline OR Aventyl Hydrochloride OR 
Pamelor 7 38 1 1.289 
chlordiazepoxide OR Librium 7 38 1 1.289 
(metformin AND rosiglitazone) OR Avandamet 5 21 1 1.190 
acetic acid OR Acetasol OR Acid Jelly OR Fem pH 
OR Klout OR Relagard 7 42 1 1.167 
metoprolol OR Lopressor OR Metoprolol Succinate 
ER OR Toprol-XL 5 22 1 1.136 
indomethacin OR Indocin OR Indocin IV OR 
Indocin SR 6 33 1 1.091 
benztropine OR Cogentin 5 23 1 1.087 
vitamin e OR Alpha E OR Amino-Opti-E OR 
Aquasol E OR Aquavite-E OR Centrum Singles-
Vitamin E OR E Pherol OR E-400 Clear OR Nutr-E-
Sol 5 24 1 1.042 
azithromycin OR Azasite OR Azithromycin Dose 
Pack OR Zithromax OR Zmax 5 25 1 1.000 
metformin OR Fortamet OR Glucophage OR 
Glucophage XR OR Glumetza OR Riomet 6 37 1 0.973 
pilocarpine OR Isopto Carpine OR Pilocar OR 
Pilopine HS OR Pilostat OR Salagen 6 37 1 0.973 
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lisdexamfetamine OR Vyvanse 5 26 1 0.962 
propranolol OR Inderal OR Inderal LA OR 
InnoPran XL 6 38 1 0.947 
sibutramine OR Meridia 5 27 1 0.926 
zolpidem OR Ambien OR Ambien CR OR Edluar OR 
Zolpimist 5 28 1 0.893 
enoxaparin OR Lovenox 5 30 1 0.833 
phenytoin OR Dilantin OR Phenytek OR Phenytoin 
Sodium, Prompt 4 20 1 0.800 
ubiquinone OR CoQ10 OR Coenzyme Q10 OR 
LiQsorb OR Liquid Co-Q10 OR NutraDrops OR 
QuinZyme 5 36 1 0.694 
dexmethylphenidate OR Focalin OR Focalin XR 5 40 1 0.625 
hyoscyamine OR A-Spaz OR Anaspaz OR 
Cystospaz OR Hyospaz OR Hyosyne OR IB-Stat 
OR Levbid OR Levsin OR Levsin/SL OR Levsinex 
OR Levsinex SR OR NuLev OR Spasdel OR Symax 
Duotab OR Symax FasTab OR Symax SL OR 
Symax SR 5 42 1 0.595 
ropinirole OR Requip OR Requip Starter Kit OR 
Requip XL 4 27 1 0.593 
tizanidine OR Zanaflex 4 29 1 0.552 
raloxifene OR Evista 4 32 1 0.500 
acetaminophen OR Acephen OR Actamin OR 
Adprin B OR Anacin Aspirin Free OR Apra OR 
Atasol OR Bromo Seltzer OR Childrens ElixSure 
OR Childrens Silapap OR Childrens Tylenol OR 
Dolono OR Ed-APAP OR Elixsure Fever/Pain OR 
Febrol Solution OR Feverall OR Genapap OR 
Genebs OR Infants Tylenol OR Jr. Tylenol OR 
Mapap OR Mapap Arthritis Pain OR Mapap 
Childrens OR Mapap Infant Drops OR Mapap 
Meltaway OR Mapap Rapid Release Gelcaps OR 
Mapap Rapid Tabs OR Pain-Eze OR Q-Pap OR Q-
Pap Extra Strength OR Silapap Childrens OR 
Silapap Infants OR St. Joseph Aspirin-Free OR 
Tactinal OR Tempra OR Tempra Quicklets OR 
Tycolene OR Tylenol OR Tylenol 8 Hour OR 
Tylenol Arthritis Pain OR Tylenol Extra Strength 
OR Tylenol GoTabs OR Tylenol Sore Throat 
Daytime OR Tylophen OR Uniserts OR Vitapap 5 50 1 0.500 
erythromycin OR A/T/S OR Akne-Mycin OR E-
Mycin OR E.E.S. Granules OR E.E.S.-200 OR 
E.E.S.-400 OR E.E.S.-400 Filmtab OR Emcin Clear 
OR Emgel OR Ery Pads OR Ery-Tab OR EryPed OR 
Eryc OR Erycette OR Eryderm OR Erygel OR 
Erymax OR Erythra-Derm OR Erythrocin OR 
Erythrocin Lactobionate OR Erythrocin Stearate 
Filmtab OR Ilosone OR Ilotycin OR PCE Dispertab 
OR Roymicin OR Staticin OR T-Stat OR 
Theramycin Z 4 35 1 0.457 
anakinra OR Kineret 3 22 1 0.409 
	  
 
 176	  
black cohosh OR Menopause Support 3 26 1 0.346 
atorvastatin OR Lipitor 3 30 1 0.300 
(sulfamethoxazole AND trimethoprim) OR Bactrim 
OR Bactrim DS OR Cotrim OR SMZ-TMP DS OR 
Septra OR Septra DS OR Sulfatrim OR Sulfatrim 
Pediatric 3 32 1 0.281 
hydrocortisone OR A-Hydrocort OR Ala-Cort OR 
Ala-Scalp HP OR Anucort-HC OR Anumed-HC OR 
Anusol-HC OR Aquanil HC OR Beta HC OR 
Caldecort OR Cetacort OR Colocort OR Cortaid OR 
Cortaid Intensive Therapy OR Cortaid Maximum 
Strength OR Cortaid with Aloe OR Cortalo with 
Aloe OR Cortef OR Cortenema OR Corticaine OR 
Cortifoam OR Cortizone for Kids OR Cortizone-10 
OR Cortizone-10 Anal Itch Cream OR Cortizone-
10 Intensive Healing Formula OR Cortizone-10 
Plus OR Cortizone-5 OR Dermarest Dricort OR 
Dermarest Eczema Medicated OR Dermarest Plus 
Anti-Itch OR Dermtex HC OR Genasone/Aloe OR 
Gly-Cort OR Gynecort Maximum Strength OR 
Hemorrhoidal HC OR Hemril-30 OR Hemril-HC 
Uniserts OR Hycort OR Hydrocortisone 1% In 
Absorbase OR Hydrocortisone with Aloe OR 
Hydrocortone OR Hytone OR Instacort OR Itch-X 
Lotion OR Locoid OR Locoid Lipocream OR MD 
Hydrocortisone OR Massengill Medicated Soft 
Cloth OR Neutrogena T-Scalp OR NuCort with 
Aloe OR NuZon OR Nutracort OR Pandel OR 
Preparation H Anti-Itch Cream Hydrocortisone 1% 
OR Procto-Kit 1% OR Procto-Kit 2.5% OR Procto-
Pak 1% OR ProctoCare-HC OR Proctocort OR 
Proctocream-HC OR Proctosert HC OR Proctosol-
HC OR Proctozone HC OR Proctozone-H OR Recort 
Plus OR Rectasol-HC OR Rederm OR Sarnol-HC 
OR Scalacort OR Scalpicin OR Solu-Cortef OR 
Texacort OR Tucks Hydrocortisone Anti-Itch 
Ointment OR U-Cort OR Westcort 3 34 1 0.265 
ampicillin OR Principen 3 36 1 0.250 
meperidine OR Demerol OR Meperitab 2 33 2 0.242 
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psyllium OR Alramucil OR Cilium OR Fiber Eze OR 
Fiberall OR Genfiber OR Hydrocil OR Konsyl OR 
Konsyl Orange Sugar-free OR Konsyl for Kids OR 
Konsyl-D OR Konsyl-Orange OR Laxmar OR 
Laxmar Orange OR Laxmar Sugar Free OR Maalox 
Daily Fiber Therapy OR Metamucil OR Metamucil 
Berry Burst Smooth Texture Sugar Free OR 
Metamucil Orange Coarse Milled Original Texture 
OR Metamucil Orange Smooth Texture OR 
Metamucil Orange Smooth Texture Sugar Free OR 
Metamucil Smooth Texture OR Metamucil 
Unflavored Coarse Milled Original Texture OR 
Metamucil Unflavored Smooth Texture Sugar Free 
OR Modane Bulk OR Natural Fiber Therapy OR 
Perdiem Fiber Powder OR Reguloid OR Serutan 
OR Syllact OR V-Lax 3 39 1 0.231 
aprepitant OR Emend OR Emend 3-Day 3 39 1 0.231 
erlotinib OR Tarceva 2 23 1 0.174 
cisapride OR Propulsid 2 24 1 0.167 
modafinil OR Provigil 2 27 1 0.148 
tranylcypromine OR Parnate 2 30 1 0.133 
(hydrocortisone AND pramoxine) OR Analpram E 
OR Analpram-HC OR Enzone OR Epifoam OR HC 
Pramoxine OR Hydropram OR Novacort OR 
Pramosone OR Proctofoam HC OR Rectocort HC 
OR Zone-A OR Zone-A Forte OR Zypram 2 31 1 0.129 
povidone iodine OR Betadine OR Betadine Aerosol 
Spray OR Minidyne OR Pharmadine OR Polydine 2 37 1 0.108 
methionine OR Me-500 2 47 1 0.085 
atovaquone OR Mepron 1 20 1 0.050 
(atropine AND diphenoxylate) OR Lomocot OR 
Lomotil OR Lonox OR Vi-Atro 1 21 1 0.048 
tacrolimus OR Prograf OR Protopic 1 22 1 0.045 
ginkgo OR Ginkgo Biloba 1 24 1 0.042 
polyethylene glycol 3350 OR ClearLax OR 
GaviLAX OR GlycoLax OR MiraLax 1 24 1 0.042 
digoxin OR Digitek OR Lanoxicaps OR Lanoxin 1 26 1 0.038 
omeprazole OR Prilosec OR Prilosec OTC 1 27 1 0.037 
ritonavir OR Norvir 1 27 1 0.037 
cefuroxime OR Ceftin OR Zinacef 1 28 1 0.036 
fat emulsion OR Intralipid OR Liposyn II 1 28 1 0.036 
diltiazem OR Cardizem OR Cardizem CD OR 
Cardizem LA OR Cardizem SR OR Cartia XT OR 
Dilacor XR OR Diltia XT OR Diltzac OR Taztia XT 
OR Tiazac 1 29 1 0.034 
pimecrolimus OR Elidel 1 30 1 0.033 
leflunomide OR Arava 1 30 1 0.033 
metaxalone OR Skelaxin 1 30 1 0.033 
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(acetaminophen AND aspirin AND caffeine) OR 
Anacin Advanced Headache Formula OR Excedrin 
OR Excedrin Extra Strength OR Excedrin 
Menstrual Complete OR Excedrin Migraine OR 
Genace OR Goodys Extra-Strength Headache 
Powders OR Goodys Extra Strength OR Goodys 
Headache Powders OR Supac OR Vanquish 1 31 1 0.032 
rotavirus vaccine OR RotaTeq OR Rotarix 1 31 1 0.032 
ondansetron OR Zofran OR Zofran ODT 1 32 1 0.031 
zaleplon OR Sonata 1 32 1 0.031 
dobutamine OR Dobutrex 1 32 1 0.031 
nitroglycerin OR Minitran OR Nitrek OR Nitro TD 
Patch-A OR Nitro-Bid OR Nitro-Dur OR Nitro-Time 
OR NitroMist OR NitroQuick OR Nitrocot OR 
Nitrogard OR Nitrol Appli-Kit OR Nitrolingual 
Pumpspray OR Nitrostat OR Nitrostat Tablets OR 
Transderm-Nitro 1 32 1 0.031 
atenolol OR Tenormin 1 33 1 0.030 
isoniazid OR Nydrazid 1 33 1 0.030 
cerivastatin OR Baycol 1 33 1 0.030 
famotidine OR Heartburn Relief OR Leader Acid 
Reducer OR Mylanta AR OR Pepcid OR Pepcid AC 
OR Pepcid AC Chewable Tablets OR Pepcid AC 
Maximum Strength OR Pepcid AC Maximum 
Strength Tablets OR Pepcid Oral Suspension OR 
Pepcid RPD 1 33 1 0.030 
pegfilgrastim OR Neulasta 1 35 1 0.029 
oxybutynin OR Ditropan OR Ditropan XL OR 
Gelnique OR Oxytrol OR Urotrol 1 38 1 0.026 
(acetaminophen AND dichloralphenazone AND 
isometheptene mucate) OR Amidrine OR 
Diacetazone OR Duradrin OR Epidrin OR Iso-
Acetazone OR Isocom OR Midrin OR Migquin OR 
Migrapap OR Migratine OR Migrazone OR Migrin-A 1 38 1 0.026 
azathioprine OR Azasan OR Imuran 1 41 1 0.024 
ramelteon OR Rozerem 1 42 1 0.024 
allopurinol OR Aloprim OR Zyloprim 1 45 1 0.022 
penicillamine OR Cuprimine OR Depen OR Depen 
Titratabs 1 46 1 0.022 
naloxone OR Narcan 1 46 1 0.022 	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Appendix K:  Potential Problematic Drug List from False 
Positives Below	  are	  the	  drugs	  and	  the	  associated	  scores	  of	  drugs	  identified	  as	  false	  positives	  from	  the	  three	  top-­‐performing	  classifiers.	  	  Next	  to	  the	  drug	  name,	  the	  Pos	  column	  denotes	  the	  number	  of	  times	  a	  classifier	  marked	  the	  drug	  as	  a	  false	  positive.	  	  Occ	  indicates	  the	  number	  of	  occurrences,	  or	  number	  of	  times	  the	  drug	  was	  classified.	  	  Class	  indicates	  the	  number	  of	  different	  types	  of	  classifiers	  (1-­‐3)	  that	  predicted	  a	  false	  positive	  for	  a	  drug.	  	  Score	  indicates	  the	  linear	  combination	  of	  Pos,	  Occ,	  and	  Class	  resulting	  in	  a	  score	  of	  the	  confidence	  in	  prediction.	  	  Drugs	  withdrawn	  from	  market	  are	  highlighted	  in	  yellow.	  	  Interesting	  results	  are	  highlighted	  in	  green.	  	  Withdrawn	  drugs	  were	  tested	  separately	  and	  not	  counted	  as	  negative	  examples;	  their	  classification	  score	  is	  shown	  for	  comparison.	  	  	  	  
Drug Pos Occ Class Score 
methylphenidate OR Concerta OR Daytrana OR 
Metadate CD OR Metadate ER OR Methylin OR 
Methylin ER OR Ritalin OR Ritalin LA OR Ritalin-SR 30 34 3 79.412 
morphine OR Astramorph PF OR Avinza OR 
Duramorph OR Infumorph OR Kadian OR MS 
Contin OR MSIR OR Morphine IR OR Oramorph SR 
OR RMS OR Roxanol 13 38 3 13.342 
quetiapine OR Seroquel OR Seroquel XR 14 31 2 12.645 
indomethacin OR Indocin OR Indocin IV OR 
Indocin SR 19 37 1 9.757 
sibutramine OR Meridia 17 34 1 8.500 
meloxicam OR Mobic 17 35 1 8.257 
vigabatrin OR Sabril 14 31 1 6.323 
losartan OR Cozaar 13 28 1 6.036 
oxycodone OR ETH-Oxydose OR OxyContin OR 
OxyIR OR Oxyfast OR Percolone OR Roxicodone 
OR Roxicodone Intensol 13 30 1 5.633 
doxepin OR Adapin OR Prudoxin OR Silenor OR 
Sinequan OR Zonalon 14 37 1 5.297 
aripiprazole OR Abilify OR Abilify Discmelt 13 32 1 5.281 
guaifenesin OR Altarussin OR Amibid LA OR 
Drituss G OR Duratuss G OR GG 200 NR OR 
Ganidin NR OR Guaifenesin LA OR Guaifenex G OR 
Guaifenex LA OR Hytuss OR Liquibid OR Mucinex 
OR Mucinex for Kids OR Muco-Fen 1200 OR 
Organidin NR OR Q-Bid LA OR Robitussin Chest 
Congestion OR Scot-Tussin Expectorant OR Tussin 13 34 1 4.971 
enoxaparin OR Lovenox 13 35 1 4.829 
risperidone OR Risperdal OR Risperdal Consta OR 
Risperdal M-Tab 12 30 1 4.800 
tizanidine OR Zanaflex 12 30 1 4.800 
Extraneal 13 36 1 4.694 
nortriptyline OR Aventyl Hydrochloride OR Pamelor 12 31 1 4.645 
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zolpidem OR Ambien OR Ambien CR OR Edluar OR 
Zolpimist 12 34 1 4.235 
clozapine OR Clozaril OR FazaClo 10 24 1 4.167 
selegiline OR Eldepryl OR Emsam OR Zelapar 10 25 1 4.000 
nicardipine OR Cardene OR Cardene IV OR 
Cardene SR 11 31 1 3.903 
(acetaminophen AND diphenhydramine) OR 
Anacin P.M. Aspirin Free OR Coricidin Night Time 
Cold Relief OR Excedrin PM OR Headache Relief PM 
OR Legatrin PM OR Mapap PM OR Midol PM OR 
Percogesic Extra Strength OR Sominex Pain Relief 
Formula OR Tylenol PM OR Tylenol Severe Allergy 
OR Tylenol Sore Throat Nighttime OR Unisom with 
Pain Relief 11 33 1 3.667 
eszopiclone OR Lunesta 10 28 1 3.571 
(dyphylline AND guaifenesin) OR COPD OR Difil G 
OR Dilex-G OR Dy-G OR Dyfilin GG OR Dyflex-G 
OR Dyphylline GG OR Jay-Phyl OR Lufyllin-GG OR 
Panfil G 11 36 1 3.361 
nifedipine OR Adalat OR Adalat CC OR Afeditab CR 
OR Nifediac CC OR Nifedical XL OR Procardia OR 
Procardia XL 10 31 1 3.226 
clomipramine OR Anafranil 10 31 1 3.226 
lisdexamfetamine OR Vyvanse 10 32 1 3.125 
dexmethylphenidate OR Focalin OR Focalin XR 9 26 1 3.115 
filgrastim OR Neupogen 11 39 1 3.103 
pneumococcal 7-valent vaccine OR Prevnar 9 28 1 2.893 
pramipexole OR Mirapex 10 35 1 2.857 
sulindac OR Clinoril 9 29 1 2.793 
albuterol OR AccuNeb OR Airet OR ProAir HFA OR 
Proventil OR Proventil HFA OR Ventolin OR 
Ventolin HFA OR Volmax OR Vospire ER 10 36 1 2.778 
thalidomide OR Thalomid 10 36 1 2.778 
(sulfamethoxazole AND trimethoprim) OR Bactrim 
OR Bactrim DS OR Cotrim OR SMZ-TMP DS OR 
Septra OR Septra DS OR Sulfatrim OR Sulfatrim 
Pediatric 9 30 1 2.700 
ampicillin OR Principen 9 30 1 2.700 
acetazolamide OR Diamox OR Diamox Sequels 9 31 1 2.613 
phenytoin OR Dilantin OR Phenytek OR Phenytoin 
Sodium, Prompt 9 31 1 2.613 
pilocarpine OR Isopto Carpine OR Pilocar OR 
Pilopine HS OR Pilostat OR Salagen 9 32 1 2.531 
verapamil OR Calan OR Calan SR OR Covera-HS 
OR Isoptin OR Isoptin SR OR Verelan OR Verelan 
PM 10 40 1 2.500 
(acetaminophen AND butalbital AND caffeine) OR 
Alagesic OR Alagesic LQ OR Anolor 300 OR Dolgic 
LQ OR Dolgic Plus OR Esgic OR Esgic-Plus OR 
Fioricet OR Geone OR Margesic OR Medigesic OR 
Repan OR Zebutal 9 34 1 2.382 
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influenza virus vaccine, live, trivalent OR FluMist 8 27 1 2.370 
ubiquinone OR CoQ10 OR Coenzyme Q10 OR 
LiQsorb OR Liquid Co-Q10 OR NutraDrops OR 
QuinZyme 9 35 1 2.314 
(conjugated estrogens AND 
medroxyprogesterone) OR Premphase OR 
Prempro 8 28 1 2.286 
temazepam OR Restoril 8 28 1 2.286 
clonazepam OR Klonopin OR Klonopin Wafer 8 30 1 2.133 
evening primrose OR Evening Primrose Oil OR 
Primrose Oil 8 30 1 2.133 
methylprednisolone OR A-methapred OR Depo-
Medrol OR Medrol OR Medrol Dosepak OR 
MethylPREDNISolone Dose Pack OR Solu-Medrol 8 30 1 2.133 
trazodone OR Desyrel OR Desyrel Dividose OR 
Oleptro 8 30 1 2.133 
fludarabine OR Fludara OR Oforta 6 19 1 1.895 
ziprasidone OR Geodon 7 26 1 1.885 
omega-3 polyunsaturated fatty acids OR Animi-3 
OR EPA Fish Oil OR Fish Oil OR Icar Prenatal 
Essential Omega-3 OR Lovaza OR Marine Lipid 
Concentrate OR MaxEPA OR MaxiTears Dry Eye 
Formula OR MaxiVision Omega-3 Formula OR Mi-
Omega OR Mi-Omega NF OR Omacor OR Omega-
500 OR Proepa OR Sea-Omega OR Sea-Omega 30 
OR Sea-Omega 70 OR TheraTears Nutrition 7 28 1 1.750 
benztropine OR Cogentin 7 28 1 1.750 
insulin lispro OR Humalog OR Humalog KwikPen 
OR Humalog Pen 8 39 1 1.641 
lorazepam OR Ativan 8 40 1 1.600 
amlodipine OR Norvasc 7 31 1 1.581 
vancomycin OR Lyphocin OR Vancocin OR 
Vancocin HCl OR Vancocin HCl Pulvules 7 31 1 1.581 
flecainide OR Tambocor 7 31 1 1.581 
vitamin e OR Alpha E OR Amino-Opti-E OR 
Aquasol E OR Aquavite-E OR Centrum Singles-
Vitamin E OR E Pherol OR E-400 Clear OR Nutr-E-
Sol 7 31 1 1.581 
metoprolol OR Lopressor OR Metoprolol Succinate 
ER OR Toprol-XL 7 34 1 1.441 
irinotecan OR Camptosar 6 27 1 1.333 
(hydrocortisone AND pramoxine) OR Analpram E 
OR Analpram-HC OR Enzone OR Epifoam OR HC 
Pramoxine OR Hydropram OR Novacort OR 
Pramosone OR Proctofoam HC OR Rectocort HC 
OR Zone-A OR Zone-A Forte OR Zypram 5 20 1 1.250 
propranolol OR Inderal OR Inderal LA OR InnoPran 
XL 6 29 1 1.241 
acetic acid OR Acetasol OR Acid Jelly OR Fem pH 
OR Klout OR Relagard 6 30 1 1.200 
chlordiazepoxide OR Librium 6 38 1 0.947 
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hydroxyzine OR Atarax OR Hyzine OR Vistaril 5 29 1 0.862 
modafinil OR Provigil 4 23 1 0.696 
acyclovir OR Zovirax OR Zovirax Cream OR 
Zovirax Ointment 5 36 1 0.694 
methotrexate OR Rheumatrex Dose Pack OR 
Trexall 4 24 1 0.667 
metformin OR Fortamet OR Glucophage OR 
Glucophage XR OR Glumetza OR Riomet 4 27 1 0.593 
levothyroxine OR Levothroid OR Levoxyl OR 
Synthroid OR Tirosint OR Unithroid 4 30 1 0.533 
meperidine OR Demerol OR Meperitab 4 32 1 0.500 
azithromycin OR Azasite OR Azithromycin Dose 
Pack OR Zithromax OR Zmax 4 33 1 0.485 
tacrolimus OR Prograf OR Protopic 4 35 1 0.457 
(chondroitin AND glucosamine) OR Cosamin DS 
OR Osteo Bi-Flex OR Osteo Bi-Flex Double 
Strength OR Osteo Bi-Flex Triple Strength OR 
Pryflex OR Relamine OR Schiff Move Free OR 
Schiff Move Free Caplets 4 36 1 0.444 
hydrocortisone OR A-Hydrocort OR Ala-Cort OR 
Ala-Scalp HP OR Anucort-HC OR Anumed-HC OR 
Anusol-HC OR Aquanil HC OR Beta HC OR 
Caldecort OR Cetacort OR Colocort OR Cortaid OR 
Cortaid Intensive Therapy OR Cortaid Maximum 
Strength OR Cortaid with Aloe OR Cortalo with 
Aloe OR Cortef OR Cortenema OR Corticaine OR 
Cortifoam OR Cortizone for Kids OR Cortizone-10 
OR Cortizone-10 Anal Itch Cream OR Cortizone-10 
Intensive Healing Formula OR Cortizone-10 Plus 
OR Cortizone-5 OR Dermarest Dricort OR 
Dermarest Eczema Medicated OR Dermarest Plus 
Anti-Itch OR Dermtex HC OR Genasone/Aloe OR 
Gly-Cort OR Gynecort Maximum Strength OR 
Hemorrhoidal HC OR Hemril-30 OR Hemril-HC 
Uniserts OR Hycort OR Hydrocortisone 1% In 
Absorbase OR Hydrocortisone with Aloe OR 
Hydrocortone OR Hytone OR Instacort OR Itch-X 
Lotion OR Locoid OR Locoid Lipocream OR MD 
Hydrocortisone OR Massengill Medicated Soft Cloth 
OR Neutrogena T-Scalp OR NuCort with Aloe OR 
NuZon OR Nutracort OR Pandel OR Preparation H 
Anti-Itch Cream Hydrocortisone 1% OR Procto-Kit 
1% OR Procto-Kit 2.5% OR Procto-Pak 1% OR 
ProctoCare-HC OR Proctocort OR Proctocream-HC 
OR Proctosert HC OR Proctosol-HC OR Proctozone 
HC OR Proctozone-H OR Recort Plus OR Rectasol-
HC OR Rederm OR Sarnol-HC OR Scalacort OR 
Scalpicin OR Solu-Cortef OR Texacort OR Tucks 
Hydrocortisone Anti-Itch Ointment OR U-Cort OR 
Westcort 3 34 1 0.265 
erlotinib OR Tarceva 3 38 1 0.237 
(metformin AND rosiglitazone) OR Avandamet 3 42 1 0.214 
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(acetaminophen AND tramadol) OR Ultracet 2 20 1 0.200 
tranylcypromine OR Parnate 2 23 1 0.174 
oxybutynin OR Ditropan OR Ditropan XL OR 
Gelnique OR Oxytrol OR Urotrol 2 25 1 0.160 
(acetaminophen AND dextromethorphan AND 
doxylamine AND pseudoephedrine) OR All-Nite 
Multi-Symptom Cold/Flu Relief OR NyQuil OR 
NyQuil Multi-Symptom OR Nyquil Cold Medicine 
OR Tylenol Severe Cold & Flu Night Time 2 26 1 0.154 
black cohosh OR Menopause Support 2 28 1 0.143 
tetracycline OR Ala-Tet OR Sumycin OR 
Topicycline 2 28 1 0.143 
(acetaminophen AND dichloralphenazone AND 
isometheptene mucate) OR Amidrine OR 
Diacetazone OR Duradrin OR Epidrin OR Iso-
Acetazone OR Isocom OR Midrin OR Migquin OR 
Migrapap OR Migratine OR Migrazone OR Migrin-A 2 28 1 0.143 
glyburide OR DiaBeta OR Glycron OR Glynase OR 
Glynase PresTab OR Micronase 2 28 1 0.143 
lactobacillus acidophilus OR Acidophilus OR 
Acidophilus Extra Strength OR Bacid OR Flora-Q 
OR Flora-Q 2 OR Novaflor OR RisaQuad OR 
Superdophilus 2 30 1 0.133 
sulfasalazine OR Azulfidine OR Azulfidine EN-tabs 
OR Sulfazine 2 30 1 0.133 
ropinirole OR Requip OR Requip Starter Kit OR 
Requip XL 2 30 1 0.133 
dronabinol OR Marinol 2 30 1 0.133 
digoxin OR Digitek OR Lanoxicaps OR Lanoxin 2 31 1 0.129 
doxycycline OR Adoxa OR Adoxa CK OR Adoxa TT 
OR Alodox OR Avidoxy OR Doryx OR Doxy 100 OR 
Doxy 200 OR Monodox OR Oracea OR Oraxyl OR 
Periostat OR Uracil OR Vibra-Tabs OR Vibramycin 2 32 1 0.125 
raloxifene OR Evista 2 32 1 0.125 
dobutamine OR Dobutrex 2 32 1 0.125 
erythromycin OR A/T/S OR Akne-Mycin OR E-
Mycin OR E.E.S. Granules OR E.E.S.-200 OR 
E.E.S.-400 OR E.E.S.-400 Filmtab OR Emcin Clear 
OR Emgel OR Ery Pads OR Ery-Tab OR EryPed OR 
Eryc OR Erycette OR Eryderm OR Erygel OR 
Erymax OR Erythra-Derm OR Erythrocin OR 
Erythrocin Lactobionate OR Erythrocin Stearate 
Filmtab OR Ilosone OR Ilotycin OR PCE Dispertab 
OR Roymicin OR Staticin OR T-Stat OR 
Theramycin Z 2 34 1 0.118 
hyoscyamine OR A-Spaz OR Anaspaz OR 
Cystospaz OR Hyospaz OR Hyosyne OR IB-Stat OR 
Levbid OR Levsin OR Levsin/SL OR Levsinex OR 
Levsinex SR OR NuLev OR Spasdel OR Symax 
Duotab OR Symax FasTab OR Symax SL OR 
Symax SR 2 36 1 0.111 
fat emulsion OR Intralipid OR Liposyn II 2 36 1 0.111 
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anakinra OR Kineret 2 37 1 0.108 
acetaminophen OR Acephen OR Actamin OR 
Adprin B OR Anacin Aspirin Free OR Apra OR 
Atasol OR Bromo Seltzer OR Childrens ElixSure OR 
Childrens Silapap OR Childrens Tylenol OR Dolono 
OR Ed-APAP OR Elixsure Fever/Pain OR Febrol 
Solution OR Feverall OR Genapap OR Genebs OR 
Infants Tylenol OR Jr. Tylenol OR Mapap OR 
Mapap Arthritis Pain OR Mapap Childrens OR 
Mapap Infant Drops OR Mapap Meltaway OR 
Mapap Rapid Release Gelcaps OR Mapap Rapid 
Tabs OR Pain-Eze OR Q-Pap OR Q-Pap Extra 
Strength OR Silapap Childrens OR Silapap Infants 
OR St. Joseph Aspirin-Free OR Tactinal OR Tempra 
OR Tempra Quicklets OR Tycolene OR Tylenol OR 
Tylenol 8 Hour OR Tylenol Arthritis Pain OR 
Tylenol Extra Strength OR Tylenol GoTabs OR 
Tylenol Sore Throat Daytime OR Tylophen OR 
Uniserts OR Vitapap 2 41 1 0.098 
cisapride OR Propulsid 2 41 1 0.098 
omeprazole OR Prilosec OR Prilosec OTC 1 17 1 0.059 
rotavirus vaccine OR RotaTeq OR Rotarix 1 21 1 0.048 
atorvastatin OR Lipitor 1 23 1 0.043 
fibrinogen OR RiaSTAP 1 25 1 0.040 
methionine OR Me-500 1 26 1 0.038 
atenolol OR Tenormin 1 27 1 0.037 
telithromycin OR Ketek OR Ketek Pak 1 27 1 0.037 
aprepitant OR Emend OR Emend 3-Day 1 27 1 0.037 
valsartan OR Diovan 1 27 1 0.037 
azathioprine OR Azasan OR Imuran 1 27 1 0.037 
leflunomide OR Arava 1 28 1 0.036 
spironolactone OR Aldactone 1 30 1 0.033 
(acetaminophen AND aspirin AND caffeine) OR 
Anacin Advanced Headache Formula OR Excedrin 
OR Excedrin Extra Strength OR Excedrin Menstrual 
Complete OR Excedrin Migraine OR Genace OR 
Goodys Extra-Strength Headache Powders OR 
Goodys Extra Strength OR Goodys Headache 
Powders OR Supac OR Vanquish 1 30 1 0.033 
pimecrolimus OR Elidel 1 30 1 0.033 
fexofenadine OR Allegra OR Allegra ODT 1 30 1 0.033 
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calcium carbonate OR Alka-Mints OR Ami-Lac OR 
Amitone OR Cal-Gest OR Calcarb OR Calci Mix OR 
Calci-Chew OR Calcium Concentrate OR Calcium 
Liquid Softgel OR Calcium Oyster Shell OR Caltrate 
OR Chooz OR Extra Strength Mylanta Calci Tabs 
OR Icar Prenatal Chewable Calcium OR Maalox 
Childrens Relief OR Maalox Regular Strength OR 
Mylanta Child OR Nephro Calci OR Os-Cal 500 OR 
Oysco 500 OR Oyst Cal 500 OR Oyster Cal OR 
Oyster Calcium OR Oyster Shell OR Pepto 
Childrens OR Rolaids Extra Strength Softchews OR 
Titralac OR Tums E-X 750 OR Tums Kids OR Tums 
Regular Strength OR Tums Ultra 1000 1 32 1 0.031 
polyethylene glycol 3350 OR ClearLax OR GaviLAX 
OR GlycoLax OR MiraLax 1 32 1 0.031 
darbepoetin alfa OR Aranesp 1 33 1 0.030 
bevacizumab OR Avastin 1 40 1 0.025 
(acetaminophen AND oxycodone) OR Endocet OR 
Magnacet OR Narvox OR Percocet OR Percocet 
10/325 OR Percocet 10/650 OR Percocet 2.5/325 
OR Percocet 5/325 OR Percocet 7.5/325 OR 
Percocet 7.5/500 OR Perloxx OR Primalev OR 
Roxicet OR Tylox OR Xolox 1 42 1 0.024 
belladonna OR Belladonna Tincture 1 43 1 0.023 
dimenhydrinate OR Dramamine OR Driminate OR 
Travel-Eze 1 44 1 0.023 	  
Drug Pos Occ Class Score 
trovafloxacin OR Trovan 33 100 1 10.89 
hydromorphone OR Dilaudid OR Dilaudid-HP OR 
Exalgo OR Palladone 33 100 1 10.89 
rofecoxib OR Vioxx 32 100 1 10.24 
cerivastatin OR Baycol 2 100 1 0.04 
 
